Four Jointed Box One, a Novel Pro-Angiogenic Protein in Colorectal Carcinoma by Al-Greene, Nicole Theresa
i 
 
FOUR JOINTED BOX ONE, A NOVEL PRO-ANGIOGENIC PROTEIN IN 
COLORECTAL CARCINOMA. 
BY 
Nicole Theresa Al-Greene 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
DOCTOR OF PHILOSOPHY 
In Cell and Developmental Biology. 
December, 2013 
Nashville Tennessee 
Approved: 
R. Daniel Beauchamp 
Susan Wente 
James Goldenring 
Albert Reynolds 
ii 
 
DEDICATION 
To my parents, Karen and John, who have helped me in every way possible, 
every single day. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
ACKNOWLEDGMENTS. 
Funding for this work was supported by grants DK052334, CA069457, 
The GI Cancer SPORE, GM088822, the VICC, the Clinical and Translational 
Science Award (NCRR/NIH UL1RR024975), the DDRC (P30DK058404), and the 
Cooperative Human Tissue Network (UO1CA094664) and U01CA094664. 
 I was lucky enough to be allowed to perform research as an 
undergraduate in the lab of Ken Belanger.  I will be forever grateful for that 
opportunity that sparked my love of research.  Equally important was my time as 
a technician in Len Zon’s lab where I confirmed the fact that I needed to go 
graduate school and earn my degree.  During my time at Vanderbilt I have been 
helped by so many individuals, and the collaborative nature of everyone I have 
met with is truly an amazing aspect of the research community here.  I am 
especially thankful for all the technical help and insightful conversations I have 
had with Natasha Deane, Anna Means, Claudia Andl, Tanner Freeman, Connie 
Weaver, Keeli Lewis, Jalal Hamaamen, Jenny Zi, John Neff, Christian Kis, 
Andries Zjistra, Trennis Palmer, Joseph Roland, and Lynn LaPierre.  My 
committee of Jim Goldenring, Al Reynolds, Stacey Huppert, and Susan Wente 
were essential in both the development and testing of my training these past 
years.  Naturally this work would not have been possible without my mentor, Dan 
Beauchamp, a man who always inspires me with both his wisdom and his 
humility.  I will never forget our first meeting after I joined the lab when I boldly 
stated “I’m ready, tell me what to do”.  He responded with a chuckle, saying that 
was entirely up to me.  His keen ability to gently guide while allowing me to 
iv 
 
stumble and learn was remarkable.  He was always encouraging, supportive, 
empathetic, and enthusiastic all at once, which made even the most frustrating of 
times bearable.   It was truly a gift to work with him and I am forever grateful.   
Finally I would like to thank my family.  My brother Shawn, and sister-in-
law Chrissy have blessed me with a niece and nephew who have provided much 
joy and comic relief over the past seven years.  My parents, Karen and John, 
who have gone above and beyond the call of duty ever since I could remember, 
and I’m sure long before that.  You have always inspired me to do my best, 
cheered with me when I have succeeded, and consoled me when I failed.  Words 
cannot ever express my gratitude.   
 
 
 
 
 
 
 
 
 
 
v 
 
TABLE OF CONTENTS 
Page 
DEDICATION…………………………………………………………………………….ii 
ACKNOWLEDGMENTS……………………….………………………………..……..iii 
LIST OF TABLES……………………………………………………………………...viii 
LIST OF FIGURES…………………………………………………………………….x 
LIST OF ABBREVIATIONS……………………………………………………..……xiii 
Chapter 
I. INTRODUCTION…………………………………………..……………………1 
Significance of colorectal cancer……………………………………….……..1 
Cyclooxygenases, angiogenesis, and colorectal cancer………………...…4 
Summary…………………………………………………………………….….11 
 
II. CHARACTERIZATION OF GENE EXPRESSION CHANGES IN 
RESPONSE TO CELECOXIB TREATMENT IN VIVO AND THE 
IDENTIFICATION OF FOUR JOINTED BOX 1…………………….……...13 
 
Introduction………………………………………………………………….….13 
Materials and Methods………………………………………………………..14 
Results………………………………………………………………………….17 
Discussion………………………………………………………………………24 
 
III. DEVELOPMENT OF FJX1 SPECIFIC VECTORS, ANTIBODIES AND 
CHARACTERIZATION OF RECOMBINANT FJX1 IN VITRO…………...26 
 
Introduction………………………………………………………..……………26 
Materials and Methods……………………………………………….……….30 
Results……………………………………………………….………...……….36 
Discussion………………………………………………………………………55 
 
IV. FJX1 PROMOTES TUMORIGENESIS THROUGH INCREASED 
ANGIOGENESIS IN COLORECTAL CARCINOMA.……………...……….59 
vi 
 
Introduction………………………………………………………………….….59 
Materials and methods……………………….…………..…………..……….60 
Results…………………………………………………………………….……64 
Discussion…………………….………………………………………….….…75 
 
V. FJX1 PROMOTES ANGIOGENESIS THROUGH REGULATION OF  
HIF1-α……………………………………………………………….………….77 
 
Introduction……………………………………………………………….….…77 
Materials and Methods………………………………………………….…….78 
Results……………………………………………………………………….…84 
Discussion………………………………………………………………………98 
 
VI. GENE EXPRESSION ANALYSIS OF SW480 CELL LINES AFTER 
ALTERED FJX1 AND HIF1A EXPRESSION…………..…………………102 
 
Introduction……………………………………………………………………102 
Materials and Methods………………………………………………………103 
Results...………………………………………………………………………104 
Discussion…………………………………………………………………….115 
 
VII. SUMMARY AND FUTURE DIRECTIONS………………………………..117 
REFERENCES……………………………………………………………..185 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
LIST OF TABLES 
Table                                                                                                                Page 
1. Genes inhibited in human rectal tumor biopsies after celecoxib 
treatment………………………………………………………………………123 
 
2. Genes stimulated in human rectal tumor biopsies after celecoxib 
treatment………………………………………………………………………126 
 
3. The top network from Ingenuity Pathway Analysis of celecoxib     
regulated genes includes known inflammatory targets and FJX1……..…20 
 
4. Patient sample demographics, pathology, and clinical follow up data…...21 
 
5. Gene symbol, gene name, and literature citation for association with  
HIF1-α for the top 43 genes found in the leading edge subset of both 
VUMC and MCC datasets after GSEA analysis……….…………………...87 
   
6. Summary of the number of genes altered between the indicated            
cell    lines after microarray analysis………………………...……………..107 
 
7. Probeset ID, gene symbol, refseq transcript ID and fold change            
from microarray analysis of SW480VEC versus SW480FJX1 colon        
cancer cells………………………………………………………..………....129 
 
8. Probeset ID, gene symbol, refseq transcript ID and fold change            
from microarray analysis of SW480FJX1 treated with scramble siRNA       
(siSCR) versus SW480FJX1 treated with FJX1 specific siRNA          
(siFJX1) colon  cancer cells………………………...………………..…..…144 
 
 
9. Probeset ID, gene symbol, refseq transcript ID and fold change             
from microarray analysis of SW480FJX1 treated with scramble            
siRNA (siSCR) versus SW480FJX1 treated with HIF1A specific           
siRNA (siHIF) colon   cancer cells….……………………………………....180 
 
10. Genes found to be significantly altered in both SW480VEC vs       
SW480FJX1 and SW480FJX1 siSCR vs SW480FJX1 siFJX1 gene lists.…..113   
 
viii 
 
11. Genes found to be significantly altered in both SW480VEC vs        
SW480FJX1 and SW480FJX1 siSCR vs SW480FJX1 siHIF1A gene lists…..114   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
LIST OF FIGURES 
Figure                                                                                                              Page 
1. Diagram of known genetic mutations involved in CRC progression.……..3  
 
2. The arachidonic acid signaling pathway……………….………………….….6 
 
3. FJX1 mRNA expression is upregulated in CRC and is associated with 
poor patient prognosis………………………………………………………...22 
 
4. FJX1 protein expression is elevated in rectal tumors ……………………..23 
 
5. Sequence alignment of human, mouse, and rat FJX1 with Drosophila 
fj………………………………………………………………………………….29 
 
6. Stably expressed recombinant MYC-tagged FJX1 increases FJX1 
protein..………………………………………………………………………....37  
 
7. FJX1 antibodies in immunoblotting……………………………..……………38 
 
8. FJX1 antibodies detect secreted recombinant FJX1 in ELISA……………40  
 
9. FJX1 antibodies in immunofluorescence…………………………………..41 
 
10. Recombinant FJX1 is glycosylated, phosphorylated, and localizes to       
the Golgi Apparatus in HEK293T cells…………..……………….……..…..44 
 
11. FJX1 ELISA detects recombinant human FJX1 and endogenous rat 
FJX1……………………………………………….……………………………45 
 
12. Endogenous and recombinant expression of FJX1 in various cell 
lines……………………………………………………………………..….…..46 
 
13. Stably expressed recombinant MYC-tagged FJX1 increases FJX1   
protein in SW480 colon cancer cells….………………….………………….48 
 
14. Stably expressed recombinant MYC-tagged FJX1 increases FJX1    
protein in colon cancer cells….………………………….……………..…….49 
 
x 
 
15. Stably expressed recombinant MYC-tagged FJX1 does not affect    
cellular proliferation in vitro…………………………………………….….….50 
 
16. FJX1 does not alter Dchs1 or Fat4 cadherin constructs mobility in 
immunoblotting…………………………………………..…………………….53 
 
17. Expression of mutant FJX1 in various cell lines…………...……………….54 
 
18. Overexpression of MYC-tagged FJX1 in SW480 colon cancer cells 
promotes tumor growth in vivo……………………………………………………65 
 
19. Overexpression of MYC-tagged FJX1 in SW480 colon cancer cells 
promotes tumor growth in vivo…………………………………………….....67 
 
20. Overexpression of MYC-tagged FJX1 in KM12C colon cancer cells 
promotes tumor growth in vivo……………………………………………....68 
 
21. FJX1 null mice have fewer polyps than wild-type littermates in a       
mouse model of tumorigenesis…………………………….……..……….…70 
 
22. Autonomous and non-autonomous expression of FJX1 selectively 
enhances endothelial capillary tube formation in vitro……………………..73 
 
23. Conditioned media from SW480FJX1 cells enhances endothelial capillary 
tube formation in vitro…………………………………………………………….....74 
 
24. FJX1 mRNA expression in human colorectal cancers correlates with 
expression of known angiogenic factors……………………………...….....86 
     
25. FJX1 expression does not alter HIF1-α mRNA expression but increase 
HIF1-α protein……………………………………………………………….....89 
 
26. Increased HIF1-α contributes to FJX1-induced increase in endothelial    
tube formation……………………………………………………………...…..90 
 
27. Autonomous and non-autonomous expression of FJX1FLAG and 
FJX1DEFLAG enhances endothelial capillary tube formation in vitro…..…..92 
 
28. Increased HIF1-α expression is sufficient to promote endothelial tube 
formation in vitro…………………………………………….....………………93 
xi 
 
29. FJX1 enhances HIF1-α protein stability by enhancing HIF1-α half-
life…………………………………………………………………………….….96 
 
30. Conditioned media from SW480FJX1 cells has increased levels of    
Annexin A1 as compared to SW480VEC cells………………………………97 
 
31. Validation of siRNA in cells used for microarray………………………….108 
 
32. Top network after IPA analysis of the genes differentially expressed 
between SW480VEC and SW480FJX1 cells………………………………….109 
 
33. Top network after IPA analysis of the genes differentially expressed 
between SW480FJX1 cells treated with scrambled siRNA and       
SW480FJX1 cells treated with FJX1 specific siRNA………………………110  
  
34. Top network after IPA analysis of the genes differentially expressed 
between SW480FJX1 cells treated with scrambled siRNA and      
SW480FJX1 cells treated with HIF1A specific siRNA…………………..…111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
LIST OF ABBREVIATIONS 
 
15-PGDH  15-hydroxyprostaglandin dehydrogenase 
ACF  aberrant crypt foci  
AOM  azoxymethane  
APC  adenomatous polyposis coli 
CD24  cluster of differentiation 24  
COX   cyclooxygenase 
COX-1  cyclooxygenase 1  
COX-2  cyclooxygenase 2 
CRC  colorectal cancer 
CYR61   cysteine-rich angiogenic inducer 61  
DS  dachsous (Drosophila) 
DSCH1 dachsous 1 (Homo sapiens) 
DSS  dextran sodium sulfate 
EGF  epidermal growth factor 
EP1  prostaglandin E receptor 1 
EP2  prostaglandin E receptor 2 
EP3  prostaglandin E receptor 3 
EP4  prostaglandin E receptor 4 
ERK1/2 extracellular signal related kinase 1/2  
FAT4  FAT4 (Homo sapiens) 
FGF  fibroblast growth factor 
FIH  factor inhibiting HIF1 
FJ  four jointed (Drosophila) 
xiii 
 
FJX1  four jointed box one (Homo sapiens) 
FT  fat (Drosophila) 
GI  gastrointestinal 
HIF1-α hypoxia inducible factor 1 
hCG  human chorionic gonadotropin  
HRE  hypoxia response elements 
HUVEC human umbilical vein endothelial cells 
HMEC-1 human microvascular endothelial cells 
IL-1  interleukin 1  
LLC  Lewis lung carcinoma cell line 
LPS  lipopolysaccharide 
MAPK  ERK mitogen-activate protein kinase  
MCC  H. Lee Moffitt Cancer Center  
NFkß   nuclear factor kappa ß  
NSAIDs  non-steroidal anti-inflammatory drugs 
p38 MAPK mitogen associated protein kinase  
PCP  planar cell polarity  
PDGF  platelet derived growth factor 
PHD  prolyl hydroxylases  
PI3K  phosphatidylinositol 3-kinase  
PG   prostaglandin 
PGE2  prostaglandin E2 
PGE-M 11α-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioc acid 
PGD2  prostaglandin D2 
PGF2α  prostaglandin F2α 
xiv 
 
PGH2  prostaglandin H2 
PGI2  prostaglandin I2 
PNGaseF peptide N-glycosidase F  
ROS  reactive oxygen species  
TGFα  transforming growth factor α 
TNF-α  tumor necrosis factor α 
TxA2  thromboxane A2 
VEGF  vascular endothelial growth factor 
PHD   prolyl hydroxylase enzme 
VEGF  vascular endothelial growth factor 
VHL  von-Hippel Lindau 
VUMC Vanderbilt Medical Center 
.  
 
1 
 
CHAPTER I. 
INTRODUCTION 
Significance of colorectal cancer 
Colorectal cancer (CRC) represents the third leading cause of cancer 
related deaths for both men and women in the United States [1].  In 2013 alone, 
it is estimated that 150,000 new cases will be diagnosed and 50,000 individuals 
will die from disease [1].  There are multiple factors involved in the development 
of CRC.  For example, there are known genetic mutations that occur during 
disease progression from normal colonic epithelium through aberrant crypt foci 
(ACF) formation, to eventual carcinoma development (Fig. 1)  [2].  Mutation of 
the adenomatous polyposis coli gene (APC) is a key initial event in the 
development of CRC, while Kristen rat sarcoma viral oncogene (KRAS), SMAD 
family member 4 (SMAD4), and tumor protein 53 (p53) mutations are involved in 
the later stages of disease.  In addition to genetic alterations, increased 
inflammation has also been linked to CRC development.  Cyclooxygenase 2 
(COX-2) is an inflammatory related gene whose expression is increased as early 
as the adenoma stage (~50%) with the majority of carcinomas expressing high 
levels (~90%).  Identification of these changes in gene expression has given 
insight into the biology of CRC and the derivation of targeted therapies.  However 
an incomplete understanding of the downstream regulatory components exists.  
Further, some therapies, including COX-2 targeted anti-inflammatory agents 
have undesirable side effects.  Ongoing research is aimed at trying to enhance 
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our knowledge of how such drugs work in vivo to provide rationale for the 
development of new reagents that potentially exhibit more specific disease 
treatment as well as less toxicity in patients. 
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Figure 1.  Diagram of known genetic mutations involved in CRC 
progression.  Modified version of known genetic mutations (adenomatous 
polyposis coli gene (APC), Kristen rat sarcoma viral oncogene (KRAS), SMAD 
family member 4 (SMAD4), and tumor protein 53 (p53)) that occur during disease 
progression from normal colonic epithelium through adenoma to carcinoma 
formation first proposed by Burt Vogelstein and colleagues [2].  
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Cyclooxygenases, angiogenesis, and colorectal cancer 
 Chronic inflammation has been linked to the development and 
progression of multiple cancers, including CRC.  One of the major pathways 
linked to inflammation involves the cyclooxygenase enzymes.  Targeting these 
enzymes has shown promise in CRC therapies but causes significant side 
effects. Cyclooxygenase enzymes 1 and 2 (COX-1, COX-2) represent the rate-
limiting step in the conversion of arachidonic acid to prostaglandins (Figure 2).  
COX-1 is found in normal colonic mucosa and thought to have a homeostatic role 
whereas COX-2 is expressed at low levels, but rapidly induced in response to 
inflammatory signals.  Arachidonic acid is first converted by COX-1 and COX-2 
into prostaglandin H2 (PGH2).  PGH2 is subsequently metabolized by 
prostaglandin synthases into prostanoids, including prostaglandin E2 (PGE2), 
prostaglandin D2 (PGD2), prostaglandin F2α (PGF2α), prostaglandin I2 (PGI2) or 
thromboxane A2 (TxA2).  An important physiological antagonist of prostaglandins 
is the prostaglandin degrading enzyme 15-hydroxyprostaglandin dehydrogenase 
(15-PGDH).  15-PGDH catalyzes the oxidization of a key hydroxyl group on the 
prostaglandins to a ketone which renders the prostaglandins biologically inactive 
[3].  Prostanoids have been implicated in tumor growth through modulation of 
survival factors, angiogenesis, and immune surveillance.  PGE2 is the 
predominant prostaglandin found in colonic tissue and has been shown to signal 
through at least four different prostaglandin receptors (prostaglandin E receptors 
1-4, EP1-4).   
Of the genes involved in the arachidonic acid pathway, much focus has 
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been placed on COX-2 and its regulation of PGE2 production in CRC.  Elevation 
of both COX-2 protein and PGE2 has been detected in CRC as compared to 
normal mucosa [4-8].  Although in vivo levels of PGE2 have been reported, data 
suggests that actual levels in patients are difficult to accurately assess.  Thus the 
urinary metabolite 11α-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioc 
acid (PGE-M) was identified as a more reliable biomarker for PGE2 production in 
vivo [9].  Increased levels of urinary PGE-M have been associated with larger 
polyps in CRC patients [10,11].  High expression of COX-2 in CRC patients has 
also been associated with poor patient prognosis leading to studies that targeted 
this enzyme in CRC. [12].   
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Figure 2.  The arachidonic acid signaling pathway.  Green symbols 
represent conversion enzymes, blue symbols represent substrates/products, 
orange symbols represent prostaglandin receptors, red symbols represent 
biological activities, and black symbols represent pharmacological or naturally 
occurring pathway antagonists.   
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Mouse models represent an important biological tool for understanding 
regulatory pathways in CRC and for preclinical studies targeting these pathways. 
Mouse models of CRC bear many similarities to human CRC.  As mentioned 
above, APC is one of the earliest and most frequent genetic mutations found in 
human CRC and several mouse models of intestinal tumorigenesis have shown 
that genetic deletion or truncation of murine Apc causes multiple intestinal 
polyps. Carcinogen induced CRC in mice can also be used to model human 
disease, including administration of the carcinogen azoxymethane (AOM).  When 
deletion of COX-2 expression is combined with an APC truncation, mice exhibit 
fewer, smaller polyps in a gene-dose dependent manner [13,14].  Similar results 
are observed when an EP2 deletion is added to the APC mutant mouse 
background, or when EP1 or EP4 KO mice are treated with AOM, suggesting 
that EP1, EP2, and EP4 are important mediators of PGE2 signaling in CRC [15-
17].  Conversely, the addition of PGE2 treatment to APC mutant mice, or mice 
treated with AOM, increases both the multiplicity and size of intestinal polyps 
[18,19].  As mentioned above, 15-PGDH is a known prostaglandin degrading 
enzyme whose expression is often diminished in CRC [20,21]  15-PGDH null 
mice have increased intestinal tumor burden compared to WT mice after AOM 
carcinogen treatment [22].  These murine studies have led to a greater 
appreciation of the pathways regulated by COX-2 expression and PGE2 
production in tumorigenesis. 
The most common COX inhibitors are nonsteroidal anti-inflammatory 
drugs (NSAIDs).  NSAIDs fall into two main classes; those that inhibit both COX-
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1 and COX-2 (‘non-specific’ i.e. aspirin, Sulindac, Indomethacin, Piroxicam) and 
those that are specific for COX-2 (‘coxibs’ i.e.  celecoxib, NS398).  NSAIDs have 
been shown to provide both a prophylactic and therapeutic benefit in both 
hereditary and sporadic human CRC [23-30].  Mouse models also support the 
role of NSAIDs in diminishing tumor burden.  For example, celecoxib treated 
mice show reduced tumor burden in AOM treated animals; an effect that is 
reversed in 15-PGDH null animals [31].  Piroxicam and sulindac treatment of 
APC min mice also decreased tumor burden, but these effects were reversed 
upon the addition of EP receptor agonists, supporting the importance of blocking 
COX-2 mediated PGE2 signaling [32] .  The therapeutic benefits of NSAIDs are 
dependent on both dose and duration of use [23]; however there are unwanted 
side effects to consider that also correlate with increased NSAID use.  Non-
specific NSAIDs (excluding aspirin) cause gastrointestinal (GI) harm including 
increased risk of ulceration, bleeding and related complications [23].  It was 
hypothesized that these effects were due to inhibition of COX-1 which is 
important to epithelial survival and functional integrity in the GI tract.  These 
observations factored into the rationale behind the development of COX-2 
specific drugs.  Unfortunately, despite having reduced GI side effects, use of 
COX-2 specific inhibitors was associated with a significantly increased risk of 
adverse cardiovascular events, such as stroke and heart attack [24,33].  
Therefore the identification of more selective therapeutic targets downstream of 
COX-2 signaling has become an important area of ongoing research.     
Targeting the blood vessels that feed tumors has also become a priority in 
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cancer therapy.  Angiogenesis is the process of recruiting and restructuring blood 
vessels from pre-existing vasculature, and is essential for tumor growth beyond 
1-2 mm in diameter.  Early in tumor development an ‘angiogenic switch’ occurs 
tipping the balance in favor of pro-angiogenic factors in contrast to angiogenesis 
inhibitors [34].  In addition to being required for enlargement of the primary tumor, 
increased tumor vascularization also provides a metastatic path for dissemination 
to other areas of the body.   Metastatic disease is thus reliant on vascular routes, 
and increased tumor angiogenesis often correlates with poor patient outcomes in 
a variety of carcinomas.  Indeed studies have shown that microvessel counts 
from CRC patient tissues increased in concordance with tumor size, local 
invasion, and lymph node metastasis and is itself a prognostic factor [35,36]. 
Secreted angiogenic factors are often overexpressed by tumor cells and 
provide cues that affect endothelial cell proliferation, migration, and invasion.  
One of the most widely studied pro-angiogenic molecules is vascular endothelial 
growth factor (VEGF).  Increased expressed of VEGF has been observed in 
colorectal tumors as compared to normal tissue, and associated with increased 
tumor vessel density and poor patient prognosis [37,38] .  While VEGF may be 
the best studied regulator of angiogenesis, there are a number of other secreted 
molecules that also regulate this process, including transforming growth factor α 
(TGFα), epidermal growth factor (EGF), platelet derived growth factor (PDGF), 
and fibroblast growth factor (FGF) [39].  COX-2 has been linked to angiogenesis 
through production of some of these factors.  In vitro, expression of COX-2 in 
CACO-2 CRC cells induces autonomous production of both VEGF and FGF, and 
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non-autonomous increases in endothelial cell motility and invasion [40].  
Conversely, COX-2 null fibroblasts secrete less VEGF in culture as compared to 
wild-type cells [41].  In vivo, growth of Lewis lung carcinoma (LLC) cells as 
xenografts in COX-2 KO mice exhibit smaller tumor formation correlated with 
decreased tumor vascularization as compared to xenografts grown in wild-type 
mice [41].  Similarly, celecoxib treatment of LLC cells grown in wild-type mice 
also resulted in attenuated tumor formation [41].  Finally, celecoxib treatment in 
the rat corneal model of angiogenesis resulted in shorter, more interspersed 
capillary formation, indicating a block in angiogenesis [42,43].  Taken together, 
the blockage of COX-2 function, either genetically or pharmacologically, has 
been shown to reduce tumor formation, in part, due to a decrease in 
angiogenesis.     
Another important mediator of tumor biology that has been linked to COX-
2 and VEGF signaling is hypoxia inducible factor 1, alpha subunit (HIF1A). HIF1A 
is widely expressed across various cell types, and increased HIF1A expression 
has been observed in multiple cancers, including CRC [44].  HIF1-α is highly 
regulated by oxygen levels in the cell, and together with HIF1-β serves to 
regulate genes containing hypoxia response elements (HREs). HIF1-α has been 
reported to regulate over 60 genes important to cellular processes including 
angiogenesis, glucose metabolism, survival factors, and invasion factors [45,46].  
Both VEGF and COX-2 are included in the list of HIF1-α gene targets [47,48].  
Forced expression of HIF1A in HCT116 colon cancer cells results in increased 
xenograft tumor formation that is associated with an increase in VEGF levels and 
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tumor vascularization [49].  Kaidi et al identified several HREs in the COX-2 
promoter, and demonstrated that COX-2 mRNA is increased during hypoxia 
through binding of HIF1-α to the COX-2 promoter in colorectal cancer cells in 
vitro [48].  Further studies have shown that there is reciprocal regulation between 
COX-2, PGE2, and HIF1-α.  In vitro, treating HCT116 cells with PGE2  increases 
HIF1-α protein and subsequent VEGF mRNA, which was blocked with inhibitors 
of EP1, MEK-ERK, and PI3K-AKT [50].  Thus in vitro data suggests a 
complicated signaling interaction among COX-2, HIF1-α and angiogenic factors 
like VEGF.     
Summary 
As the third leading cause of cancer related morbidity and deaths, there is 
a need to find better targeted therapies for CRC.  Although a great deal is known 
about the contribution of inflammation and genetic alterations to disease 
progression, a detailed understanding of key regulatory pathways is needed for 
clinical translation of this knowledge.  There are complex interactions between 
inflammation, cyclooxygenase enzymes, angiogenesis, and HIF1-α that play a 
vital role in tumor formation and advancement.  The benefit of anti-inflammatory 
drugs has proven to be extremely effective in both CRC prevention and 
treatment.  However, like most drugs, unwanted complications of extended use 
of such drugs exist.  Non-selective anti-inflammatory drugs burden the gastric 
and intestinal compartments, while more selective inhibitors can pose severe 
cardiovascular risk, especially in certain populations.  In this context, we sought 
to understand the biological responses of tumors in vivo to the selective COX-2 
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drug, celecoxib.  Herein we describe changes in gene expression in human rectal 
tumors that occur in response to celecoxib treatment and characterize one such 
identified novel target. Through this work, we have a clearer understanding of the 
COX/HIF1-α/angiogenesis pathway.  
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CHAPTER II. 
CHARACTERIZATION OF GENE EXPRESSION CHANGES IN 
RESPONSE TO CELECOXIB TREATMENT IN VIVO, AND THE 
IDENTIFICATION OF FOUR JOINTED BOX 1. 
Introduction 
A large body of data indicates the role of inflammation in cancer formation 
and progression, including CRC.  COX-2 is a well-described target of 
inflammation, whose expression is increased in CRC and is associated with poor 
patient prognosis [4,6,12].  Non-steroidal anti-inflammatory drugs (NSAIDs), 
including the coxib series that specifically inhibit COX-2 activity, are very efficient 
in preventing both tumor formation and disease progression.  However, the use 
of COX-2-specific NSAIDs been associated with adverse cardiovascular side 
effects, including heart attack and stroke.  Aside from the effects of coxibs on 
inhibition of COX-2 activity and associated effects in vitro, little is known about 
actual biological responses to therapies in vivo.  Understanding biological 
responses in tumors that might be different from responses in other tissues may 
identify better targets for the treatment of CRC.  With this goal in mind we sought 
to identify novel therapeutic targets that are altered in response to celecoxib 
treatment in primary human rectal tumors in vivo.  Through this screen we have 
identified gene expression changes previously undescribed in colorectal tumor 
biology.  Importantly, we found a novel potentially COX-2 regulated gene, Four 
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jointed box 1, that was down-regulated after celecoxib treatment, and that 
contributes to tumor angiogenesis.   
Materials and Methods 
Ethics statement 
Human tissues used for microarray analysis were collected and annotated 
according to established protocols and approved by the appropriate Institutional 
Review Boards (IRB) at the Moffitt Cancer Center (MCC) and Vanderbilt 
University (VUMC) (GSE17536 and GSE17537).  Written informed consent was 
obtained from all patients prior to inclusion in the studies. De-identified human 
rectal tumor tissue for immunohistochemistry was obtained with VUMC IRB 
approval.  All murine experiments were approved by the Vanderbilt Institutional 
Animal Care and Use Committee and performed in accordance with the 
standards of the Association of Assessment and Accreditation of Laboratory 
Care (AAALAC).   
Analysis of human-expression profiling  
Tissue preparation, quality control, RNA isolation, and hybridization were 
performed as previously described [51]. The raw .CEL files of platform Affy 133 
plus 2 from MCC and VUMC were combined and pre-processed using the robust 
multi-array average (RMA) expression measure with quantile normalization 
method. The Bioconductor package Affy 
(http://www.bioconductor.org/packages/release/bioc/html/affy.html) was 
employed.  Affyprobeset 219522_at was used to compare gene expression 
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levels of FJX1 between different stages of colon cancer with Wilcoxon rank-sum 
test. Kaplan-Meier estimates for disease free and overall survival from 191 stage 
I-III colon cancer patients were generated using R software (http://www.r-
project.org). Patients were classified as FJX1 high and low expression groups 
based on a median expression value cut-off using probeset 219522_at and the 
log rank test was applied to determine significance. 
Celecoxib sub-group statistical analysis 
The celecoxib treatment protocol was previously described [10].  Raw 
gene expression data (.CEL files, Affymetrix 133 plus 2 array platform) from 16 
patient biopsies taken pre- and post- celecoxib treatment (32 tissue samples 
total), were preprocessed and normalized, as above, and expressed in log2 
format. The bioconductor limma package was employed for array data analysis 
(http://www.bioconductor.org/packages/release/bioc/html/limma.html).  A 
moderated paired t-test was used to select one hundred fifty-nine probes based 
on a cutoff p-value <0.01 (un-adjusted).  The 159 probes were next imported into 
Ingenuity Pathway Analysis (IPA®, www.ingenuity.com) and analyzed for 
network enrichment by mapping to the IPA global molecular network by 
knowledge-based connectivity. 
 RNA extraction and qRT-PCR 
RNA was extracted using the Qiagen RNeasy Kit (Qiagen) per 
manufacturer's instructions.  qRT-PCR reactions analyzing FJX1 in human 
tumors were performed using superscript III reverse transcriptase (Invitrogen), 
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SYBR Green (SA Biosciences) and analyzed on an iCycler (Bio-Rad, Inc.).  
Primers used :  FJX1:  5’-CGTGCTGGCACAGTAAAGAA-3’ and 5’-
TTCAAAGTTCTGGGAGGACG-3’ or 5’-AGCTGGTGGACCTAGTACAATGGA-3’ 
and 5’-ACTGCAGGCTGAAGAGGTTGCTTA-3’ (Integrated DNA technologies 
(IDT)); 18S (SAbiosciences).  Relative fold change of expression was calculated 
by 2-ΔCt.   
Immunohistochemistry 
Eleven de-identified formalin fixed and paraffin embedded human 
colorectal tumor tissues were obtained from the Vanderbilt Ingram Cancer Center 
Tissue Acquisition and Pathology Core.  Slides were sectioned at 5μm thickness 
and processed as described [52] except slides were heated in 10 mM sodium 
citrate, pH6.0 instead of in 100 mM Tris. Partially purified anti-FJX1 antibody 
(rabbit polyclonal, 209) was applied at a dilution of 1:2000 and incubated 
overnight at 4°C. Slides were washed, incubated in 1:500 goat anti-rabbit 
antibody for 30 min., washed and incubated in avidin biotin complex (Vector Labs 
Elite ABC kit) for 30 min and washed. Color was developed in 3, 3’ 
diaminobenzidine (Vector Labs) and nuclei were stained with Gill’s #3 
hematoxylin (Sigma).  Images were taken on an Axioskop 40 upright light 
microscope (Carl Zeiss, Inc.).   
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Results 
Gene expression responses in human rectal tumors treated with celecoxib 
Inhibition of COX-2 activity in colon cancer patients by the selective 
inhibitor celecoxib showed early promise in prevention of disease progression 
until clinical trials were suspended in light of new evidence that use of the agent 
was associated with a high incidence of cardiac arrests [24,53].  We wanted to 
identify downstream therapeutic targets of COX-2 in CRC that might be used to 
bypass side effects associated with selective COX-2 inhibitors. To accomplish 
this, we extracted RNA from paired rectal tumor biopsies taken before and after 5 
day treatment with celecoxib (400mg taken twice daily; n=32 total biopsies; 16 
pre and 16 post-treatment) [10].  Efficacy of COX-2 inhibition was confirmed by 
demonstrating a significant decrease in patient urinary PGE-M levels post-
treatment [10].  Differential microarray analysis revealed 159 expression 
elements mapping to 136 human genes that were significantly altered after 
celecoxib treatment (Raw P value <0.01, Tables 1 and 2).  We conducted 
pathway enrichment analysis on the 136 known genes using a commercially 
available knowledge-based database. The collection of genes differentially 
expressed in the tumors before and after celecoxib treatment was significantly 
enriched in a network known to regulate hematological system development and 
function, cell death, and cellular growth and proliferation, (P < 0.005, Table 3).  
The analysis was supported by the presence of central nodes (defined as 
genes/complexes having at least four direct or indirect interactions with celecoxib 
regulated genes) within the network that are known regulators of inflammation 
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and cancer progression. These nodes included nuclear factor kappa B (NFkB), 
interleukin 1 (IL-1), and p38 mitogen-activated protein kinase (p38 MAPK).   
FJX1 mRNA and protein expression is increased in CRC and is associated with 
poor patient prognosis. 
One of the genes that exhibited decreased expression after celecoxib 
treatment and was present in the top network was four jointed box one (FJX1), a 
unique gene with no known function in tumor biology.   In silico analysis of FJX1 
mRNA expression in clinically annotated samples collected at Vanderbilt Medical 
Center (VUMC) and the H. Lee Moffitt Cancer Center (MCC) (Clinical 
information, Table 4) revealed that FJX1 mRNA is significantly increased across 
all stages of CRC as compared to normal colorectal tissue and colorectal 
adenomas (Figure 3A, stage 1, P < 0.02; stages 2, 3 and 4, P < 0.00001).  There 
was also a significant difference between FJX1 mRNA expression when stages 1 
and 2 were compared to stages 3 and 4 (P < 0.02), indicating that FJX1 
expression is further increased in more advanced stages of colon cancer. 
To validate our microarray findings, we conducted quantitative RT-PCR 
analysis for FJX1 mRNA and found FJX1 mRNA expression levels were between 
five- and seventy-fold higher in colon cancer tissues than in normal adjacent 
tissue from the same patient (Figure 3B, one-sided t-test P < 0.0004).  Next, we 
examined if FJX1 expression correlated with patient survival in a subset of stage 
I-III CRC patient samples from the VUMC and MCC colorectal cancer gene 
expression array datasets (n=191).  Samples were stratified into two groups 
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based on lower (n=95) and higher (n=96) than median expression of FJX1 and 
the relationship between sample FJX1 mRNA expression and patient survival 
was determined by Kaplan-Meier analysis.  In this retrospective analysis, patients 
with higher than median FJX1 mRNA expression had significantly worse disease-
free and overall survival as compared to those with lower FJX1 expression 
(Figure 3, C and D).  These data show that FJX1 mRNA expression is increased 
in human colorectal cancer and that higher expression in tumors is associated 
with worse patient outcomes.  
By immunohistochemical analysis of colorectal tumors and adjacent 
normal tissues, we found that FJX1 was expressed in eight of eleven tumors at 
moderate to high levels that varied across the tumor in most cases, while little to 
no FJX1 was detected in normal mucosa (Figure 4 and data not shown). In more 
differentiated tumors, FJX1 was primarily located in apical cytoplasm of the 
epithelial cells but was also found in basal cytoplasm in less well differentiated 
tumors and those with greater intensity of FJX1 immunoreactivity.  These data 
support that FJX1 protein levels are elevated in CRC tissue as compared to 
normal in concordance with elevated mRNA levels observed via microarray and 
qPCR data.     
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TABLE 3:  The top network from Ingenuity Pathway analysis of 
celecoxib regulated genes includes known inflammatory targets and FJX1.  
Gene symbol and name of the genes found in the top network after IPA analysis 
of celecoxib regulated genes.   * Indicates central nodes. 
Gene 
Symbol Gene Name 
BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) 
COL24A1 collagen, type XXIV, alpha 1 
COL5A1 collagen, type V, alpha 1 
CSNK2A1 casein kinase 2, alpha 1 polypeptide 
CXCL6 chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2) 
ENO1 enolase 1, (alpha) 
ENPP1 ectonucleotide pyrophosphatase/phosphodiesterase 1 
ERCC1 
excision repair cross-complementing rodent repair deficiency, 
complementation group 1 (includes overlapping antisense sequence) 
FJX1 four jointed box 1 (Drosophila) 
FKBP10 FK506 binding protein 10, 65 kDa 
FKBP1A FK506 binding protein 1A, 12kDa 
FRZB frizzled-related protein 
GJB2 gap junction protein, beta 2, 26kDa 
HYOU1 hypoxia up-regulated 1 
ITCH itchy E3 ubiquitin protein ligase homolog (mouse) 
JUN jun proto-oncogene 
MAP2K5 mitogen-activated protein kinase kinase 5 
OSBPL2 oxysterol binding protein-like 2 
PCBP2 poly(rC) binding protein 2 
PPME1 protein phosphatase methylesterase 1 
UNC5B unc-5 homolog B (C. elegans) 
WNT5A wingless-type MMTV integration site family, member 5A 
YPEL1 yippee-like 1 (Drosophila) 
CN* Calcineurin proteins 
hCG* Chorionic Gonadotropin 
IL1* Interleukin 1 
LDL* Beta Lipoprotein, Low density lipoprotein, Oxidised LDL 
NFkB* nuclear factor kappa beta 
P38 MAPK* P38 Mitogen-activated protein kinase 
PDGF BB* Platelet-Derived Growth Factor 
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Table 4.  Patient Sample Demographics, Pathology and Clinical Follow-up 
data.  The numbers of patient samples used in this study are broken down by 
demographic, pathologic and clinical follow up characteristics.  The celecoxib 
treatment cohort consists of 16 matched pairs of samples (pre-treatment and 
post-treatment) and was used to identify FJX1 as a celecoxib responsive gene 
element. VUMC and MCC are publicly available datasets of fresh tumor biopsies 
from newly diagnosed CRC cases which had received no prior treatment and 
were used for establishing the association between FJX1 expression and AJCC 
stage and clinical outcome.  Pre-treatment celecoxib samples were included in 
the VUMC dataset.   The proportion of patient samples correlated with each 
demographic, pathologic and clinical characteristic is given in parenthesis.  N/A = 
Not Applicable. 
 
 Celecoxib 
Treatment   VUMC + MCC 
Total number of 
patients  N=16    N=250  
Mean age  +/- SD   
 60.0 +/- 
10.00     65.0 +/- 13.26   
Male  8 (50.0%)   132 (52.8%)   
Stage I   4 (25.0%)    33 (13.2%)   
Stage II  4 (25.0%)   76 (30.4%)   
Stage III     8 (50.0%)    82 (32.8%)   
Stage IV  0 (0.0%)    59 (23.6%)   
Median follow-up 
(months)   N/A 42.7 
Deaths   N/A  84 (33.6%) 
Caucasian     14 (88.0%)   215 (86.0%) 
African-American   2 (12.0%)    15 (6.0%)   
Unknown/Other    0  20 (8.0%)   
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Figure 3.  FJX1 mRNA expression is upregulated in CRC and is associated with 
poor patient prognosis.  (A)  Normalized microarray-based signal intensity from FJX1- 
specific mRNA across 250 carcinoma and 16 normal CRC tissues.  Significance was 
determined by Wilcoxon rank sum test as compared to normal.  *P < 0.02; **P < 
0.00001.  N = normal; S1, S2, S3, and S4 = stage 1, 2, 3, and 4 respectively; all = 
stages 1-4.  (B)  Log2 fold change of FJX1 specific mRNA in tumor tissue as compared 
to matched normal adjacent tissue as determined by qPCR.  Datapoints represent the 
mean calculated values of four technical replicates/patient.  Significance was determined 
using a one sample t-test.  (C/D) Kaplan-Meier estimates relative to (C) disease free 
survival (c index 0.75) and to (D) overall survival (c index 0.57) for CRC patients (stages 
1-3, n=191) separated into lower than median (solid line, n=95) and higher than median 
(dashed line, n=96) FJX1 mRNA expression groups.  Significance was determined by 
Log-rank test. 
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Figure 4.  FJX1 protein expression is elevated in rectal tumors.  (A)  FJX1 
(brown) is detected at a high level in apical cytoplasm of a well-differentiated 
rectal tumor.  (B)  Nearby adjacent normal epithelium is negative for FJX1.  (C) A 
rectal tumor with low to moderate expression has FJX1 present mostly apically 
but occasionally basally.  (D)  In a rectal tumor showing loss of cellular polarity, 
FJX1 is located throughout the cytoplasm of most cells.  Nuclei are 
counterstained in blue.  Arrows indicate apical FJX1 localization; arrowheads 
indicate basal FJX1 localization.  Scale bar = 50 µm. 
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Discussion 
FJX1 expression is increased in CRC and associated with poor patient prognosis 
 NSAIDs, which inhibit COX activity, are one of the most widely used 
classes of drugs, and numerous studies have shown their efficacy in limiting both 
tumor formation and progression.  COX-2 selective NSAIDs were developed in 
the hopes of bypassing gastrointestinal side effects commonly associated with 
the extended use of non-selective NSAIDs.  However, the discovery that 
selective COX-2 inhibitors pose severe cardiovascular risk has driven the field to 
look for alternative solutions.  To address this problem we performed microarray 
analysis on human rectal tumors before and after treatment with the selective 
COX-2 inhibitor, celecoxib.  Pathway analysis of the genes altered after 
treatment revealed a network involved in regulation of hematological system 
development and function, cell death, and cellular growth and proliferation.  
Included in this network were genes that are known regulators of inflammation 
and cancer progression, including genes encoding nuclear factor kappa B 
(NFkB), interleukin 1 (IL-1), and p38 mitogen-activated protein kinase (p38 
MAPK).  To our knowledge, this is the first experiment analyzing the biological 
mechanism of COX-2 inhibition in actual human tumors in vivo.  These gene 
changes provide a basis for further exploration not only into relevant alternative 
therapeutic targets in vivo, but also to the alterations of genes potentially involved 
in cardiovascular homeostasis that are altered upon COX-2 inhibition.   
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Of those genes present in the top network was FJX1, a unique gene that 
was previously uncharacterized in cancer biology.  In a large CRC microarray 
dataset, we found FJX1 mRNA levels increased in concordance with the 
progression from normal tissue through later stages of cancer.  In freshly 
prepared samples we confirmed that FJX1 mRNA and protein was increased in 
tumor tissue compared to normal adjacent.  The association between high FJX1 
expression and poor patient prognosis supports the hypothesis that FJX1 is an 
oncogene in CRC.  Further, the identification of FJX1 as a putative COX-2 
regulated gene suggests it could be a relevant therapeutic target.   A biological 
basis for these observations will be further discussed in the next chapters. 
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CHAPTER III. 
DEVELOPMENT OF FJX1 SPECIFIC VECTORS, ANTIBODIES AND 
CHARACTERIZATION OF RECOMBINANT FJX1 IN VITRO.   
Introduction 
 We identified Four jointed box 1 (FJX1) as a candidate oncogene in CRC 
as it was inhibited in rectal tumors in response to celecoxib treatment, and its 
expression is increased in CRC compared to normal tissue.  FJX1 is the human 
ortholog of four jointed (fj) in Drosophila.  In the fly, fj is a Golgi-associated kinase 
that contributes to planar cell polarity (PCP), limb development, and wing 
development [54-58].  Wingless, Jak/Stat, Notch, and Fat signaling have been 
shown to influence fj expression, and fj in turn can regulate expression of notch 
ligands, wingless, and fat [54,58,59].  Phenotypes observed upon abnormal 
expression of fj have been largely attributed to the ability of fj to phosphorylate 
specific cadherin residues on two large atypical cadherins, dachsous (ds) and fat 
(ft) [57,60,61].  Initial experiments identified amino acids 490-492 (DNE) as being 
required for fj kinase activity, while later experiments demonstrated mutation of 
amino acid 490 (D) alone was sufficient to lose kinase function [57,61].  
Together, ft, ds, and fj influence growth through the Hippo-warts pathway, and  
PCP through a pathway which likely lies in parallel to frizzled/starry night 
signaling [62].   
Mammalian FJX1 has been far less studied that fj.  Murine FJX1 is highly 
expressed throughout the central nervous system and in several epithelial 
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structures during development, including the gut [63,64].  FJX1 knockout mice 
are viable and fertile. However, they display a neuronal defect characterized by 
an increase in dendrite length or a decrease in dendrite arborization [65].  One 
report has suggested that FJX1 is influenced by Notch signaling, citing the 
observation of increased FJX1 promoter activity after transfection with Notch1, 2, 
or 3 [63] but we have failed to reproduced these results in our laboratory (data 
not shown). 
As noted above, Drosophila fj is a kinase that phosphorylates specific 
cadherin residues on the large atypical cadherins ft and ds [57,61].  Sequence 
alignment of fj and various species, including mouse, rat, and human show 
complete conservation of all three residues (Figure 5).  Further, McNeill and 
colleagues have provided some data that the ft/ds/fj cassette may be conserved 
in mammals [66].  Sequence analysis of the mammalian ft and ds homologues 
show highest conservation between Fat4 and ft, and between Dachsous (Dchs1) 
and ds [66].   Upon genetic deletion of Fat4 various PCP defects are observed, 
as well as an increase in FJX1 mRNA [66] .  Further, the combined deletion of 
FJX1 and Fat4 has an additive cystic kidney phenotype that is more severe than 
defects observed in either single mutant animal [66].   
At the onset of these studies, there were no commercially available FJX1 
expression vectors or FJX1-specific antibodies.  Here we describe our 
recombinant versions of FJX1, Fat4, and Dchs1 and their transient or stable 
expression in various cell lines.  We also describe the generation of multiple 
FJX1 specific antibodies and their characterization in enzyme-linked 
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immunoassays (ELISA), immunoblotting, and immunofluorescence.    
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Human      309   LFSLQWDPRVMQRATSNLHRG-PGGALVFLDNEAGLVHGYRV   349 
Mouse         309   LFSLQWDPRVMHRATSNLHRG-PGGALVFLDNEAGLVHGYRV   349 
Rat              419   LFSLQWDPRVMHRATSNLHRG-PGGALVFLDNEAGLVHGYRV   459 
Drosophila  460    LYNFQWNADIMAAPAHNLARQSASQLLVFLDNESGLLHGYRL   501 
 
Figure 5.  Sequence alignment of human, mouse, and rat FJX1 with 
Drosophila fj.  Residues identified in Drosophila as being essential for kinase 
activity, which are conserved in mammals, are highlighted in yellow. 
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Materials and Methods 
Plasmid construction and generation of stable lines. 
Full length human FJX1 cDNA (hFJX1) was obtained from the Vanderbilt 
University Genome Science Shared Resource (clone id 5482332).  hFJX1 was 
MYC tagged (hFJX1MYC) at the C terminus using the primers 5’-
GATCGAATTCGGGAGCATGGGCAGGAGGATG-3’ and 5’-
CTAATGCAGATCCTCTTCTGAGATGAGTTTTTGTTCAGTCCCAGACCGGCGG
CCGTAC-3’ , cloned into the EcoRV site of pIRES-EGFP (Clontech), and 
subcloned into the EcoRI site of pcDNA3.1 zeo (Invitrogen).  HEK293T cells 
were transfected with pcDNA3.1 or pcDNA3.1 hFJX1MYC using Effectene 
(Qiagen) per manufacturer’s instructions and stable polyclonal populations 
HEK293TPC and HEK293TPCFJX1 were selected using 200 ug/mL zeocin 
(Invitrogen).  hFJX1 cDNA was FLAG tagged (hFJX1FLAG) at the C terminus by 
PCR amplification with the primers 5’- 
GATCGAATTCGGGAGCATGGGCAGGAGGATG-3’ and 5’-
GATCCTCGAGAGTCCCAGACCGGCGGCCGTAC-3’ and cloned into the 
EcoR1 and Xho1 sites of pCMV4a (Stratagene).  hFJX1 cDNA was also mutated 
at amino acids 338 (aspartate, D) and 340 (glutamate, E) to alanine and FLAG 
tagged at the C terminus (hFJX1DEFLAG).  Two separate PCR reactions were 
performed on hFJX1 cDNA using the primers: A) 5’-TAT ACT CGA GAG TCC 
CAG ACC GGC GGC CG-3’ and 5'-CTG GTC TTT CTG GCC AAT GCG GCG 
GGC TTG GTG-3' or B) 5’: 5’-GAT CGA ATT CGG GAG CAT GGG CAG GAG 
GAT G-3 and 5'-CAC CAA GCC CGC CGC ATT GGC CAG AAA GAC CAG-3'.  
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The products of reactions A and B were then set up in another PCR reaction 
using primers 5’-GAT CGA ATT CGG GAG CAT GGG CAG GAG GAT G-3’ and 
5’-TAT ACT CGA GAG TCC CAG ACC GGC GGC CG-3’ to engineer  5’ EcoRI 
and 3’ XhoI sites.  Purified PCR products were cloned into the EcoRI and XhoI 
sites of pCMV4a.  hFJX1MYC, hFJX1FLAG, and hFJX1DEFLAG were 
subcloned into the EcoRI site, EcoR1/Sgf1 sites, and EcoR1/Sgf1 sites 
respectively of LZRS-MS-GFP (gift of Dr. Al Reynolds).  HEK293T Phoenix cells 
were transfected with LZRS-MS-GFP, LZRS-MS-GFP hFJX1MYC, LZRS-MS-
GFP hFJX1FLAG or LZRS-MS-GFP hFJX1DEFLAG using effectene.  At 48 and 
72hrs post transfection, viral supernatant containing 5 ug/mL hexadimethrine 
bromide (Sigma Aldrich) was filtered (0.45 micron) and added to target cells 
(LZRS-MS-GFP, LZRS-MS-GFP hFJX1MYC to CACO2, KM12C, SW480; LZRS-
MS-GFP, LZRS-MS-GFP hFJX1FLAG, or LZRS-MS-GFP hFJX1DEFLAG to 
SW480, HMEC-1 and HEK293T) for 4-8hrs.  Stable polyclonal populations were 
obtained via flow cytometry.  Nucleotides 1-1170 of Dachsous1 (represents 
cadherins 1-3, amino acids 1-390) were amplified from HEK293T RNA using the 
primer 5’ CGT ACT CGA GCT GGG CAC TTA TAC TGG CAG C 3’, purified, 
then re-amplified with 5’- GCA TGA ATT CAT GCA GAA GGA GCT GGG CAT 
TG -3’ and 5’- CGT ACT CGA GCA CAG AGA TGC GAG CAA CGA GC- 3’ to 
engineer EcoR1 and XhoI sites at the 5’ and 3’ termini respectively.  The purified 
PCR product was cloned into the EcoR1 and XhoI sites of pCMV4a to create a C 
terminal FLAG tag, hDachsousFLAG.  Nucleotides 1-1075 of FAT4 (represents 
cadherins 1-3, amino acids 1-358) were amplified from HEK293T RNA using the 
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primer 5’ CGT ACT CGA GGG ACC GGG TAG AAG ACA GGG C-3’, purified, 
then re-amplified with GCA TGA GCT CAT GGA CTT AGC ACC AGA CAG G-3’ 
and 5’-CGT ACT CGA GGG AAG TAG CGG AAC TTC ACT ACC G-3’ to 
engineer SacI and XhoI sites at the 5’ and 3’ termini respectively.  The purified 
PCR product was cloned into the SalI site of pCMV4C to create a C terminal 
FLAG tag, hFAT4FLAG.   
Cell culture 
HEK293T, HEK293T Phoenix, HCT116, HCT8, CACO2, LS174T, HCA7 
and SW480 (ATCC) were cultured in RPMI 1640 (Gibco) with 10% FBS (Atlanta 
Biologicals), 100U/mL pen/strep (Gibco), and 100U/mL L-glutamine (Gibco) at 37 
oC with 5% CO2.  HMEC-1 cells (F. Candl, Center for Disease Control) were 
cultured in MCDB131 (Gibco), supplemented with 10% FBS, 10ng/mL epidermal 
growth factor (Becton-Dickson), 100U/mL L-glutamine (Gibco), and 1μm/mL 
hydrocortisone (Sigma Chemical). KM12C (Gift of Dr. Isiah Fidler) [67] were 
cultured in MEM (Gibco) with 10% FBS (Atlanta Biologicals), 100U/mL pen/strep 
(Gibco), 100U/mL L-glutamine (Gibco), sodium pyruvate (Gibco), non-essential 
amino acids (Gibco) and MEM vitamins (Gibco). YAMC cells (Gift of Bob 
Whitehead) were cultured in RPMI supplemented with 5% FBS (Atlanta 
Biologicals), 100U/mL pen/strep (Gibco), 100U/mL L-glutamine (Gibco), ITS 
(Gibco) and 5U/mL gamma interferon (Roche) at 33 oC with 5% CO2.   
Immunological detection methods and reagents 
Generation of FJX1-specific antibodies:  
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FJX1 peptide antibody (Covance, rabbit peptide).  The peptide sequence Ac-
CVFRERTARRVLE-amide (corresponding to amino acids 364-376) was used for 
immunization of 4 rabbits (156, 157, 158, 159), in collaboration with Covance.  
Antibody from 158 serum was affinity purified using an affinity purification column 
made from the immunization peptide (Thermo Scientific, 44999) 
FJX1 recombinant protein antibody (Covance rabbit polyclonal).  Nucleotides 
352-1314 of human FJX1 were amplified by PCR (5’-
GATCGAATTCGTGCACGGGGGCGTCTTCTGG-3’ and 5’-
GATCGTCGACCTCCCGGTGACACTAAGTCCCAGAC-3’), cloned into the 
EcoRI and SalI sites of pET44A (Novagen) and transformed into BL21-codon 
plus (DE3)-RIL (Stratagene).  Transformed cells were treated with isopropyl β-D-
1-thiogalactopyranoside to produce recombinant HIS tagged FJX1 protein.  
Recombinant HIS-FJX1 was purified using Ni-NTA beads (Invitrogen) under 
denaturing conditions, eluted with 2M pH = 3.0 glycine buffer, and dialyzed 
before immunization in rabbits (208, 209) in collaboration with Covance, Inc.   
208 and 209 sera have been effective in western blotting, ELISA and 
immunofluorescence.  Partial purification of 209 serum using G protein coupled 
column (Pierce) enabled its use in immunohistochemistry.    
ELISA:  Sub-confluent cell lines were cultured in serum-free conditioned media 
for 24 hours before collection (5mL/60cm2).  Conditioned media was spun at 300 
x g for five minutes to pellet debris, and then transferred to a fresh tube.  100uL 
of conditioned media/well of a 96 well plate (COSTAR 3590) was incubated 
overnight at 4oC.   Plates were washed four times with PBST (PBS+1.0% 
34 
 
TWEEN).  Plates were blocked with 5% milk-PBST for one hour at room 
temperature and FJX1 antibody (208 or 209) diluted 1:1000 – 1:5000 in 5% milk 
was incubated overnight at 4oC.  Plates were washed four times with PBST.  
Anti-rabbit secondary (Jackson Immunoresearch) was diluted 1:2500 in 5% milk-
PBST and incubated for 30 minutes at room temperature.  Plates were washed 
four times with PBST.  Reagent A and B (R and D systems, DY999) were mixed 
1:1 and 100uL was added per well for 20 min at room temperature.  The reaction 
was terminated by adding 50uL of 2NH2SO4 and plates were read at 450 nm with 
the reference set at 562 nm.   
Immunoblotting:  Cells were lysed in radio-immunoprecipitation assay (RIPA) 
buffer (150Mm sodium chloride, 1% Igepal, 0.5% sodium deoxycholate, 1% 
sodium dodecyl sulfate, 50mM Tris-Cl) supplemented with aprotinin, leupeptin, 
sodium orthovanadate, sodium fluoride, and phenylmethylsulfonyl fluoride before 
resolution by SDS-polyacrylamide gel electrophoresis (SDS-PAGE).  FJX1 
peptide antibody:  Affinity purified 159 was diluted 1:1000 in 5% milk-PBST 
overnight at 4oC.  FJX1 polyclonal antibodies:  Whole serum from 208 and 209 
was diluted 1:3000 in 5% milk-PBST overnight at 4oC.  Commercial antibodies:  
β-actin (Sigma Chemical, 5% milk-PBST 1:10,000), MYC 9E10 (Vanderbilt 
Monoclonal Antibody Core, mouse monoclonal, 5% milk-PBST 1:1000); Abcam 
FJX1 (5% milk-PBST 1:1000); Sigma FJX1 (5% milk-PBST 1:1000).  Anti-rabbit 
HRP and Anti-mouse HRP were diluted 1:5000 in 5% milk-PBST and incubated 
for 30 minutes at room temperature.  For de-glycosylation and de-
phosphorylation reactions, cells were lysed in RIPA without additional inhibitors.   
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Peptide N-Glycosidase F and Antarctic phosphatase (New England Biolabs) 
were used according to manufacturer’s protocols.      
Immunofluorescence: Cells were fixed in 4% paraformaldehyde for 15 minutes, 
blocked with 3% BSA-PBS , and incubated with primary antibodies:  MYC 9E10 
(Vanderbilt Monoclonal Antibody Core, 1:100); GM130 (BD Biosciences, 1:300); 
FJX1 (Abcam, 1:200).  Secondary antibodies were: anti-rabbit DyLight 488 and 
anti-mouse DyLight 594 (Jackson ImmunoResearch Laboratories, 1:100).  Nuclei 
were stained with 4',6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich).  Images 
were captured on an Axioplan 2 upright fluorescent microscope (Carl Zeiss).   
Cell proliferation 
Cell proliferation was determined from at least 3 biological replicates 
performed in triplicate at each time point using the Quick Cell Proliferation Assay 
Kit (Biovision) per the manufacturer’s instructions.  
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Results 
Characterization of FJX1 specific antibodies.   
Since there is a paucity of published information on FJX1 function in 
mammalian systems, we determined the cellular and biological effects of FJX1 
expression in human cell lines.  In collaboration with Covance, we derived 6 
rabbit polyclonal antibodies; 4 from immunization with a peptide (156-159) and 2 
from immunization with recombinant human FJX1 (208 and 209).  We stably 
expressed a C-terminally MYC tagged version of human FJX1 in human 
embryonic kidney cells, HEK93T, (HEK293TPCFJX1) for use in characterization of 
our antibodies as well as the vector alone for use as a control (HEK293TPC).  
Based on amino acid composition, the full-length human FJX1 protein (protein 
ID, NP_055159) has a predicted size of 48.5 kDa.  There is a potential signal 
sequence cleavage site after amino acid 24, that would predict a processed form 
of approximately 46 kDa (Figure 6A). In whole cell lysates from MYC-tagged 
FJX1 transfected HEK293TPCFJX1 cells, we consistently detect four FJX1 specific 
protein bands of approximately 48kDa, 46kDa, 40kDa, and 37 kDa sizes using 
the 208 polyclonal FJX1 antibody (Figure 6B, lane 2) and these bands matched 
the bands recognized by the commercially available anti-MYC antibody (Figure 
6C, lane 2).  Conditioned media from HEK293TPCFJX1 cells also contained 40kDa 
and 37 kDa FJX1-specific bands (Figure 6, B and C, lane 4) which is consistent 
with observations that both D. melanogaster four-jointed (FJ) and M. musculus 
FJX1 proteins are secreted [59,63]. 
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Figure 6. Stably expressed recombinant MYC-tagged FJX1 increases FJX1 
protein.  (A)  Schematic diagram of human FJX1 protein, with N-terminus (NH2) 
and C-terminus (CO2H) indicated.  SS indicates predicted signal sequence site 
after amino acid 24.    Approximate locations of predicted phosphorylation (P), N-
linked (N) and O-linked (O) glycosylation sites are shown.  Antigenic region (solid 
line, amino acids 118-437) used to generate recombinant FJX1 sequence is 
underlined.  (B, C)  Matched immunoblots of HEK293T whole cell lysate (lanes 1, 
2) or conditioned media (lanes 3, 4) stably expressing vector (lanes 1,3) or MYC-
tagged FJX1 (lanes 2,4) probed with  (B) Anti FJX1 or (C) Anti MYC.  β-actin 
served as the loading control.   
 
38 
 
Figure 7. FJX1 antibodies in immunoblotting.  For all panels lane 1 = 
HEK293TVEC whole cell lysate, 2 = HEK293TPCFJX1 whole cell lysate, 3 = 
HEK293TVEC conditioned media, and 4 = HEK293TPCFJX1 conditioned media.  
Immunoblots were probed with FJX1 antibodies as notes.  β-actin served as the 
loading control. 
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Similar to the polyclonal 208 antibody, the polyclonal 209 antibody 
detected the same bands in HEK293TPCFJX1 whole cell lysate and conditioned 
media, while the peptide antibodies only recognized secreted FJX1 (Figure 7 and 
data not shown).  More recently, several commercially available FJX1 antibodies 
were developed, and we tested one from Abcam and one from Sigma.  
Interestingly, the Abcam antibody only detected intracellular FJX1, and neither 
the Abcam nor the Sigma antibodies detected secreted FJX1 (Figure 7).   
Both polyclonal FJX1 antibodies (208 and 209) were able to detect 
secreted FJX1 from HEK293TPCFJX1 conditioned media in an ELISA (Figure 8).  
The increase in signal intensity nicely correlated with the amount of conditioned 
media (Figure 8).  Serum from animal 208 gave the best signal to noise ratio, and 
was used for subsequent experiments.  
Finally, we tested the ability of the polyclonal antibodies in 
immunofluorescence.  Patterns of FJX1 expression in the HEK293TPCFJX1 cells 
were similar using 208, 209, MYC and Abcam-FJX1 antibodies (Figure 9).  The 
Abcam FJX1 antibody gave the most robust signal.  We confirmed the specificity 
of FJX1 staining by showing co-localization with MYC staining in HEK293TPCFJX1 
cells (Figure 10, panels i-iii).   
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Figure 8.  FJX1 antibodies detect secreted recombinant FJX1 in 
ELISA.  Absorbance representing detection of secreted FJX1 in conditioned 
media from vector (VEC) or FJX1 MYC (FJX1) stably transduced HEK293T cells 
using antibodies from rabbits 208 (A) and 209 (B).    
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Figure 9.  FJX1 antibodies in immunofluorescence.   Representative FJX1 staining in 
HEK293TPCFJX1 cells using the following antibodies:  (A) MYC (B) Abcam FJX1 (C) 208 
pre bleed (D) 208 bleed 1 (E) 208 bleed 2 (F) 209 pre bleed (G) 209 bleed 1 (H) 209 
bleed 2.  Pre-bleeds (animal bleeds before antigen immunization, C and F) served as 
negative controls.   
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Recombinant FJX1 localizes to the Golgi apparatus and is glycosylated and 
phosphorylated in both the cellular and the secreted form. 
Studies by Strutt and colleagues have shown that D. melanogaster fj 
protein localizes to the Golgi apparatus [56].  Using the Abcam FJX1 antibody to 
track the intracellular pool of FJX1 in HEK293TPCFJX1 we found it co-localized with 
the Golgi marker GM130 (Figure 10, panels iv-vi).  Based upon amino acid 
sequence, various post-translational modifications are predicted for FJX1 protein, 
including two putative N-glycosylation (amino acids 248 and 277), one O-
glycosylation (amino acid 53), and thirteen potential phosphorylation sites (Figure 
6A).  It was previously reported that the majority of exogenously expressed 
mouse Fjx1 in HEK293T cells is a secreted protein that is sensitive to digestion 
with endoglycosidase H [63].  We extended this analysis by treating whole cell 
lysate and conditioned media from HEK293TPCFJX1 cells with peptide N-
glycosidase F (PNGaseF), which cleaves all polysaccharide moieties; and 
antarctic phosphatase, which removes phosphorylation groups.  Treatment with 
PNGaseF resulted in a relatively uniform increase in gel electrophoresis mobility,  
corresponding to an approximate 5kDa decrease in size, with the upper double 
band collapsing into a single species (46-48kDa to 41kDa; 40kDa to 35kDa; 
37kDa to 32kDa) suggesting that all forms of recombinant, MYC-tagged FJX1 
are N-glycosylated (Figure 10, B and C, lane 1 vs. lane 3).  Phosphatase 
treatment alone failed to significantly alter mobility of FJX1, possibly due to 
masking of any subtle shift by the larger effect of protein glycosylation (Figure 10, 
B and C, lane 1 vs. lane 2).  Treatment of lysates and conditioned media with 
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both PNGase F and phosphatase resulted in the 40kDa and 37 kDa bands 
collapsing into one band, suggesting that FJX1 is phosphorylated (Figure 10, B 
and C, lane 1 vs. lane 4).  Thus, recombinant MYC-tagged FJX1 behaves 
similarly to recombinant forms of the protein that have been described in both D. 
melanogaster and in M. musculus. 
After determining the accuracy of the FJX1 antibodies we next screened 
various cell lines for endogenous FJX1 expression.  Surprisingly, we failed to 
detect secreted endogenous FJX1 in either normal (HEK293T, YAMC, HMEC-1, 
HUVEC, MCF10A, RAW264.7, MCT, HT-22) or cancerous lines (SW480, 
SW620, HT29, HCT116, HCA7, KM12C, HCT8, DKO1, DLD1, MCF7, 
MDMB468, CAD, HL60, BXPC3, PANC1) (Figure 11 and 12 and data not 
shown), even when conditioned media was concentrated at least 30 fold (Figure 
11C).  Conversely, we were able to detect endogenous FJX1 in conditioned 
media from primary rat hippocampal neurons by both ELISA (Figure 11, A and B) 
and immunoblot (Figure 12). We did occasionally observe bands that migrated 
similarly to the smaller secreted forms of recombinant FJX1 in whole cell lysate 
from some CRC cell lines (Figure 12).  However these bands were very faint and 
RNA levels as determined by qPCR were very low (data not shown).  Further, 
although we confirmed FJX1 specific siRNA inhibited FJX1 at the mRNA level, 
we observed no changes in FJX1 protein banding pattern in whole cell lysates in 
one such cell line, SW480 (Figure 13 and data not shown).    
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Figure 10.  Recombinant FJX1 is glycosylated, phosphorylated, and 
localizes to the Golgi apparatus in HEK293T cells.  (A) Representative 
fluorescent images of HEK293T FJX1 cells dual stained for FJX1 (i, green) and 
MYC (ii, red) or FJX1 (iv, green) and the Golgi marker, GM130 (v, red).  Nuclei 
were stained with DAPI (blue).  Respective merged images are shown (iii, vi).  
Scale bar = 100 mm. FJX1-specific immunoblots using (B) whole cell lysate 
(WCL) or (C) conditioned media (CM) from HEK293T FJX1 cells with (+) and 
without (-) treatment with PNGaseF and/or antarctic phosphatase.   
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Figure 11.  FJX1 ELISA detects recombinant human FJX1 and endogenous 
rat FJX1.  (A-C).  Absorbance representing FJX1 specific signal in conditioned 
media from cell cultures as labeled.  Each data point represents a technical 
replicate.  Samples in (C) were concentrated ~30X. 
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Figure 12. Endogenous and recombinant expression of FJX1 in various cell 
lines.  Representative FJX1 protein immunoblots of conditioned media (CM) or 
whole cell lysate (WCL) from various cell cultures.  Note, all WCL were run on 
the same gel but cropped for ordering purposes.  VEC = vector and FJX1 = FJX1 
stable transduction respectively.  Anti-β-actin served as loading controls for WCL.   
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Because FJX1 expression was lost when CRC cells were established as 
cell lines, we used expression vectors to test the biological function of FJX1 in 
cancerous cells. We expressed the C-terminal MYC-tagged version of human 
FJX1 in the CRC lines SW480, KM12C, and CACO2.  Similar to what we 
observed in the HEK293TPCFJX1 cells, SW480FJX1MYC whole cell lysates exhibited 
FJX1-specific bands of approximately 46kDa, 40kDa, and 37kDa, with additional 
bands migrating at 80kDa and 75kDa; again proteins corresponding to the 
smallest two peptides were secreted (Figure13, A and B).  All of these forms 
detected in SW480FJX1MYC whole cell lysate and conditioned media were ablated 
upon treatment with siRNA specific to FJX1.  Since no alteration in banding 
pattern was observed in SW480VEC whole cell lysate after FJX1 siRNA treatment, 
we conclude that endogenous levels of FJX1 are either absent, or low enough to 
preclude detection by immunoblotting in these cells.  Expression of FJX1 protein 
in both whole cell lysate and conditioned media from CACO2FJX1MYC and  
KM12CFJX1MYC was also confirmed (Figure 14).  Estimations of cellular 
proliferation in the presence or absence of serum showed no significant 
difference between vector and MYC-tagged FJX1-transduced cell lines in vitro 
(Figure 15, A and B, and data not shown).    
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Figure 13. Stably expressed recombinant MYC-tagged FJX1 increases FJX1 
protein in SW480 colon cancer cells. VEC = SW480VEC.  FJX1 = 
SW480FJX1MYC.   (A) Whole cell lysate or (B) conditioned media from cells treated 
with scrambled control oligonucleotide (siSCR) or FJX1 targeted (siFJX1) RNAi.  
Anti-β-actin and Coomassie stain served as loading controls for A, and B 
respectively.  Solid arrow indicates FJX1 species detected only in whole cell 
lysate, dashed arrows indicate FJX1 specific secreted forms.   
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Figure 14. Stably expressed recombinant MYC-tagged FJX1 increases FJX1 
protein in colon cancer cells.  Representative FJX1 protein immunoblot of 
whole cell lysate (WCL) and conditioned media (CM) from vector (-) or FJX1 (+) 
transfected CACO2 and KM12C cell lines.  Anti-β-actin and Coomassie stain 
served as loading controls for WCL and CM respectively.   
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Figure 15.  Stably expressed recombinant MYC-tagged FJX1 does not affect 
cellular proliferation in vitro.   (A, B) Representative experiments of 
metabolized WST-1 reflecting an estimation of cellular proliferation over 5 days in 
(A) HEK293T and (B) SW480 cells stably expressing either empty vector (VEC) 
or MYC-tagged FJX1 (FJX1) grown in 0% or 10% serum as indicated.  The mean 
values of replicates are graphed with bars indicating the standard deviation. 
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 Construction of Fat4, Dchs1 cadherin constructs and mutant FJX1. 
Drosophila fj is a kinase that phosphorylates specific cadherin residues on 
the large atypical cadherins, ft and ds [57,61].  In mammals there are two ds 
homologues, (Dchs1 and Dchs2) and four ft homologues (Fat1-4), with Dchs1 
and Fat4 exhibiting the most sequence homology to their respective Drosophila 
counterparts.  We aligned the cadherin domains between Dchs1 and ds and 
found that cadherin domain 3 of human Dchs1 has a conserved serine residue 
that has been identified as a fj target [57].  Similarly, comparison of Fat4 and ft 
revealed that cadherin domains 3 and 13 both have a conserved serine residue.  
In the fly, subtle but distinct mobility shifts are observed when ft and fj or ds and fj 
are co-expressed.  We thus generated FLAG-tagged versions of each protein 
that contained the first 3 cadherin domains (Fat4cad1-3 or Dchs1cad1-3) and 
transiently expressed them in HEK293TVEC and HEK293TPCFJX1 cells.  Since 
these constructs represent extracellular portions of Fat4 and Dchs1 that lack the 
transmembrane region, they were readily detectable in conditioned media using 
the anti-FLAG antibody (Figure 16).   We detected no altered mobility of either 
Fat4cad1-3 or Dchs1cad1-3 in the presence of FJX1 (Figure 16).   Co-expression of 
FJX1 and Dchs1cad1-3 may have caused a slight decrease in Dchs1cad1-3 
expression, however further experimentation will be required to determine if 
Dchs1cad1-3   levels are actually altered in the presence of FJX1.   
 In Drosophila, mutation of all three amino acids 490-492 (DNE) or single 
mutation of amino acid 490 completely abolished fj kinase activity [57,61].  
Sequence alignment of fj and various species, including mouse, rat, and human 
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show complete conservation of these residues (Figure 5).  To test if mutation of 
these conserved residues altered FJX1 function in our assays, we engineered a 
recombinant C terminally FLAG- tagged version of human FJX1 with the 
conserved D and E amino acids mutated to A (FJX1FLAGDE) and expressed it in 
HEK293T, SW480, and HMEC-1 cells.  Immunoblot analysis showed similar 
expression levels between the mutant and wild-type versions of FJX1, however 
we noticed that mutant FJX1 was migrating slightly faster (Figure 17).  We 
hypothesized that the altered mobility could be due to a potential auto-
phosphorylation event, which has been observed in the fly [57], and would be lost 
upon mutation of a putative kinase sequence.  We treated conditioned media 
from the FJX1 and FJX1DE transduced HEK293T and SW480 cell lines with 
peptide N-glycosidase F (PNGaseF) and/or antarctic phosphatase.  Treatment 
with PNGaseF resulted in a relatively uniform increase in gel electrophoresis 
mobility for both wild-type and mutant FJX1, with an approximately 5kDa 
decrease in size suggesting that mutant FJX1 is N-glycosylated similarly to wild-
type (Figure 17).  Phosphatase treatment alone failed to alter mobility of both 
versions of FJX1 significantly, possibly due to masking of any subtle shift by the 
larger effect of protein glycosylation (Figure 17).  Treatment with both PNGase F 
and phosphatase resulted in wild-type FJX1 collapsing into one band, while 
mutant FJX1 remained a distinct doublet, suggesting that wild-type but not 
mutant FJX1 is phosphorylated (Figure 17).The relevance of this mutant to FJX1 
biological function in vitro will be discussed further in chapter IV.   
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Figure 16.  FJX1 does not alter Dchs1 or Fat4 cadherin constructs mobility 
in immunoblotting.  Representative FLAG immunoblot of conditioned media 
from HEK293TVEC (lanes 1 and 3) or HEK293TPCFJX1 (lanes 2 and 4) cells with 
(+) or without (-) transient transfection of (A) Dchs1cad1-3 or (B) Fat4cad1-3 .  
Ponceau staining served as a loading control.
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Figure 17.  Expression of mutant FJX1 in various cell lines.  (A) 
Representative FJX1 immunoblot of whole cell lysates from indicated cell lines 
stably transfected with vector control, wild-type FJX1 (FJX1 FLAG) or mutant 
FJX1 (FJX1DEFLAG). β–actin served as the loading control.  (B)  Representative 
FJX1 immunoblot of HEK293TFJX1FLAG , HEK293TFJX1FLAGDE , SW480FJX1FLAG and 
SW480FJX1FLAGDE conditioned media with (+) and without (-) treatment with 
PNGaseF (PF) and/or antarctic phosphatase (AA).   
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Discussion 
FJX1 is the mammalian homologue of drosophila fj, a kinase involved in 
body patterning and limb development.  Mouse studies have described the 
normal physiological expression pattern of FJX1 and its role in neuron formation; 
however little else is known about FJX1.  Despite microarray data demonstrating 
that FJX1 mRNA expression is increased in a variety of cancers, ours is the first 
to characterize expression of human FJX1 in vitro.  Due to the paucity of FJX1 
specific reagents, we developed several rabbit polyclonal antibodies using either 
a peptide sequence or a recombinant version of human FJX1 as the antigen.  Of 
the peptide antibodies (156-159) 159 proved to be useful in detecting secreted 
FJX1 via immunoblot.  The polyclonal antibodies (208 and 209) generated 
against recombinant FJX1 were by far superior, and were effective in ELISA, 
immunoblotting, and immunofluorescence.  These FJX1-specific antibodies 
allowed us to screen for endogenous FJX1 expression as well as characterize 
recombinant FJX1 localization and processing.  Surprisingly we failed to detect 
endogenous FJX1 in conditioned media from immortalized normal or cancerous 
cell lines, including those derived from breast, lung, colon, enodothelial, and 
neuronal tissue.  Conversely we were able to detect endogenous secreted FJX1 
from primary rat hippocampal neurons.  Loss of FJX1 expression in extensively 
cultured cells in vitro may be caused by a lack of paracrine interactions that are 
supported in vivo.   
We used our antibodies to characterize recombinant FJX1 expression and 
processing in vitro.  Like Drosophila fj [56], the intracellular pool of human FJX1 
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protein is found to localize to the Golgi apparatus.  We detected four to five 
distinct bands in cells transduced with recombinant FJX1, with the smaller two 
species also being detected in conditioned media.  In HEK293TPCFJX1 cells we 
showed that all four forms of FJX1 are glycosylated, while the secreted doublet 
collapses into a single species when both glycosylation and phosphorylation 
groups are removed.  The secreted forms of FJX1 likely occur from a cleavage 
event subsequent to the normal processing that removes the signal sequence, 
due to their size.  Additionally, a commercially available antibody from Abcam 
only detects the intracellular forms of FJX1.  Although the exact sequence used 
for rabbit immunization is proprietary (personal communication) it was confirmed 
that the region lies somewhere after the signal sequence but before amino acid 
80.  It will be interesting to determine where exactly FJX1 is cleaved, and which 
proteins are responsible for this processing.    
Drosophila fj is a kinase that phosphorylates specific cadherin residues on 
two large atypical cadherins fat and dachsous [57,61].  The three key residues of 
fj involved in kinase function (DNE) are completely conserved across multiple 
species, including mouse and human.  Mutation of the conserved aspartic acid 
within this region was sufficient to inhibit the biological function of fj [61].  
Additionally, the serine residues that fj phosphorylates on ft and ds [57] are also 
conserved in mammalian Fat4 and Dchs1.  Since Fat4 and Dchs1 are extremely 
large proteins (~5147 and 3298 amino acids respectively) we expressed smaller, 
recombinant versions that only contained domains surrounding the first 
conserved serine residue (Fat4cad1-3 or Dchs1cad1-3).  We were unable to observe 
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an obvious change in immunoblot mobility upon expression of Fat4cad1-3 in 
HEK293TPCFJX1 cells, however it appeared that there was some alteration in 
Dchs1cad1-3 abundance.  Further experiments will be needed to determine if the 
alteration in Dchs1cad1-3 is only at the level of protein expression, or if it is due to a 
change in post translational modification.  The addition of phosphatase treatment 
may help to clarify this point, but a more direct test will be to use fully 
recombinant versions in an in vitro kinase assay.  
Alternatively, we created a FLAG-tagged version of FJX1 in which the 
aspartic acid and glutamic acid residues in the putative kinase domain were 
mutated to alanine.  Interestingly, the smaller secreted forms of FJX1 differed in 
gel mobility upon mutation of these D and E residues.  It has been suggested 
that fj undergoes autophosphorylation in vitro [57], and thus we tested whether 
mutant FJX1 was phosphorylated or otherwise modified.  Both wild-type and 
mutant FJX1 were altered by glycosidase treatment, suggesting both forms 
undergo glycosylation.  While phosphatase treatment in combination with 
PNGase treatment of wild-type FJX1 results in the collapsing of FJX1 into a 
single band, mutant FJX1 did not show a mobility shift, suggesting mutant FJX1 
is not phosphorylated.  Unfortunately, due to the similarity in size of recombinant 
mutant FJX1, Fat4cad1-3 and Dchs1cad1-3 , and the fact that they are all FLAG-
tagged we were unable to test whether protein levels of Fat4cad1-3 or Dchs1cad1-3 
were altered in the presence of FJX1 wild-type as compared to the FJX1 DE 
mutant.  However, using MYC-tagged FJX1 expression in HEK293T cell, we 
found no evidence that specific domains of Ft and Dchs were phosphorylated.  It 
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may be that these cadherins require the full-length protein for correct regulation 
or it may be that they are not phosphorylated by FJX1 in all cells or species. 
Whichever the case may be, this negative result indicated that other studies were 
needed to understand FJX1 function in mammalian cells, particularly in CRC 
cells.    
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CHAPTER IV. 
FJX1 PROMOTES TUMORIGENESIS THROUGH INCREASED 
ANGIOGENESIS IN COLORECTAL CARCINOMA 
Introduction 
We identified FJX1 as a gene regulated by celecoxib inhibition in CRC.  
As discussed above, FJX1 is elevated at both the mRNA and protein levels in 
human CRC tissue, and high expression of FJX1 is associated with poor patient 
prognosis. Therefore, understanding its biological role in CRC may identify 
pathways and targets for more effective treatment of this disease.  The role of 
human FJX1 has not been biologically tested to date, however tumor gene 
expression analysis data have suggested a potential oncogenic role in a variety 
of cancers.  FJX1 gene amplification and increased mRNA expression have been 
observed in oral squamous carcinomas and in derived squamous carcinoma cell 
lines [68,69].  FJX1 mRNA expression is upregulated in ovarian tumor 
endothelial cells as compared to normal ovarian endothelial cells [70,71] and 
thus has been suggested as a candidate tumor vasculature marker in ovarian 
cancer [72].  Despite these observations of altered FJX1 mRNA expression in 
other cancers, the biological function of FJX1 and its effects on tumor 
progression are unknown.  Here we describe FJX1 as tumor promoter through its 
ability to enhance tumor angiogenesis. 
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Material and Methods 
Cell culture 
HEK293T, CACO2, and SW480 (ATCC) cells were cultured in RPMI 1640 
(Gibco) with 10% FBS (Atlanta Biologicals), 100U/mL pen/strep (Gibco), and 
100U/mL L-glutamine (Gibco) at 37 oC with 5% CO2.  HMEC-1 cells (F. Candl, 
Center for Disease Control) were cultured in MCDB131 (Gibco), supplemented 
with 10% FBS, 10ng/mL epidermal growth factor (Becton-Dickson), 100U/mL L-
glutamine (Gibco), and 1μm/mL hydrocortisone (Sigma Chemical). KM12C (Gift 
of Dr. Isiah Fidler) [67] were cultured in MEM (Gibco) with 10% FBS (Atlanta 
Biologicals), 100U/mL pen/strep (Gibco), 100U/mL L-glutamine (Gibco), sodium 
pyruvate (Gibco), non-essential amino acids (Gibco) and MEM vitamins (Gibco).  
Immunological detection methods and reagents 
Immunoblotting:  Cells were lysed in radio-immunoprecipitation assay 
(RIPA) buffer (150Mm sodium chloride, 1% Igepal, 0.5% sodium deoxycholate, 
1% sodium dodecyl sulfate, 50mM Tris-Cl) supplemented with aprotinin, 
leupeptin, sodium orthovanadate, sodium fluoride, and phenylmethylsulfonyl 
fluoride before resolution by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE).   Whole serum from rabbit 208 was diluted 1:3000 in 5% milk-PBST 
overnight at 4oC.  Commercial antibodies:  β-actin (Sigma Chemical, 5% milk-
PBST 1:10,000).   Anti-rabbit HRP and Anti-mouse HRP were diluted 1:5000 in 
5% milk-PBST and incubated for 30 minutes at room temperature.   
Immunohistochemistry: Immunohistochemistry was performed by the 
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Vanderbilt Immunohistochemistry Core Shared Resource for Ki-67 (Vector 
Laboratories), Cleaved caspase 3, and CD34 (Santa Cruz Biotechnology).  
Staining was quantified using the Ariol SL-50 automated slide scanner (Applied 
Imaging) as previously described [74].  Cross sections of CD34 stained tissue 
were used to determine the number of vessels per mm2 tissue (including 
perivasculature for xenograft tumors).  Significance was determined using Mann-
Whitney and t test.   
Partially purified anti-FJX1 antibody (rabbit 209 polyclonal) was applied at 
a dilution of 1:2000 and incubated overnight at 4°C. Slides were washed, 
incubated in 1:500 goat anti-rabbit antibody for 30 min., washed and incubated in 
avidin biotin complex (Vector Labs Elite ABC kit) for 30 min and washed. Color 
was developed in 3, 3’ diaminobenzidine (Vector Labs) and nuclei were stained 
with Gill’s #3 hematoxylin (Sigma).  Images were taken on an Axioskop 40 
upright light microscope (Carl Zeiss, Inc.).   
Collection of conditioned medium and siRNA   
Epithelial cell lines (HEK293T, SW480, KM12C, CACO2) were allowed to 
grow to ~60% confluence (typically 24 hrs) before media was refreshed 
(5mL/10cm; containing  0% FBS).  After 16-24 hours, conditioned media were 
collected, spun at 300 g for 5 minutes, and supernatant transferred to a fresh 
tube.  For fractionation experiments, 4mL of conditioned media was spun at 4000 
g for 30 minutes at 4oC in an Amicon ultra 30K membrane tube (Millipore).  
Serum free medium was added to the fraction that was retained on the column to 
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equal the volume that flowed through the column.  Conditioned media was used 
for endothelial tube assays within one hour of collection.   SW480VEC or 
SW480FJX1 cells were transfected with 100nM pooled siRNA specific to FJX1 
(Qiagen) or non-targeting scrambled siRNA (Dharmacon) replated at 48 hours 
post transfection, and re-fed with serum free media after 72 hours.  After 96 
hours, media was collected and processed as above.   
Endothelial tube formation 
Phenol red free growth factor reduced matrigel (BD biosciences) was 
allowed to solidify in 96 well plates (50uL/well) for 30 minutes at 37°C.  HMEC1 
(30,000 cells) in complete media were plated on top of the matrix and an equal 
volume of conditioned media containing 0% FBS or 10% FBS from epithelial cell 
lines (HEK293T, SW480, KM12C, CACO2) was added.  For autonomous 
experiments, 20,000 HMEC1VEC or HMEC1FJX1 cells were plated on top of the 
matrix.  Images were taken 16-18 hours after HMEC-1 cells were plated for tube 
formation, with three images taken per well.  Experiments were performed in 
triplicate at least three times, with each data point being the average of three 
images of three technical replicates.  Significance was determined by Mann-
Whitney, ANOVA, or Student’s t test as noted. 
Xenograft and mouse carcinogenesis models 
One million SW480VEC or SW480FJX1 cells were injected subcutaneously 
onto single flanks of athymic female nu/nu mice (Harlan Sprague Dawley).  For 
KM12CVEC and KM12CFJX1 cell lines, a single female nu/nu mouse received 
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1X106 cells on one flank, and 2X106 cells on the opposite flank with the same cell 
line injected subcutaneously per mouse. Tumor growth was monitored by taking 
external measurements on the animal and at the time of sacrifice (volume = 
4/3πr3).   
FJX1 -/- (KO) mice on a C57BL/6 genetic background were obtained from 
H. McNeil [66].  Azoxymethane (AOM, Sigma) was given intraperitoneally at 12.5 
ug/g.  Dextran sodium sulfate (DSS, MP Biomedicals, formula weight 36,000-
50,000) was prepared in drinking water at 3%.  At eight weeks of age the mice 
were randomized into one of four treatment groups; no treatment (KO n=8; WT; 
n=6), AOM alone (KO; n=3; WT n=1), DSS alone (KO n=8; WT n=8), or AOM 
and DSS (KO n=8; WT n=8).  Mice were injected with AOM (day 1), given three 
cycles of DSS (days 6-10, 27-31, and 48-51) and allowed a four week recovery 
period [75,76].  After experimental completion, mice were euthanized and 
analyzed for the number of colonic polyps.  Formalin fixed paraffin embedded 
colonic tissue sections were then subjected to histological analysis by M.K. 
Washington as previously described [77] by Dieleman and colleagues.  Briefly, 
intensity, location (mucosal, submucosal, transmural), and extent of involvement 
of the inflammatory infiltrate was assessed, as well as severity and extent of 
crypt injury.   
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Results 
FJX1 expression promotes tumor growth in vivo 
To determine whether FJX1 expression alters xenograft tumor formation in 
vivo, we injected vector and FJX1 transduced cells (SW480 or KM12C) on the 
flanks of athymic nude mice.  One million SW480 cells were injected onto a 
single flank of each mouse with 10 mice in each group.  At 26 days post injection, 
both groups of mice exhibited 100% tumor incidence; however, SW480FJX1MYC 
tumors were larger than SW480VEC tumors so tumors were excised for 
histological examination (Figure 18A).  After excision, the SW480FJX1MYC derived 
tumors were approximately twice the size (Figure 18B; average volume: 58.0 +/-
5.8 mm3  vs 27.1 +/- 2.9 mm3,P < 0.0005) and with a mass 1.5 times greater than 
the SW480VEC tumors (Figure 18C; average weight: 71.0 +/- 6.75 mg vs 45.1 +/- 
5.8 mg, P < 0.05).  SW480VEC cells produced tumors with no detectable FJX1 
protein while SW480FJX1MYC cells continued to produce FJX1 protein in vivo 
(Figure 18D).   
We next examined whether this change in tumor size was determined by 
differences in rates of proliferation or apoptosis.  SW480FJX1MYC tumors had 
significantly more Ki67-positive nuclei compared to SW480VEC tumors (P < 0.05), 
indicating an increase in the number of actively proliferating cells (Figure 19A). 
There was no significant difference in levels of cleaved caspase 3 (Figure 19B).  
Thus, overexpression of FJX1 affected xenograft tumor size due primarily to 
differences in the rate of tumor cell proliferation. 
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Figure 18.  Overexpression of MYC-tagged FJX1 in SW480 colon cancer 
cells promotes tumor growth in vivo.  For all panels, VEC = SW480VEC (n=11); 
FJX1 = SW480FJX1MYC (n=14).  (A) Estimation of tumor volume (mm3) measured 
in vivo over time.  (B) Final tumor volume measured following removal from 
animal. (C) Final tumor weight (mg) measured following removal from animal. (D) 
Representative FJX1 immunohistochemistry on SW480 xenograft tumors.  Scale 
bar = 50 μm. 
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Since FJX1 enhanced tumor cell proliferation in vivo but it had no direct 
effect on cell proliferation in vitro (Figure 15), we postulated that factors 
associated with the tumor microenvironment such as angiogenesis contributed to 
this discrepancy.  To test this hypothesis, tumor vasculature was measured using 
the endothelial marker CD34.  Total CD34 staining showed a slight increase in 
SW480FJX1MYC tumors as compared to SW480VEC (data not shown).  Focusing on 
the presence of larger vessels, that is CD34+ vessels with an area of at least 50 
µm2, showed SW480FJX1MYC tumors contained approximately twice as many of 
these larger vessels than SW480VEC tumors per mm2 of tumor section (5.84 +/- 
.56 vs 3.18 +/- .44 .respectively, P < 0.005, Figure 19C, representative images in 
19D).  These data suggest that FJX1 overexpression promotes xenograft tumor 
growth in vivo by non-cell-autonomous effects, increasing recruitment of 
vasculature, thereby allowing increased tumor cell proliferation. 
For KM12C transduced cells, one million cells were injected 
subcutaneously into the right flank and two million cells were injected 
subcutaneously into the left flank of each athymic nude mouse, with ten mice per 
group.   KM12C transduced cells grew rapidly and tumors were excised on day 7 
due to size of left flank tumors.   Tumors grown from a million cells had no 
significant difference between KM12CVEC and KM12CFJX1 tumor weight or volume 
(data not shown).  However, KM12CFJX1 tumors grown from two million cells were 
significantly larger than KM12CVEC tumors (Figure 20).   
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Figure 19.  Overexpression of MYC-tagged FJX1 in SW480 colon cancer 
cells promotes tumor growth in vivo.  For all panels, VEC = SW480VEC (n=11); 
FJX1 = SW480FJX1MYC (n=14).  (A) Percent of Ki67 positively stained nuclei.  (B) 
Percent of cleaved caspase positively stained cells. (C) Number of blood vessels 
larger than 50 µm2 per mm2 per tumor section. A/B/C Each data point represents 
quantification of an entire cross section of tumor.  Significance was determined 
by the Mann-Whitney test; ns= not significant *P < 0.05, **P < 0.005.  Bars and 
whiskers represent mean and standard error of the mean respectively. (D)  
Representative light images from CD34 stained SW480VEC (i-ii) or SW480FJX1MYC 
(iii-iv) tumor sections.    Scale bar = 20 microns. 
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Figure 20.  Overexpression of MYC-tagged FJX1 in KM12C colon cancer 
cells promotes tumor growth in vivo.  For all panels, VEC = KM12CVEC (n=10); 
FJX1 = KM12CFJX1MYC (n=10).   Final tumor weight (A) and volume (B) after 
removal from animal. Significance was determined by the Mann-Whitney test; 
ns= not significant, *P < 0.05.  Bars and whiskers represent mean and standard 
error of the mean respectively.  
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In order to determine whether endogenous expression of FJX1 has an 
influence on tumorigenesis, we employed a well-characterized model of 
inflammation/carcinogenesis using azoxymethane (AOM) and dextran sodium 
sulfate (DSS) to induce colonic tumors in mice [75,76].  For this experiment we 
used C57BL/6 mice that were homozygous null for FJX1 (KO, n=8) and 
compared them with wild-type C57BL/6 littermates (WT, n=8).   The mice were 
given an initial dose of AOM followed by three cycles of DSS as described in 
Methods.  Upon gross examination, FJX1 null mice had significantly fewer 
colonic polyps than the wild-type control mice (Figure 21A).  We assessed the 
inflammation and crypt damage of formalin fixed paraffin embedded colonic 
sections from the FJX1 null and WT mice as described by Dieleman et al.  This 
method takes into account both the inflammation severity/crypt damage and the 
percentage of tissue affected.  There was no significant difference between FJX1 
null and WT mice when assessing the inflammation score, extent of 
inflammation, and crypt damage, which combined is known as the total 
histological score (Figure 21B).  We then assessed the vasculature associated 
with FJX1 null and WT colonic sections by quantifying CD34 stained colonic 
tissue sections.  We found that FJX1 null colonic sections had significantly fewer 
blood vessels per mm2 than WT mice (Figure 21C).  Thus, genetic deletion of 
endogenous FJX1 in mice results in inhibition of colonic tumorigenesis in 
association with reduced tissue angiogenesis, consistent with the increase in 
tumor vasculature observed in SW480FJX1MYC cells grown as xenografts.  
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Figure 21.  FJX1 null mice have fewer polyps than wild-type littermates in a 
mouse model of tumorigenesis.  For all graphs WT = wild-type (n=8); KO = 
FJX1 null (n=8).  (A)  Number of colonic polyps counted in mice after treatment 
with AOM/DSS.  (B) Histological colitis score as determined on hematoxylin and 
eosin stained colonic sections after treatment with AOM/DSS.  (C) Number of 
blood vessels per mm2 of tissue section as determined on CD34 stained colonic 
sections after treatment with AOM/DSS.   * = p<0.05.  ns = not significant.   
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 Conditioned media from FJX1-overexpressing tumor cells increases endothelial 
cell tube formation in vitro. 
Since overexpression of FJX1 in the SW480 xenograft tumors resulted in 
increased angiogenesis, we used the widely accepted endothelial tube assay 
[78,79] to test whether FJX1-conditioned media affected HMEC-1 endothelial 
cells in vitro.  We found that conditioned media from FJX1 transduced HEK293T, 
SW480, and KM12C cells significantly increased the number of endothelial tubes 
formed by HMEC-1 cells on Matrigel as compared to conditioned media from 
vector transduced control cells (Figure 22).  Interestingly, autonomous 
expression of FLAG-tagged FJX1 in HMEC-1 cells also promoted tube formation 
in vitro (Figure 22, note for the autonomous experiment 20,000 cells were used 
as opposed to 30,000 cells for non-autonomous).  We failed to observe a 
difference in endothelial tube formation when cells were treated with conditioned 
media from FJX1 transduced CACO2 cell lines as compared to VEC transduced 
control cells (Figure 22).  It is interesting to note that conditioned media from 
CACO2VEC cell lines greatly stimulated endothelial tube formation as compared 
with conditioned media from other cell lines, perhaps accounting for why the 
addition of FJX1 did not further enhance tube formation.   
To demonstrate that increased tube formation by SW480FJX1MYC 
conditioned media is specifically a result of increased FJX1 expression, we used 
oligonucleotides specific for FJX1 (siFJX1) to inhibit FJX1 expression.  Inhibition 
of FJX1 protein expression was confirmed by immunoblotting of both whole cell 
lysate and conditioned media (Figure 23).  Although conditioned media from 
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SW480FJX1MYC cells untreated (UT) or transfected with scrambled siRNA (siSCR) 
maintained the ability to promote HMEC1 tube formation as compared to 
SW480VEC, SW480FJX1MYC cells transfected with siFJX1 failed to augment tube 
formation (Figure 23).  
To determine if secreted FJX1 protein (approximately 40 and 37 kDa) is 
directly responsible for the non-autonomous increase in capillary tube formation, 
conditioned medium was fractionated using a 30,000 nominal molecular weight 
cut-off filter.  Elimination of FJX1 protein from the flow-through fraction was 
confirmed by immunoblotting (Figure 23).  Interestingly, the flow-through fraction 
of media maintained the ability to promote HMEC-1 tube formation (Figure 23).  
Thus, our data indicate that overexpression of FJX1 by tumor cells is associated 
with increased secretion of other pro-angiogenic factors contained within the 
flow-through fraction.
73 
 
Figure 22.  Autonomous and non-autonomous expression of FJX1 
selectively enhances endothelial capillary tube formation in vitro.  Data 
represent the number of HMEC-1 tube structures formed on Matrigel following 
treatment with FJX1 conditioned media as compared with VEC conditioned 
media for the cell lines indicated (293T, SW480, CACO2, KM12C).  No CM = no 
conditioned media treatment.  For HMEC1 cell lines, data represent the number 
of tube structures formed in Matrigel after stable expression of vector (VEC) or 
FJX1 (FJX1).   
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Figure 23.  Conditioned media from SW480FJX1 cells enhances endothelial capillary 
tube formation in vitro. (A) Relative number of HMEC-1 tube structures formed in the 
presence of conditioned media from SW480 cells treated as noted as compared to VEC 
untreated.  (B)  Representative FJX1 immunoblot of whole cell lysate from SW480FJX1MYC 
cells treated as noted.  (A/B) siFJX1 and siSCR denotes treatment with FJX1 specific 
siRNA and scrambled siRNA respectively.  β-actin and Coomassie stain served as 
loading controls for whole cell lysate (WCL) and conditioned media (CM), respectively.  
Asterisks (*) = non-specific band. (C)  Relative number of HMEC-1 tube structures as 
compared with VEC after fractionation of the conditioned media. (D)  Representative 
FJX1 immunoblot of conditioned media from SW480 cells after fractionation.  RET = 
retained on column; FT = flow through. (A/C) Each data point represents the value of a 
biological replicate and bars and whiskers represent the mean and standard error of the 
replicates, respectively.  Significance was determined by Student’s t-test; *P < 0.05; **P 
< 0.005; ns=not significant.   
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Discussion 
In chapter II we described our discovery of FJX1 through an in vivo screen 
to identify celecoxib regulated genes.  We demonstrated that FJX1 mRNA and 
protein are increased in CRC tissue as compared with normal, and that patients 
with high FJX1 have significantly worse prognosis.  We postulated that our 
observation that patients with higher FJX1 mRNA expression have worse 
survival outcomes is related to the functional effects of FJX1 on tumor formation.  
This hypothesis is supported by our experimental observations.  First, mice 
lacking endogenous FJX1 had fewer colonic polyps after AOM/DSS treatment as 
compared to wild-type littermates, suggesting that FJX1 expression enhances 
tumor formation in vivo.  Second, when we performed xenograft experiments in 
athymic mice, we found that tumors from SW480 and KM12C cells transduced 
with FJX1 exhibited increased size and proliferation as compared to vector 
transduced controls.  In both the FJX1 KO mice, and the SW480 xenograft 
models we found an association between vascularization and FJX1 expression; 
colonic sections and tumor xenografts lacking FJX1 had fewer blood vessels.  It 
will be of interest to determine if the KM12CFJX1 xenografts also exhibit increased 
tumor angiogenesis.  It is well recognized that without angiogenesis, tumors 
remain limited in both size and location, thus posing limited threat to the overall 
health of the individual [80].  It is likely that the correlation between high 
expression of FJX1 and poor patient survival can be attributed to the pro-
angiogenic effects of increased FJX1 expression and its downstream targets.   
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We demonstrated that conditioned media from HEK293T, SW480, and 
KM12C cells with augmented FJX1 expression promoted endothelial capillary 
tube formation.  This non-autonomous phenotype was maintained even upon 
exclusion of secreted FJX1 protein, suggesting that enhanced expression of 
FJX1 is associated with increased secretion of other factors that are pro-
angiogenic.  It was also interesting that autonomous expression of FJX1 in the 
endothelial cell lines promotes capillary tube formation, indicating that angiogenic 
effects of FJX1 are not specific to a single cell type.  It is unclear why CACO2 
cells transduced with FJX1 did not promote capillary tube formation, but may 
reflect tumor-specific variation and/or more subtle differences that were not 
measurable in these assays. Since three of the cell lines in our studies, SW480, 
KM12C and HEK293T, do not express detectable levels of COX-2, results from 
these experiments argue that the effect is FJX1 specific and not due to 
previously described angiogenic effects of COX-2 [40].  Furthermore, this 
supports our gene expression data from human tumor samples indicating that 
FJX1 expression is downstream of COX-2 function. 
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CHAPTER V. 
  FJX1 PROMOTES ANGIOGENESIS THROUGH REGULATION OF 
HIF1-α. 
Introduction  
We have found that FJX1 is upregulated in colorectal cancer (chapter II), 
and that FJX1 can promote tumor formation by increasing tumor vasculature 
(chapter IV).  Prior to our work, human FJX1 had only been described in terms of 
microarray expression data.  By microarray analysis, alteration in FJX1 mRNA 
expression occurs in various cell types treated with different cytokines, including 
tumor necrosis factor α (TNF-α) treatment of HMEC-1 cells [81]; interleukin 1 (IL-
1) treatment of HUVEC cells [82]; lipopolysaccharide (LPS) treatment of human 
monocytes [83]; and human chorionic gonadotropin (hCG) treatment of 
fibroblasts from endometriosis patients [84].  There are no reports concerning 
what signaling molecules may be downstream of FJX1.  Since the non- 
autonomous effect of FJX1 expression is not a direct effect of secreted FJX1, we 
wanted to identify both the secreted pro-angiogenic factor found in conditioned 
media from FJX1 transduced cells, as well as identify potential signaling 
pathways that were altered intracellularly by FJX1 expression.   We began by 
analyzing microarray data from two independent human CRC databases to look 
for genes that were concordantly regulated with FJX1.  We also specifically 
tested the association between FJX1 expression and known angiogenesis 
related genes.  Finally we used a proteomic approach to analyze conditioned 
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media from SW480VEC and SW480FJX1 cells.  Here we describe our identification 
of HIF1-α as an important mediator of the FJX1 pro-angiogenic program.   
Materials and Methods 
FJX1 angiogenesis correlation analysis 
WebGestalt  [85] was used to identify biological processes that are 
significantly associated with FJX1 expression and gene set enrichment analysis 
(GSEA) [86] was used to specifically test the association between FJX1 
expression and expression of other angiogenesis related genes. Two human 
CRC datasets GSE17536 and GSE17537 were normalized using the RMA 
algorithm and pairwise absolute Pearson’s correlation coefficient was calculated 
between the FJX1 probe set 219522_at and all other probe sets. The probe sets 
were ranked based on their correlation with FJX1. The top 500 probe sets for 
each dataset were subjected to the Gene Ontology biological process enrichment 
analysis respectively using WebGestalt. The ranked lists were analyzed using 
GSEA to test whether known angiogenesis genes (Gene Ontology annotation 
GO:0001525) were enriched at the top of the lists, identify the leading edge 
subset, and determine the gene set’s enrichment signal [86]. 
RNA extraction and qRT-PCR 
 RNA was extracted using the Qiagen RNeasy Kit (Qiagen) per 
manufacturer's instructions.  qRT-PCR reactions analyzing  HIF1A, PMM1, 18S 
and VEGF-A mRNA levels in cell lines were performed using the Roche 
transcriptor universal cDNA master and analyzed on the Lightcycler 480 II 
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(Roche).  Primers used; HIF1A: 5’-GGTTCACTTTTTCAAGCAGTAGG-3’ and 5’-
GTGGTAATCCACTTTCATCCATT-3’ (IDT) with probe #3 (Roche); 18S:  5’-
GCAATTATTCCCCATGAACG-3’ and 5-GGGACTTAATCAACGCAAGC-3’ (IDT) 
with probe #48 (Roche); VEGF-A:  5’-CCTTGCTGCTCTACCTCCAC-3’ and 5’-
CCACTTCGTGATGATTCTGC-3’ (IDT) with probe #29 (Roche); PMM1: 5’-
TTCTCCGAACTGGACAAGAAA-3’ and 5’-CTCTGTTTTCAGGGCTTCCA-3’ 
(IDT) with probe #7  (Roche).   Relative fold change of expression was calculated 
by 2-ΔCt.   
Cell culture 
HEK293T, CACO2, and SW480 (ATCC) were cultured in RPMI 1640 
(Gibco) with 10% FBS (Atlanta Biologicals), 100U/mL pen/strep (Gibco), and 
100U/mL L-glutamine (Gibco) at 37 oC with 5% CO2.  HMEC-1 cells (F. Candl, 
Center for Disease Control) were cultured in MCDB131 (Gibco), supplemented 
with 10% FBS, 10ng/mL epidermal growth factor (Becton-Dickson), 100U/mL L-
glutamine (Gibco), and 1μm/mL hydrocortisone (Sigma Chemical). KM12C (Gift 
of Dr. Isiah Fidler) [67] were cultured in MEM (Gibco) with 10% FBS (Atlanta 
Biologicals), 100U/mL pen/strep (Gibco), 100U/mL L-glutamine (Gibco), sodium 
pyruvate (Gibco), non-essential amino acids (Gibco) and MEM vitamins (Gibco). 
Hypoxic conditions were achieved using a hypoxia chamber equilibrated with 1% 
O2, 5% CO2 and 94% N2.  MG132 (Enzo life sciences) and cycloheximide 
(Sigma) were used at 50uM and 100uM.   
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Immunoblotting 
Cells were lysed in radio-immunoprecipitation assay (RIPA) buffer 
(150Mm sodium chloride, 1% Igepal, 0.5% sodium deoxycholate, 1% sodium 
dodecyl sulfate, 50mM Tris-Cl) supplemented with aprotinin, leupeptin, sodium 
orthovanadate, sodium fluoride, and phenylmethylsulfonyl fluoride before 
resolution by SDS-polyacrylamide gel electrophoresis (SDS-PAGE).   Whole 
serum from 208 was diluted 1:3000 in 5% milk-PBST overnight at 4oC.  
Commercial antibodies:  β-actin (Sigma Chemical, 5% milk-PBST 1:10,000), HA 
(Cell signaling, rabbit polyclonal, 5% milk-PBST 1:1000), HIF1-α (Novus, rabbit 
polyclonal, 5% milk-PBST 1:1000), and Annexin I (Invitrogen, Rabbit polyclonal, 
5% milk-PBST 1:2000)   Anti-rabbit HRP and Anti-mouse HRP were diluted 
1:5000 in 5% milk-PBST and incubated for 30 minutes at room temperature.   
Collection of conditioned medium and siRNA   
SW480VEC or SW480FJX1 cells were transfected with 100nM pooled siRNA 
specific to HIF1-α (Dharmacon) or non-targeting scrambled siRNA (Dharmacon), 
and HEK293T cells were transfected with pcDNA3.1, HA-HIF1-α or pcDNA3.1 
hFJX1, replated at 48 hours post transfection, and re-fed with serum free media 
after 72 hours.  After 96 hours, media was collected, spun at 300g for 5 minutes 
and transferred to a fresh tube and directly used in endothelial tube assays.  For 
fractionation experiments, 4mL of 5mL total conditioned media was spun at 4000 
g for 30 minutes at 4oC in an Amicon ultra 30K membrane tube (Millipore).  
Serum free medium was added to the fraction that was retained on the column to 
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equal the volume that flowed through the column.  Conditioned medium from 
sub-confluent SW480VEC and SW480FJX1 cells was analyzed using the VEGF 
ELISA (R&D Systems) per manufacturer's instructions.  ELISA data was derived 
from three biological replicates performed in duplicate and significance was 
determined using Student’s t-test.   
Proteomic sample preparation 
        Conditioned media from SW480VEC or SW480FJX1 cells was spun at 4000 g 
for 30 minutes at 4oC in an amicon ultra 30K membrane tube (Millipore) from six 
10cM plates.  The flow through fraction from each biological replicate was 
MEOH/CHCl3 precipitated.  An equal volume of methanol and .25% of 
chloroform was added and the samples were spun at 13,000 RPM for 15 
minutes.  The supernatant was removed and the samples werer washed with 
1mL of 100% methanol and spun for an additional 10 minutes.  The protein pellet 
was then dried with a SpeedVac (Thermo Fisher)  and then was suspended in 
200 uL of 50% 2,2,2-trifluoroethanol (Acros Organics), 50% 50 mM ammonium 
bicarbonate (Fisher Scientific) (v/v).  Protein concentration was measured using 
the BCA protein assay (Pierce Biotechnology). A total of 200ug of protein from 
the conditioned media was reduced with 100uL of 100mM dithiothreitol (Pierce 
DTT, No-Weigh Format) an incubated at 60oC for 30 minutes with shaking. After 
cooling down the tubes, 100 uL of 200 mM iodoacetamide was added and 
incubated 20 min at room temperature in the dark. Samples were diluted with 
600 uL of 50 mM ammonium bicarbonate. In order to generate peptides suitable 
for MS-MS analysis, the samples were digested by adding trypsin (20g, 
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trypsin/protein ratio of 1:50 (w/w), Promega) and digestion was carried out at 
37°C overnight.  After lyophilizing the resulting peptide mixture, samples were 
reconstituted by distilled water and applied to Sep-Pak C18 cartridges (Waters). 
After washing the column with 1 ml of distilled water, digested peptides were 
eluted from the column with 1 ml of 80% acetonitrile. Eluted peptides were 
evaporated to dryness in a SpeedVac (Thermo-Fisher) and reconstituted with 2.5 
ml of 6 M urea for isoelectric focusing (IEF) of peptides. 
IEF Fractionation of Peptide Digests and LC-MS/MS Analyses  
Four independent IEF peptide separations were performed on each 200 ug 
sample. Immobilized pH gradient (IPG) strips, 24 cm, pI 3.5– 4.5 (IPGphor, GE 
Health Care), were rehydrated overnight, then loaded and focused using an 
Ettan IPGphor 3 IEF system (GE Health Care) for 25 hours. Immediately after 
focusing, IPG strips were cut into 20 pieces and peptides were extracted, the 
extracts were dried down, desalted, dried down again and then reconstituted in 
0.1 ml of 0.1% formic acid for LC-MS/MS analysis  LC-MS/MS analysis were 
performed on an LTQ-Velos mass spectrometer (Thermo Fisher). 
Endothelial tube formation 
Phenol red free growth factor reduced matrigel (BD biosciences) was 
allowed to solidify in 96 well plates (50uL/well) for 30 minutes at 37°C.  HMEC1 
(30,000 cells) in complete media were plated on top of the matrix and an equal 
volume of conditioned media containing 0% FBS from epithelial cell lines 
(HEK293T, SW480) was added.  Images were taken 16-18 hours after HMEC-1 
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cells were plated for tube formation, with three images taken per well.  
Experiments were performed in triplicate at least three times, with each data 
point being the average of three images of three technical replicates.  
Significance was determined by Mann-Whitney, ANOVA, or Student’s t test as 
noted. 
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Results 
FJX1 expression is associated with expression of known angiogenesis genes.   
In order to identify the mechanism by which FJX1 elicits pro-angiogenic 
activity in tumor cells, we analyzed the top 500 genes that are most highly 
correlated with FJX1 expression in two human colorectal cancer datasets from 
VUMC and MCC. Gene Ontology enrichment analysis by WebGestalt revealed 
significant enrichment of angiogenesis genes in both tumor datasets.  This 
observation was further confirmed by gene set enrichment analysis (GSEA) that 
directly compares the correlations between FJX1 expression and 186 predefined 
angiogenic factors (GO:0001525) to those between FJX1 expression and all 
other genes (Figure 24, P < 0.001).  This GSEA analysis identified 43 angiogenic 
factors with strong and consistent association with FJX1 expression in both 
datasets, representing the core genes that account for the enrichment signal (the 
leading edge subset).  These genes, including HIF1A, VEGF receptors Flt1 and 
KDR, and VEGFC (Table 5), suggest an association of FJX1 and angiogenic 
gene expression in human colorectal cancer tumor samples.   
Of the significant genes from the GSEA, HIF1-α is a well-characterized 
transcription factor that regulates the expression of many pro-angiogenic 
molecules.  Furthermore, at least ten of the 43 genes found in the leading edge 
subset have been shown to be regulated by HIF1-α (Table 5) [87-92] [93-96].  
We observed no changes in HIF1A mRNA comparing vector transfected controls 
and FJX1 expressing cells (Figure 25 A-C).  However, we found increased HIF1-
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α expression in FJX1 transduced cells (Figure 25D).  To test if enhanced HIF1-α 
protein expression contributed to the increased capillary tube-stimulating activity 
in SW480FJX1MYC conditioned media, we suppressed HIF1A expression with 
siRNA specific to HIF1A.   Inhibition of HIF1A was confirmed at both the mRNA 
(Figure 26A) and protein levels (Figure 26B).  While conditioned media from 
SW480FJX1MYC cells that were untreated or were transfected with scrambled 
siRNA (siSCR) maintained the ability to promote increased HMEC1 tube 
formation as compared to conditioned medium from SW480VEC cells, 
SW480FJX1MYC cells transfected with HIF1A specific siRNA failed to do so (Figure 
26C P < 0.0001).  Further, inhibition of HIF1A did not affect secreted levels of 
FJX1 protein (Figure 26D), supporting the conclusion that secreted FJX1 is not 
the direct effector of endothelial cell capillary tube formation. Rather, FJX1 
expression causes secretion of other pro-angiogenic proteins in a HIF1-α 
dependent manner. 
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Figure 24.  FJX1 mRNA expression in human colorectal cancers correlates 
with expression of known angiogenic factors.  Gene-set enrichment analysis 
of 186 defined angiogenic factors (GO:0001525) ranked by correlation from left 
(highest rank) to right (lowest rank) with FJX1 expression in independent publicly 
available colon cancer microarray datasets (A) MCC and (B) VUMC.  The 
enrichment score is shown by the green curve. Vertical black lines indicate the 
position of known angiogenic genes in the ranked list, with the density of these 
genes (and corresponding enrichment score) decreasing with declining 
correlation to FJX1.  
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Table 5.  Gene symbol, gene name, and literature citation for association 
with HIF1-α for the top 43 genes found in the leading edge subset of both 
VUMC and MCC datasets after GSEA analysis 
Gene 
Symbol Gene name 
Reference for regulation 
by HIF1-α 
ANGPT1 angiopoietin 1   
ANGPT2 
angiopoietin 2 
Simon et al., J Cell Phys 
2008 
ANGPTL3 angiopoietin-like 3   
ANPEP alanyl (membrane) aminopeptidase   
CDH13 cadherin 13, H-cadherin (heart)   
COL15A1 collagen, type XV, alpha 1   
COL18A1 collagen, type XVIII, alpha 1   
COL4A2 collagen, type IV, alpha 2   
COL4A3 collagen, type IV, alpha 3 (Goodpasture antigen)   
CTGF connective tissue growth factor   
CYR61 
cysteine-rich, angiogenic inducer, 61 
Wolf et al., Endocrinology 
2010; Wan et al., J. Exp 
Clin Can Res 2011 
DDAH1 dimethylarginine dimethylaminohydrolase 1   
EDNRA endothelin receptor type A   
ELK3 ETS-domain protein (SRF accessory protein 2)    
ENG 
endoglin  
Sanchez-Elsner et al., JBC 
2002 
ENPEP glutamyl aminopeptidase (aminopeptidase A)   
FLT1 
(VEGFR1) 
fms-related tyrosine kinase 1 (vascular 
endothelial growth factor/vascular permeability 
factor receptor Okuyama et al., JBC 2006 
HDAC5 histone deacetylase 5   
HIF1A hypoxia inducible factor 1, alpha subunit (basic 
helix-loop-helix transcription factor)   
JAG1 jagged 1   
KDR 
(VEGFR2) 
kinase insert domain receptor (a type III receptor 
tyrosine kinase)   
KLK3 kallikrein-related peptidase 3   
MMP14 
matrix metallopeptidase 14 (membrane-inserted) 
Wan et al., J. Exp Clin Can 
Res 2011 
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Table 5 Continued. 
Gene 
Symbol Gene name 
Reference for regulation 
by HIF1-α 
MYH9 myosin, heavy chain 9, non-muscle   
NRP1 neuropilin 1   
PLAU plasminogen activator, urokinase   
PLXDC1 plexin domain containing 1   
PLXND1 plexin D1   
PTEN phosphatase and tensin homolog   
PTPRM protein tyrosine phosphatase, receptor type, M   
RHOB ras homolog gene family, member B    
ROBO1 roundabout, axon guidance receptor, homolog 1   
SERPINE1 serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type1), member 1 Elvidge et al., JBC 2006 
SERPINF1 
serpin peptidase inhibitor, clade F (alpha-2 
antiplasmin, pigment epithelium derived factor) 
member 1   
SLIT2 slit homolog 2   
SOX18 SRY (sex determining region Y)-box 18   
SPHK1 sphingosine kinase 1 Anelli et al, JBC 2008 
TEK tyrosine kinase, endothelial Lai et al., J Mol Med 2012 
TGFB2 transforming growth factor, beta 2   
THBS1 
thrombospondin 1 
Osada-Oka et al., J Cell 
Biochem 2008 
THY1 Thy-1 cell surface antigen   
TIE1 tyrosine kinase with immunoglobulin-like and 
EGF-like domains 1   
VEGFC 
vascular endothelial growth factor C 
Spinella et al, Can Res.  
2009 
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Figure 25.  FJX1 expression does not alter HIF1-α mRNA expression 
but increase HIF1-α protein.   Relative fold change in HIF1-α mRNA expression 
in (A) SW480, (B) HEK293T and (C) KM12C transfected with vector (VEC) or 
FJX1 (FJX1). Each data point is the mean of a biological replicate.  Bars and 
whiskers represent mean and standard error of the mean respectively. 
Significance was determined by a Student’s t-test. ns = not significant.  (D) 
Representative HIF1-α protein levels as determined by immunoblot of whole cell 
lysates from VEC and FJX1 transduced cell lines.  β-actin served as the loading 
control.   
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Figure 26. Increased HIF1-α contributes to FJX1-induced increase in 
endothelial tube formation (A) Relative fold change in HIF1-α mRNA 
expression in SW480FJX1MYC (FJX1) as compared to SW480VEC (VEC). (B) 
Representative HIF1-α immunoblot of whole cell lysates.  β-actin served as the 
loading control.  (C)  Relative number of HMEC-1 tube structures as compared 
with SW480VEC (VEC) UT after treatment with conditioned media from SW480 
cell derivatives as noted. (D)  Representative immunoblot of FJX1 in conditioned 
media from SW480FJX1MYC cells.  Coomassie stain represents loading control.  
UT= untreated.  siSCR = treated with scrambled siRNA.  siHIF1 = treated with 
HIF1A siRNA. Each data point is the mean of a biological replicate.  Bars and 
whiskers represent mean and standard error of the mean respectively.  
Significance was determined by ANOVA.  *** = p<0.0001. 
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Next we analyzed whether expression of a mutated version of FJX1 
affected endothelial tube formation and HIF1A expression.  This mutation was 
based upon sequence homology with Drosophila fj:  residues essential for fj 
kinase activity that were conserved in FJX1 were mutated from aspartic acid and 
glutamine to alanine (FJX1DEFLAG).  We found that conditioned media from 
HEK293T and SW480 cells expressing FJX1DEFLAG promoted tube formation 
similarly to conditioned media from wild-type FJX1 expressing cells (Figure 27, A 
and B).  Similarly, expression of either wild-type or mutant FJX1 in HMEC-1 cells 
promoted autonomous capillary tube formation as compared to vector expressing 
control cells (Figure 27C).  Finally, we observed a similar increase in HIF1-α 
protein levels regardless of whether wild-type or mutant FJX1 was expressed in 
cell lines (Figure 27D).  Taken together, we found that mutation of the putative 
kinase domain of FJX1 has no effect on capillary tube formation.  
HIF1-α is sufficient to promote endothelial capillary tube formation in vitro.   
We then determined whether transient HIF1A expression alone in the 
HEK293T cells was sufficient to induce release of the angiogenic factor into the 
conditioned medium.  Upon transient transfection of either FJX1-MYC or HA-
HIF1A, HIF1-α protein expression was increased compared to vector transduced 
cells (Figure 28B) whereas HIF1A mRNA was only increased when HA-HIF1A 
was transfected (Figure 28A).  Conditioned media from HEK293T cells 
transiently transfected with either HA-HIF1A or FJX1-MYC stimulated HMEC-1 
tube formation as compared to conditioned media from vector  
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Figure 27.  Autonomous and non-autonomous expression of FJX1FLAG and 
FJX1DEFLAG enhances endothelial capillary tube formation in vitro.  (A/B)  
Data represent the number of HMEC-1 tube structures formed on matrigel 
following treatment with FJX1, or FJX1DE conditioned media as compared with 
VEC conditioned media for (A) HEK293T and (B) SW480.  (C) For HMEC1 cell 
lines, data represent the number of tube structures formed in matrigel after stable 
expression of vector (VEC), FJX1, or FJX1DE.  (D)  Representative immunoblot of 
HIF1-α in whole cell lysates from SW480 and HMEC-1 cell lines stably 
expressing VEC, FJX1, or FJX1DE. 
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Figure 28.  Increased HIF1-α expression is sufficient to promote endothelial 
tube formation in vitro.  (A) Relative fold change in HIF1A mRNA expression in 
HEK293T transiently transfected with vector (VEC), FJX1 (FJX1) or HIF1A 
(HIF1). Each data point is the mean of a technical replicate.  β-actin served as 
the loading control. (B) Representative western blot of HIF1-α and FJX1 protein 
in HEK293T cells transiently transfected with VEC, FJX1, or HA-HIF1A   (C) 
Relative number of HMEC-1 tube structures after treatment with conditioned 
media from vector, FJX1 or HIF1A transduced HEK293T cells including 
fractionation of the media.  RET = retained on column; FT = flow through.  
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transduced controls (Figure 28C).  Furthermore, fractionation of conditioned 
media using a 30,000 nominal molecular weight cut-off filter revealed that the 
pro-angiogenic factor was found in the flow through (Figure 28C), similar to what 
we observed with the SW480FJX1MYC cells (Figure 23C).   
VEGF-A is a transcriptional target of HIF1-α [47] and has been well 
characterized as an angiogenic stimulus.  VEGF-A mRNA was upregulated in 
SW480FJX1 cells as compared with SW480VEC (Figure 28D) and VEGF-A protein 
was increased in total SW480FJX1MYC conditioned media as compared with 
SW480VEC by ELISA (Figure 28E).  However, species of VEGF-A detected by 
commercially available antibodies was excluded from the flow through fraction 
that contained the pro-angiogenic factor that promoted HMEC-1 tube formation 
(data not shown).     
FJX1 post-transcriptionally regulates HIF1-α protein levels.   
To determine how HIF1-α protein levels were regulated by FJX1 we 
transiently expressed HA-tagged HIF1A with and without FJX1 in HEK293T cells.  
When co-expressed with FJX1, HIF1-α protein levels were increased under both 
normoxic and hypoxic conditions (Figure 29A).  Addition of the proteasome 
inhibitor MG132 equalized HIF1-α protein levels whether or not FJX1 was 
present, suggesting elevated HIF1-α protein levels were a reflection of reduced 
degradation rather than increased translation (Figure 29A).  The addition of 
cycloheximide, which halts new protein translation, showed that HIF1-α protein 
was stabilized in the presence of FJX1 (Figure 29B).  Our data therefore support 
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a model whereby FJX1 expression can increase HIF1-α protein stability and 
promote secretion or release of pro-angiogenic molecules. 
Proteomic analysis of conditioned media from SW480 cell lines.   
Our data thus far have shown that conditioned media from SW480FJX1 
cells contains pro-angiogenic factors.  These factors are found in the flow 
through compartment after fractionation based on a 30,000 nominal molecular 
weight cut off.  To identify this secreted pro-angiogenic factor we performed 
proteomics on the flow through fraction of conditioned media from SW480VEC and 
SW480FJX1 cells.  The top 16 peptides identified as being increased in SW480FJX1  
conditioned media mapped to Annexin A1; Ina-D like protein and Ina-D like 
protein isoforms 2,4,5; tenascin C and tenascin C isoforms 
2,3,4,5,6,1414AD1/16.  Of the three proteins and related isoforms, annexin A1 
was smallest in size and known to be secreted from cells.  We confirmed by 
immunoblot that annexin A1 was indeed increased in conditioned media from 
SW480FJX1 as compared to SW480VEC cells.  However, we were unable to detect 
annexin A1 in the flow through fraction (Figure 30).  This may be due to a failure 
of the antibody to detect smaller peptides (Figure 30).  Further analysis will be 
required to see if annexin A1 is cleaved into smaller active fragments that 
account for the pro-angiogenic factor in SW480FJX1 conditioned media.     
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Figure 29.  FJX1 enhances HIF1-α protein stability by enhancing HIF1-α 
half-life.  (A) Representative HA immunoblot of whole cell lysates from HEK293T 
cells transfected with HA-HIF1A and VEC or FJX1 cultured in normoxia or 
hypoxia (4 hours) with or without treatment of MG132 (50uM 2hrs).  (B) 
Representative HA immunoblot of whole cell lysates from HEK293T cells 
transfected with HA-HIF1A and VEC or FJX1 pre-cultured in hypoxia (2hrs) and 
treated with cycloheximide (100uM) for the indicated time in minutes.  
Quantification is graphed on the right.  
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Figure 30.  Conditioned media from SW480FJX1 cells has increased levels of 
Annexin A1 as compared to SW480VEC cells.  Representative Annexin A1 
immunoblot of conditioned media from SW480 cells after fractionation.  RET = 
retained on column; FT = flow through.  
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Discussion 
We identified FJX1 as a protein that is overexpressed in CRC and 
demonstrated a pro-tumorigenic role for FJX1 through its ability to promote 
angiogenesis. To correlate our observations linking increased angiogenesis with 
enhanced FJX1 expression (either in vivo or in vitro) we queried two human 
colorectal cancer datasets for association between expression of FJX1 and 
known angiogenesis factors.  Indeed, we found strong correlations between 
FJX1 expression and expression of pro-angiogenic genes such as HIF1A, VEGF-
C, and angiopoietin 1 and 2.   
We detected increased HIF1-α protein in FJX1 transduced HEK293T, 
SW480, KM12C, and CACO2 cells and experimentally linked HIF1-α levels to 
increased capillary tube formation. HIF1-α has been shown to induce pro-
angiogenic programs through modulation of a variety of molecules including but 
not limited to VEGF, FLT1, ANGPT2, THBS1 and CYR61  [87-89,91,95,96].  The 
ability of several known targets to either promote or hinder endothelial cell 
function is complex and context dependent.  For example, ANGPT2 promotes 
endothelial sprouting in the presence of VEGF, but promotes endothelial 
regression in the absence of VEGF [97,98].  Also, proteins may undergo 
proteolytic processing into smaller peptides that are functionally distinct from the 
full length form, i.e. VEGF and COL18A1 [99,100]   Although we detected 
increased expression of the HIF1-α-regulated VEGF-A in FJX1 expressing cells, 
VEGF-A was excluded from the flow through fraction of conditioned media that 
contained the angiogenic stimulus associated with FJX1 expression.  This 
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molecule may represent a smaller VEGF related fragment or peptide not 
detectable by available reagents, or indeed a novel HIF1-α regulated modulator 
of angiogenesis  
Expression of FJX1 caused increased levels of HIF1-α through an 
increase in HIF1-α protein stability.  Although we initially identified a concordant 
relationship between FJX1 mRNA and HIF1-α mRNA expression in human 
colonic tumors, we were only able to attribute a post-translational role of FJX1 on 
HIF1-α regulation in vitro.  This discrepancy may be due to the complex 
interactions within the tumor microenvironment that are not supported by our in 
vitro model.  Alternatively, it is possible that a common co-regulatory factor 
influences both FJX1 and HIF1-α mRNA expression in vivo.  Under normoxic 
conditions, HIF1-α protein is hydroxylated at proline residues by prolyl 
hydroxylases (PHD) allowing for ubiquitin mediated proteasomal degradation 
involving von Hippel-Lindau [101,102]. Since PHD enzymes have an absolute 
requirement for molecular oxygen, hypoxic conditions inhibit PHD function and 
allow for HIF1-α protein stabilization.  Altered mitochondrial function has also 
been linked to PHD activity with prevailing hypotheses being 1, that reactive 
oxygen species (ROS) from complex III inhibit the PHD enzymes[103,104], or 2, 
that oxygen being shunted through the complex limits the availability of oxygen 
which is required by the PHD enzymes independently of ROS production 
[105,106].  It will be interesting to determine whether FJX1 is interfering with PHD 
activity, perhaps by altering mitochondrial function or affecting more downstream 
targets that are part of the degradation complex.   
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Drosophila fj is a kinase that phosphorylates specific cadherin residues on 
two large cadherins fat and dachsous [57,61].  The three key residues of the fj 
putative kinase domain (DNE) are completely conserved across multiple species, 
including mouse and human.  Mutation of the conserved aspartic acid within this 
region was sufficient to inhibit the biological function of fj [61].  When we mutated 
the aspartic acid and glutamic acid residues, we found no functional change in 
our in vitro assays.  Specifically, expression of either wild-type or mutant FJX1 
promoted both autonomous and non-autonomous endothelial capillary tube 
formation as compared to vector expressing control cells.  Similarly, increased 
HIF1-α protein was observed in both cells that express wild-type or mutant FJX1 
as compared to control cells.  This may be because FJX1 is not a kinase, or 
perhaps these specific mutations in FJX1 do not prohibit kinase activity.  It would 
be surprising if FJX1 was not a kinase, as the fj kinase residues are completely 
conserved among numerous organisms.  However, Strutt and colleagues have 
reported evidence that fj need not be secreted to be functional, while Probst et al. 
have reported that FJX1 is functional as a secreted protein.  Perhaps mammalian 
homologues have acquired additional function through evolution.  Regardless, 
much more work will be required to determine if FJX1 is indeed a kinase, and if 
so, what is the biological relevance of its kinase activity.   
We also performed proteomic analysis on the flow through fraction of 
conditioned media from SW480VEC and SW480FJX1 cell lines to identify the 
secreted angiogenic peptide(s) regulated by FJX1 and HIF1-α. We found 
increased expression of peptides from annexin A1, tenascin C, and InaD-like 
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proteins.  Annexin A1 is a relatively small secreted protein that has been 
historically thought of as anti-inflammatory. However, the generation of annexin 
A1 KO mice revealed an important role in angiogenesis and wound healing 
[107,108].  We detected higher levels of secreted annexin A1 in conditioned 
media from FJX1 transduced cells, but failed to detect species in the flow through 
fraction that contained the pro-angiogenic stiumulus.  Again, it is possible that 
annexin a1 undergoes a modification into smaller peptides undetectable by the 
available regents.  Tenascin C is a huge glycoprotein that is secreted into the 
extracelluar space, and is thought to play a role in tissue remodeling.  Ina-D like 
protein is a scaffolding protein found localized to tight junctions.  Neither tenascin 
C or ina-d like proteins have been described as active small peptides in the 
literature, but it will be of interest to determine if their expression is altered in 
FJX1 transduced cells.  Further we could use siRNA mediated inhibition of all 
these potential candidates (VEGFA, annexin A1, tenascin C, and Ina-D) in the 
FJX1 transduced cells to see if capillary tube formation is reliant on their 
expression.   
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CHAPTER VI.   
GENE EXPRESSION ANALYSIS OF SW480 CELL LINES AFTER 
ALTERED FJX1 AND HIF1A EXPRESSION. 
Introduction 
Four jointed box 1 (FJX1) is the human orthologue of four jointed (fj) in 
Drosophila.  Wingless, Jak/Stat, Notch, and Fat signaling have been shown to 
influence fj expression, and fj in turn can regulate expression of notch ligands, 
wingless, and fat [54,58,59].  Fj has also been associated with the hippo tumor 
suppressor pathway through its effects on fat and dachsous signaling.  Studies 
on the role of mammalian FJX1 in signaling pathways have been extremely 
limited.  One report has suggested that FJX1 is influenced by Notch signaling, 
citing the observation of increased FJX1 promoter activity after transfection with 
Notch1, 2, or 3 [63] but we have failed to reproduced these results in our 
laboratory (data not shown).  McNeill and colleagues have provided some data 
that the ft/ds/fj cassette may be conserved in mammals [66] .  There have also 
been a variety of microarray datasets that suggest various cytokines can 
influence FJX1 expression including inflammatory stimuli such as TNF-α, IL-1 
and LPS [81-83].  We have demonstrated that expression of FJX1 in the SW480 
colorectal cancer cell line causes an increase in xenograft tumor formation 
associated with an increase in tumor vascularization.  In vitro, the FJX1 specific 
effect on endothelial cells requires HIF1-α.  In order to try to understand how 
FJX1 regulates HIF1-α protein levels and angiogenesis, we performed 
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microarray analysis on SW480 cells transduced with vector or FJX1 and treated 
with siRNA specific to FJX1, HIF1A or scrambled control.   
Materials and Methods 
SW480 cell line microarray 
Microarray analysis was performed on four biological replicates of the 
following cells: SW480VEC, SW480FJX1, SW480FJX1 treated with scrambled siRNA, 
SW480FJX1 treated with HIF1A specific siRNA, and SW480FJX1 treated with FJX1 
specific siRNA.  siRNA treatment lasted a total of 96 hours, and the cells were in 
serum free media for the final 24 hours in culture.  RNA was extracted using the 
Qiagen RNeasy Kit (Qiagen) per manufacturer's instructions.  Quality of RNA 
samples was assessed using an Agilent Bioanalyzer.  Target generation is 
performed using the Ambion WT Sense reaction kit from Affymetrix and following 
the manufacturer’s protocol with 130ng of intact RNA. cDNA target is then 
enzymatically fragmented and end-labeled using the Affymetrix labeling reagents 
according to manufacturer’s protocols.  The cRNA, cDNA, and fragmented and 
end-labeled targets are assessed using an Agilent bioanalyzer to ensure that the 
amplified targets meet the recommended smear range and to also assess 
whether fragmentation and end-labeling are complete. For 3’ U133 array plate, 
the requisite amount of fragmented target (6ug) is then added to the hybridization 
cocktail for each array. Fragmented and labeled targets in hybridization cocktail 
are heat denatured, centrifuged, and then added on the appropriate Affymerix 
array plate and loaded onto the Affymetrix GeneTitan.  Multi Channel (MC) 
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platform and array plate undergo an overnight incubation/hybridization according 
to manufacturer’s protocol.  After hybridization, the array plate is washed, and 
stained per standard Affymetrix GeneTitan automation platform protocol 
instructions. After washing is complete, the arrays are scanned on the Affymetrix 
Gene Titan scanner.  Resulting data is analyzed by Affymetrix Expression 
Console v. 1.3 using an RMA normalization algorithm producing log base 2 
results.  
The differentially expressed probes were imported into Ingenuity Pathway 
Analysis (IPA®, www.ingenuity.com) and analyzed for network enrichment by 
mapping to the IPA global molecular network by knowledge-based connectivity. 
Results 
Microarray analysis of SW480 cell lines. 
In order to better understand the signaling pathways altered upon FJX1 
expression and subsequent HIF1A silencing, we performed microarray analysis 
on untreated SW480VEC and SW480FJX1 cells, as well as SW480FJX1 cells treated 
with scrambled siRNA, siRNA specific to FJX1 or siRNA specific to HIF1A 
(summary of gene changes in Table 6).  Normalized mRNA levels from the 
experiment confirmed that the FJX1 and HIF1A siRNA were effective at lowering 
mRNA from their respective genes (Figure 31, A and B).  It should be noted that 
the microarray probe for FJX1 lies in the 3’ untranslated region, thus accounting 
for why SW480FJX1 mRNA levels, which were achieved by stable transduction of 
FJX1 cDNA, are not increased compared to SW480VEC cells (Figure 31A).   
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We identified 335 expression elements as differentially expressed 
(minimum 1.5 fold change) between SW480VEC UT and SW480FJX1 UT cells 
(unadjusted p value > 0.05, Table 7).   We then conducted pathway enrichment 
analysis using a commercially available knowledge-based database. The 
collection of genes differentially expressed in SW480 cells transduced with FJX1 
were significantly enriched in a network known to regulate RNA Post-
Transcriptional Modification, Cell Cycle, and Protein Synthesis (P < 0.005, Figure 
32). Central nodes (defined as genes having at least four direct or indirect 
interactions within the network) included cluster of differentiation 24 (CD24), 
extracellular signal related kinase 1/2 (ERK1/2) and RNA polymerase II.  When 
comparing SW480FJX1 cells treated with scrambled siRNA or siRNA specific to 
FJX1 we identified 819 elements showing a 1.5 fold change between cell lines 
(unadjusted p value > 0.05, Table 8).  Using a cutoff of 2 fold or greater the list 
was narrowed to 98 genes, and this list was used for pathway analysis.  The top 
network identified was characterized by genes involved in Cardiovascular 
System Development and Function, Organismal Development, and Organ 
Morphology (P < 0.005, Figure 33).  Central nodes included cysteine-rich 
angiogenic inducer 61 (CYR61), p38 mitogen associated protein kinase (p38 
MAPK), and ERK 1/2.  Finally, we compared SW480FJX1 cells treated with 
scrambled siRNA or siRNA specific to HIF1A and found 108 elements showing a 
1.5 fold change between cell lines (unadjusted p value > 0.05, Table 9).  The top 
network identified from these 108 was characterized by genes involved in 
Cellular Movement, Embryonic Development, and Cardiovascular System 
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Development and Function (P < 0.005, Figure 34).  Central nodes included HIF1-
α, TGF-β, p38 MAPK, and ERK 1/2.   
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Table 6.  Summary of the number of genes altered between the 
indicated cell lines after microarray analysis.  VEC = SW480VEC.  FJX1 = 
SW480FJX1.  FJX1siSCR = SW480FJX1 cells treated with scrambled siRNA.   
FJX1siFJX1  = SW480FJX1 cells treated with FJX1 specific siRNA. FJX1siHIF1 = 
SW480FJX1 cells treated with HIF1-α specific siRNA.
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Figure 31.  Validation of siRNA in cells used for microarray.  
Normalized microarray signal for (A) FJX1 and (B) HIF1A for cell lines as 
indicated.  *** = p<0.0001.  
 
 
 
109 
 
 
 
Figure 32.  Top network after IPA analysis of the genes differentially 
expressed between SW480VEC and SW480FJX1 cells.  
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 Figure 33.  Top network after IPA analysis of the genes differentially 
expressed between SW480FJX1 cells treated with scrambled siRNA and 
SW480FJX1 cells treated with FJX1 specific siRNA.   
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 Figure 34.  Top network after IPA analysis of the genes differentially 
expressed between SW480FJX1 cells treated with scrambled siRNA and 
SW480FJX1 cells treated with HIF1A specific siRNA.   
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Next, we overlapped the gene lists derived from comparison of SW480VEC 
UT vs SW480FJX1 UT and SW480FJX1 siSCR vs SW480FJX1 siFJX1.  This analysis 
was performed to try to identify molecules that were increased upon FJX1 
expression and subsequently silenced after FJX1 siRNA treatment or vice versa.  
We identified 18 elements mapping to 17 unique genes, 6 of which exhibited 
opposing expression patterns based upon FJX1 expression or silencing; inhibin 
beta e, lethal (3) malignant brain tumor-like protein, CD24, nebulette, proline rich 
20, and serine protease 33 (Table 10).   
We also overlapped the gene lists derived from comparison of SW480VEC 
UT vs SW480FJX1 UT and SW480FJX1 siFSCR vs SW480FJX1 siHIF1A.  Our 
hypothesis was that genes increased by FJX1 transduction that subsequently 
were inhibited after HIF1A siRNA would be potential candidates to analyze for 
their role in the endothelia phenotype.  There were six genes that exhibiting 
significant changes in both gene lists:  CD24; serine palmitoyltransferase, long 
chain base subunit 3; CD55 molecule, decay accelerating factor for complement 
(Cromer blood group); Insulin-like growth factor binding protein-like 1; Lix1 
homolog (chicken); and Vacuolar protein sorting 8 homolog (S. cerevisiae) (Table 
11).  Of the six genes, CD55 was the only molecule shown to be increased after 
FJX1 expression and subsequently decreased upon HIF1-α silencing.  Ongoing 
experiments will be required to see if CD55 plays a role in the pro-angiogenic 
phenotype associated with such gene changes in SW480 cells. 
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Table 10.  Genes found to be significantly altered in both SW480VEC 
vs SW480FJX1 and SW480FJX1 siSCR vs SW480FJX1 siFJX1 gene lists.  Gene 
symbol, title and fold change for the 19 elements is shown.  Negative and 
positive values reflect a decrease and increase in gene expression respectively. 
Gene 
Symbol Gene Title 
Fold-Change 
(FJX1 UT vs. 
VEC UT) 
Fold-Change 
(FJX1 SIFJX1 vs. 
FJX1 SCR) 
AK5 adenylate kinase 5 1.60558 2.08229 
EREG epiregulin 1.81392 1.61777 
FRMD5 
FERM domain containing 
5 1.57505 2.3398 
INHBE inhibin, beta E 1.93314 -4.16243 
L3MBTL3 
l(3)mbt-like 3 
(Drosophila) 1.60835 -1.52025 
OLR1 
oxidized low density 
lipoprotein receptor 1 1.56132 1.93603 
PRSS23 Protease, serine, 23 1.75382 1.85366 
SPTLC3 
serine 
palmitoyltransferase, long 
chain base subunit 3 1.58785 1.73475 
CBFA2T2 
core-binding factor, runt 
domain, alpha subunit 2; 
translocated to, 2 -1.67661 -1.52391 
CD24 CD24 molecule -1.55722 1.96449 
IGF2 /// 
INS-IGF2 
insulin-like growth factor 
2 (somatomedin A) /// 
INS-IGF2 readthrough 
transcript -1.7717 -2.39021 
METTL3 methyltransferase like 3 -1.57098 -1.55455 
MYH7B 
myosin, heavy chain 7B, 
cardiac muscle, beta -2.26467 -2.03838 
NEBL nebulette -1.58306 1.51457 
PCP4 Purkinje cell protein 4 -2.24821 -2.37463 
PRR20A /// 
PRR20B /// 
PRR20C /// 
PRR20D /// 
PRR20E 
proline rich 20A /// proline 
rich 20B /// proline rich 
20C /// proline rich 20D /// 
pro -1.64367 3.3548 
PRSS33 protease, serine, 33 -1.61552 3.32338 
ROBO1 
Roundabout homolog 1 
(Drosophila) -1.52572 -1.61176 
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Table 11.  Genes found to be significantly altered in both SW480VEC 
vs SW480FJX1 and SW480FJX1 siSCR vs SW480FJX1 siHIF1A gene lists.  Gene 
symbol, title and fold change for the 19 elements is shown.  Negative and 
positive values reflect a decrease and increase in gene expression respectively. 
Gene 
Symbol Gene Title 
Fold-
Change 
(FJX1 UT 
vs. VEC UT) 
Fold-Change 
(FJX1 SIHIF 
vs. FJX1 
SCR) 
SPTLC3 
serine 
palmitoyltransferase, 
long chain base 
subunit 3 1.58785 2.16876 
CD55 
CD55 molecule, 
decay accelerating 
factor for 
complement 
(Cromer blood 
group) 1.7142 -1.50861 
IGFBPL1 
Insulin-like growth 
factor binding 
protein-like 1 -1.70416 1.68164 
LIX1 
Lix1 homolog 
(chicken) -2.03114 1.57 
VPS8 
Vacuolar protein 
sorting 8 homolog 
(S. cerevisiae) -1.78746 -1.64178 
CD24 CD24 molecule -1.55722 1.55706 
.   
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Discussion 
In efforts to understand signaling patterns altered by expression of FJX1 
we performed microarray analysis on the SW480 cell lines.  The top genes 
altered by FJX1 expression were enriched in genes involved in RNA post 
translational modification, cell cycle, and protein synthesis.  As neither FJX1 nor 
Drosophila fj have been found in the nucleus, we predict that FJX1 would 
function downstream of transcription.  By far the most robust changes in gene 
expression were between SW480FJX1 cells treated with scrambled or FJX1 
specific siRNA.  Raw expression data shows that FJX1 mRNA was significantly 
silenced after FJX1 siRNA treatment of the SW480FJX1, so much so that these 
cells had lower expression that untreated SW480VEC control cells, suggesting 
that cultured cell lines did express endogenous FJX1 but at a level below our 
limit of detection.  Interestingly, genes altered with this treatment were involved in 
cardiovascular system development and function.  These data nicely correlate 
with the angiogenesis driven biological effect we observe upon FJX1 
manipulation.  Additionally, the top network associated with gene changes 
included cysteine-rich angiogeneic inducer (CYR61) as a central node, a gene 
we also found to change concordantly with FJX1 expression in our human CRC 
datasets.  Further, CYR61 expression can be induced by hypoxia treatment or by 
PGE2 in various cell lines [109,110].  The known role of CYR61 in promoting 
angiogenesis, and its association with inflammatory genes make it an exciting 
candidate to analyze in our cell lines.   
In chapter IV we described our findings that conditioned media from 
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SW480 cells transduced with FJX1 promotes endothelial capillary tube formation 
in vitro in a HIF1-α dependent manner.  Thus we hypothesized that global gene 
expression analysis of SW480 transduced with FJX1 and subsequently treated 
with HIF1A siRNA might provide insight into potential candidates associated with 
this phenotype.  There was one gene that fit this criteria; CD55/decay 
accelerating factor (DAF).  CD55 is a glycoprotein involved in the complement 
cascade; binding of CD55 to complement causes their rapid decay.  Although the 
predominant isoform is transmembrane bound, smaller soluble peptides have 
been identified, but not attributed a biological function.  CD24 was uniquely found 
in all three gene lists:  CD24 was downregulated upon FJX1 expression and 
upregulated with both FJX1 and HIF1A specific siRNA.   Increased expression of 
CD24 has been demonstrated in CRC [111,112] however studies in breast 
cancer have described putative cancer stem cells as being CD44+/CD24- [113].  
Interestingly, CD44+/CD24- cells grow more rapidly in vivo and are associated 
with increased COX-2 expression[114].  Further work will be needed to 
determine both the level of CD55 and CD24 mRNA and protein in CRC cell lines, 
and if they contribute to the biological phenotypes we observe in vitro and in vivo.  
Nevertheless, the global analysis of gene changes in the SW480 cell lines will 
provide a framework for reference of potential signaling pathways that are altered 
upon FJX1 expression.   
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CHAPTER VII. 
SUMMARY AND FUTURE DIRECTIONS 
There is substantial experimental evidence in both mouse models and in 
humans documenting the effectiveness of non-steroidal anti-inflammatory drugs, 
particularly selective COX-2 inhibitors, in reducing both colorectal tumor 
formation and progression [24,25,115,116].   The studies described herein have 
contributed to our understanding of the biological responses to one such 
selective COX-2 inhibitor, celecoxib, by analyzing human tumor gene expression 
in vivo.  To date this is the first genome wide analysis of human rectal tumors in 
response to celecoxib treatment in vivo.  Through this screen we were able to 
identify a novel protein, Four jointed box 1, that was previously uncharacterized 
in human tumor biology.  We generated a variety of reagents, including 
expression vectors and specific polyclonal antibodies that are applicable to 
ELISA, immunoblotting, immunofluorescence, and immunohistochemistry.  
Whereas previous studies had only analyzed FJX1 mRNA, we have provided the 
first evidence that FJX1 protein expression is increased in the epithelial cell 
compartment of advanced colorectal cancers.  It will be interesting to determine if 
protein levels are indeed increased in some of these other cancers, and if our 
antibody can demonstrate epithelial expression.  Also, as we were only able to 
screen a dozen or so human tumor samples using FJX1 IHC, it will be of use to 
stain more tissues to strengthen our current data.  Since FJX1 protein is a 
secreted molecule, FJX1 protein levels might be detectable in patient blood or 
urinary samples and serve as a biomarker for colorectal or other cancers.   
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Interestingly, despite our findings that rectal tumors expressed moderate 
to high levels of FJX1 protein, we were unable to detect endogenous FJX1 
protein expression in cultured colon cancer, human embryonic kidney or 
endothelial cells, and thus were unable to demonstrate an effect of celecoxib on 
FJX1 expression.   Our ability to reliably detect endogenous FJX1 in the epithelial 
cells of colon tumor specimens, but not in immortalized colon cancer cell lines 
suggests that expression of FJX1 may require paracrine signaling or matrix 
interactions not supported through standard cell culture conditions.  Since we 
also failed to detect expression of FJX1 in SW480 vector-transduced cells grown 
as subcutaneous tumor xenografts, but detected FJX1 protein in human 
colorectal tumors, it is highly likely that some component of the colonic niche is 
crucial in maintaining FJX1 expression in colonic cells.  Similarly, despite COX-2 
expression being upregulated in the majority of CRC, expression in cell lines is 
much more limited.  One study identified a common sequence in both the COX-2 
and FJX1 promoters although the factors binding this type of element are 
unknown.  Perhaps there is a common paracrine factor that regulates expression 
of both COX-2 and FJX1 in vivo that is absent from cell cultures. 
We postulated that our observation that patients with higher FJX1 mRNA 
expression have worse survival outcomes is related to the pro-angiogenic effects 
of FJX1 on tumor formation.  In both xenograft and inflammatory/carcinogen 
induced mouse models of tumorigenesis we found an association between 
vascularization and FJX1 expression; colonic sections and tumor xenografts 
lacking FJX1 had fewer blood vessels.  It is well recognized that without 
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angiogenesis, tumors remain limited in both size and location, thus posing limited 
threat to the overall health of the individual [80].  Converging evidence supports 
the role of axon-guidance cues in both normal vasculature development (for 
review, [117]) and tumor associated angiogenesis [118,119].  FJX1 is highly 
expressed throughout the central nervous system during development and in the 
adult mouse [64,65].   In Fjx1 KO mice, specific subsets of hippocampal neurons 
exhibit either increased dendrite length or decreased arborization [65]. The 
observation that neuronal cues (neuropilins, ephrins, netrins, slits) are also 
expressed in certain tumors raised questions as to how these proteins might 
influence tumor development.  Our observations suggest that FJX1 may 
represent another protein that exhibits a dual function in neuron/endothelial 
biology.   
In vitro, conditioned media from FJX1 expressing cells was able to 
stimulate endothelial capillary tube formation.   This non-autonomous phenotype 
was maintained even upon exclusion of secreted FJX1 protein, suggesting that 
FJX1 regulates secretion of other angiogenic factors.  The cell lines used in our 
studies, SW480, KM12C and HEK293T, do not express detectable levels of 
COX-2, arguing that the pro-angiogenic phenotype is  FJX1 specific and not due 
to previously described angiogenic effects of COX-2 [40]. We also found strong 
correlations between expression of FJX1 and known angiogenic genes in two 
human colorectal cancer datasets, supporting our experimental data showing 
FJX1 regulates tumor angiogenesis.   
We detected increased HIF1-α protein in FJX1 transduced cells and 
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experimentally linked HIF1-α levels to increased capillary tube formation.  HIF1-α 
has been shown to induce pro-angiogenic programs through modulation of a 
variety of molecules including but not limited to VEGF, FLT1, ANGPT2, THBS1 
and CYR61 [87-89,91,95,96].  Some of these proteins can undergo proteolytic 
processing into smaller peptides that are functionally distinct from the full length 
form, i.e. VEGF and COL18A1 [99,100].  Although we detected increased 
expression of the HIF1-α-regulated VEGF and annexin A1 in conditioned media 
from FJX1 transduced cell lines, these proteins were excluded from the flow 
through fraction of conditioned media that contained the angiogenic stimulus 
associated with FJX1 expression.   We have argued that smaller processed 
forms of VEGF or annexin A1 might not be detectable with the antibodies used in 
our study, but may contribute to the endothelial phenotype.  Although one could 
argue that this may also be true for FJX1, our proteomics data on the flow 
through fraction only detected annexin A1 peptides, but not VEGF or FJX1.  
Inhibition of annexin A1 in our FJX1 transduced cell lines will help determine if 
annexin A1 does contribute to the capillary tube phenotype.     
 We found that FJX1 increases HIF1-α protein stability.  Post 
transcriptionally, HIF1- α is tightly regulated by oxygen levels in the cell, as 
molecular oxygen is absolutely required for PHD and FIH-mediated modification 
of HIF1-α.   We will need to assess if cellular oxygen levels are altered in our 
FJX1 expressing cells.  Altered cellular oxygen levels may be due to an alteration 
of mitochondrial function which has been proposed to interfere with PHD activity 
in either a ROS dependent or independent fashion.  The addition of mitochondrial 
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inhibitors (i.e. sodium azide) or anti-oxidant reagents (i.e. n-acetyl cysteine) to 
our cell lines will help us tease out where FJX1 may be limiting the ability to 
degrade HIF1-α.  It will also be necessary to determine if FJX1 regulates the 
interaction of HIF1-α with components of its degradation complex, including VHL.     
Our FJX1-specific antibodies allowed us to characterize FJX1 localization 
and processing.  Despite the development of commercially available antibodies 
since the onset of these studies, our reagents seem much more specific and 
widely effective thereby enabling us to characterize human FJX1.  Like 
Drosophila fj [56], human FJX1 protein is found to localize to the Golgi apparatus 
where it is processed by glycosylation and phosphorylation, before secretion.   It 
is interesting that fj retains function in a Golgi tethered form [56] while murine 
FJX1 was shown to function as a secreted protein [65].  In our experiments, we 
found that FJX1 induces secretion of other molecules that were responsible for 
effects on endothelial cells in vitro.  Expression of FJX1 in Drosophila failed to 
show any activity (David Strutt, personal communication), which may be due to a 
divergence of sequence or perhaps altered function altogether.   The residues in 
fj that are required for kinase activity are completed conserved across numerous 
species, including vertebrate.  Mutation of these conserved regions in FJX1 did 
not affect the ability of FJX1 to stimulate endothelial cells or increase HIF1-α 
protein.  Thus more experimental testing will be required if FJX1 is indeed a 
kinase, and if so what domains are required for function.   
In conclusion, we have identified a novel, pro-angiogenic protein in 
colorectal carcinoma.  Our discovery of FJX1 as a potential COX-2 regulated 
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gene in vivo is of particular interest since numerous studies show the benefits of 
COX-2 inhibition in the formation and progression of CRC.  The ability of FJX1 
protein to enhance angiogenesis is particularly intriguing, especially if this 
biological function holds true in other cancers where increased FJX1 mRNA has 
been observed.  The large amount of expression data from our FJX1 
manipulated cell lines provides a wide array of potential mechanisms to explore 
to help explain the biological function of FJX1.    
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Table 1.  Genes inhibited in human rectal tumor biopsies after celecoxib 
treatment.  Affymetrix probe ID, Gene ID, symbol and name for the 96 
expression elements inhibited after celecoxib treatment.   
Affymetrix Probe 
ID 
Entrez Gene 
ID 
Gene 
Symbol Gene Name 
219249_s_at 60681 FKBP10 FK506 binding protein 10, 65 kDa 
242444_at 114904 C1QTNF6 
C1q and tumor necrosis factor 
related protein 6 
230281_at 123775 C16orf46 
chromosome 16 open reading frame 
46 
240258_at 2023 ENO1 enolase 1 
218410_s_at 283871 PGP phosphoglycolate phosphatase 
223001_at 58505 OSTC 
oligosaccharyltransferase complex 
subunit 
230440_at 84627 ZNF469 zinc finger protein 469 
219785_s_at 79791 FBXO31 F-box protein 31 
241903_at 
 
NA 
 221932_s_at 51218 GLRX5 glutaredoxin 5 
213230_at 30850 CDR2L 
cerebellar degeneration-related 
protein 2-like 
228655_at 
 
NA 
 
201052_s_at 9491 PSMF1 
proteasome (prosome, macropain) 
inhibitor subunit 1 (PI31) 
241392_at 55254 TMEM39A transmembrane protein 39A 
225484_at 95681 TSGA14 testis specific, 14 
222768_s_at 51605 TRMT6 
tRNA methyltransferase 6 homolog 
(S. cerevisiae)  
205406_s_at 53340 SPA17 sperm autoantigenic protein 17 
218739_at 51099 ABHD5 abhydrolase domain containing 5 
217831_s_at 55968 NSFL1C NSFL1 (p97) cofactor (p47) 
1565644_at 
 
NA 
 206514_s_at 
 
NA 
 
223748_at 83959 SLC4A11 
solute carrier family 4, sodium borate 
transporter, member 11 
201695_s_at 
 
NP 
 210187_at 2280 FKBP1A FK506 binding protein 1A, 12kDa 
218809_at 80025 PANK2 pantothenate kinase 2 
217958_at 51399 TRAPPC4 trafficking protein particle complex 4 
217042_at 51109 RDH11 
retinol dehydrogenase 11 (all-
trans/9-cis/11-cis) 
212072_s_at 1457 CSNK2A1 casein kinase 2, alpha 1 polypeptide 
219324_at 
 
NA 
 226276_at 153339 TMEM167A transmembrane protein 167A 
225819_at 84897 TBRG1 
transforming growth factor beta 
regulator 1 
124 
 
236901_at 
 
NA 
 
213419_at 323 APBB2 
amyloid beta (A4) precursor protein-
binding, family B, member 2 
1555778_a_at 10631 POSTN periostin, osteoblast specific factor 
1558487_a_at 222068 TMED4 
transmembrane emp24 protein 
transport domain containing 4 
225648_at 140901 STK35 serine/threonine kinase 35 
57703_at 205564 SENP5 SUMO1/sentrin specific peptidase 5 
238542_at 80328 ULBP2 UL16 binding protein 2 
227628_at 493869 GPX8 glutathione peroxidase 8 (putative) 
209596_at 25878 MXRA5 matrix-remodelling associated 5 
218840_s_at 55191 NADSYN1 NAD synthetase 1 
225196_s_at 64949 MRPS26 mitochondrial ribosomal protein S26 
232150_at 
 
NA 
 
213425_at 7474 WNT5A 
wingless-type MMTV integration site 
family, member 5A 
222040_at 3178 HNRNPA1 
heterogeneous nuclear 
ribonucleoprotein A1 
220969_s_at 
 
NA 
 208823_s_at 5127 PCTK1 cyclin-dependent kinase 16 
205990_s_at 7474 WNT5A 
wingless-type MMTV integration site 
family, member 5A 
204327_s_at 7753 ZNF202 zinc finger protein 202 
213799_s_at 5786 PTPRA 
protein tyrosine phosphatase, 
receptor type, A 
231227_at 
 
NA 
 
235588_at 157570 ESCO2 
establishment of cohesion 1 homolog 
2 (S. cerevisiae) 
223278_at 2706 GJB2 gap junction protein, beta 2, 26kDa 
200825_s_at 10525 HYOU1 hypoxia up-regulated 1 
201692_at 10280 SIGMAR1 
sigma non-opioid intracellular 
receptor 1 
216175_at 
 
NA 
 210809_s_at 10631 POSTN periostin, osteoblast specific factor 
218357_s_at 26521 TIMM8B 
translocase of inner mitochondrial 
membrane 8 homolog B (yeast) 
203325_s_at 1289 COL5A1 collagen, type V, alpha 1 
219522_at 24147 FJX1 four jointed box 1 (Drosophila) 
220002_at 55083 KIF26B kinesin family member 26B 
214074_s_at 2017 CTTN cortactin 
203459_s_at 64601 VPS16 
vacuolar protein sorting 16 homolog 
(S. cerevisiae) 
201715_s_at 22985 ACIN1 
apoptotic chromatin condensation 
inducer 1 
226572_at 30837 SOCS7 suppressor of cytokine signaling 7 
218159_at 65992 DDRGK1 DDRGK domain containing 1 
225554_s_at 51434 ANAPC7 
anaphase promoting complex 
subunit 7 
226899_at 219699 UNC5B unc-5 homolog B (C. elegans) 
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235511_at 
 
NA 
 234111_at 
 
NA 
 205543_at 22824 HSPA4L heat shock 70kDa protein 4-like 
239228_at 
 
NA 
 212691_at 23511 NUP188 nucleoporin 188kDa 
222380_s_at 10016 PDCD6 programmed cell death 6 
1556055_at 
 
NA 
 
200874_s_at 10528 NOP56 
NOP56 ribonucleoprotein homolog 
(yeast) 
209246_at 10061 ABCF2 
ATP-binding cassette, sub-family F 
(GCN20), member 2 
212624_s_at 1123 CHN1 chimerin (chimaerin) 1 
215011_at 8420 SNHG3 
small nucleolar RNA host gene 3 
(non-protein coding) 
1562352_at 
 
NA 
 
219709_x_at 65990 FAM173A 
family with sequence similarity 173, 
member A 
1565786_x_at 645566 FLJ45482 hypothetical LOC645566 
219678_x_at 64421 DCLRE1C DNA cross-link repair 1C 
230469_at 219790 RTKN2 rhotekin 2 
238732_at 255631 COL24A1 collagen, type XXIV, alpha 1 
221637_s_at 79081 C11orf48 
chromosome 11 open reading frame 
48 
236250_at 172 AFG3L1 
AFG3 ATPase family gene 3-like 1 
(S. cerevisiae) 
206336_at 6372 CXCL6 
chemokine (C-X-C motif) ligand 6 
(granulocyte chemotactic protein 2) 
217841_s_at 51400 PPME1 
protein phosphatase methylesterase 
1 
232278_s_at 55635 DEPDC1 DEP domain containing 1 
225649_s_at 140901 STK35 serine/threonine kinase 35 
233216_at 340481 ZDHHC21 zinc finger, DHHC-type containing 21 
221598_s_at 9442 MED27 mediator complex subunit 27 
210532_s_at 9556 C14orf2 
chromosome 14 open reading frame 
2 
1556111_s_at 
 
NA 
 237486_at 
 
NA 
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Table 2.  Genes stimulated in human rectal tumor biopsies after celecoxib 
treatment. Affymetrix probe ID, Gene ID, symbol and name for the 96 
expression elements stimulated after celecoxib treatment.   
Affymetrix Probe 
ID 
Entrez Gene 
ID 
Gene 
Symbol Gene Name 
201369_s_at 678 ZFP36L2 
zinc finger protein 36, C3H type-like 
2 
239066_at 
 
NA 
 
214156_at 25924 MYRIP 
myosin VIIA and Rab interacting 
protein 
226525_at 9262 STK17B serine/threonine kinase 17b 
223469_at 54858 PGPEP1 pyroglutamyl-peptidase 
225207_at 5166 PDK4 
pyruvate dehydrogenase kinase, 
isozyme 4 
221756_at 113791 PIK3IP1 
phosphoinositide-3-kinase 
interacting protein 1 
219195_at 10891 PPARGC1A 
peroxisome proliferator-activated 
receptor gamma, coactivator 1 alpha 
229146_at 136895 C7orf31 
chromosome 7 open reading frame 
31 
236235_at 83737 ITCH 
itchy E3 ubiquitin protein ligase 
homolog 
205066_s_at 5167 ENPP1 
ectonucleotide 
pyrophosphatase/phosphodiesterase 
1 
225498_at 128866 CHMP4B chromatin modifying protein 4B 
201368_at 
 
ZFP36L2 
 
209221_s_at 9885 OSBPL2 oxysterol binding protein-like 2 
213268_at 23261 CAMTA1 
calmodulin binding transcription 
activator 1 
201367_s_at 
 
ZFP36L2 
 
210482_x_at 5607 MAP2K5 
mitogen-activated protein kinase 
kinase 5 
223169_s_at 58480 RHOU ras homolog gene family, member U 
205960_at 5166 PDK4 
pyruvate dehydrogenase kinase, 
isozyme 4 
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203719_at 2067 ERCC1 
excision repair cross-complementing 
rodent repair deficiency, 
complementation group 1 
205997_at 10863 ADAM28 
a disintegrin and metalloproteinase 
domain 28 
1553704_x_at 163049 ZNF791 zinc finger protein 791 
201466_s_at 3725 JUN jun oncogene 
239934_x_at 
 
NA 
 
225380_at 91461 
SGK493 
(PKDCC) 
protein kinase domain containing, 
cytoplasmic homolog 
229026_at 56990 CDC42SE2 CDC42 small effector 2 
205094_at 5193 PEX12 peroxisomal biogenesis factor 12 
219132_at 57161 PELI2 pellino homolog 2 
223130_s_at 29116 MYLIP 
myosin regulatory light chain 
interacting protein 
228788_at 29799 YPEL1 yippee-like 1 
213385_at 1124 CHN2 chimerin (chimaerin) 2 
201360_at 1471 CST3 cystatin C 
216871_at 23390 ZDHHC17 
zinc finger, DHHC-type containing 
17 
212929_s_at 
 
NA 
 
202080_s_at 22906 TRAK1 trafficking protein, kinesin binding 1 
222891_s_at 53335 BCL11A 
B-cell CLL/lymphoma 11A (zinc 
finger protein) 
225130_at 54764 ZRANB1 
zinc finger, RAN-binding domain 
containing 1 
219801_at 80778 ZNF34 zinc finger protein 34 
215315_at 256051 ZNF549 zinc finger protein 549 
211504_x_at 9475 ROCK2 
Rho-associated, coiled-coil 
containing protein kinase 2 
215559_at 368 ABCC6 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 6 
226470_at 2686 GGT7 gamma-glutamyltransferase 7 
229984_at 56986 DTWD1 DTW domain containing 1 
211370_s_at 5607 MAP2K5 
mitogen-activated protein kinase 
kinase 5 
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223044_at 30061 SLC40A1 
solute carrier family 40 (iron-
regulated transporter), member 1 
241962_at 
 
NA 
 1552455_at 158471 PRUNE2 prune homolog 2 
223283_s_at 10194 TSHZ1 teashirt zinc finger homeobox 1 
205236_x_at 6649 SOD3 
superoxide dismutase 3, 
extracellular 
203187_at 1793 DOCK1 dedicator of cytokinesis 1 
225132_at 26224 FBXL3 
F-box and leucine-rich repeat protein 
3 
1558293_at 23285 KIAA1107 KIAA1107 
223897_at 91661 ZNF765 zinc finger protein 765 
232336_at 57643 ZSWIM5 zinc finger, SWIM-type containing 5 
201236_s_at 7832 BTG2 BTG family, member 2 
203697_at 2487 FRZB frizzled-related protein 
219497_s_at 53335 BCL11A 
B-cell CLL/lymphoma 11A (zinc 
finger protein) 
226555_at 54891 INO80D INO80 complex subunit D 
228503_at 
 
NA 
 219548_at 7564 ZNF16 zinc finger protein 16 
1553375_at 114781 BTBD9 BTB (POZ) domain containing 9 
226679_at 284129 SLC26A11 solute carrier family 26, member 11 
213263_s_at 5094 PCBP2 poly(rC) binding protein 2 
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Table 7.  Probeset ID, gene symbol, refseq transcript ID and fold 
change from microarray analysis of SW480VEC versus SW480FJX1 colon 
cancer cells. 
Probeset ID Gene Symbol 
RefSeq Transcript 
ID 
Fold-
Change 
(FJX1 UT 
vs. VEC UT) 
229777_PM_at CLRN3 NM_152311 -3.03735 
234989_PM_at --- --- -2.79504 
227062_PM_at --- --- -2.57087 
205347_PM_s_at TMSB15A NM_021992 -2.48453 
236752_PM_at --- --- -2.36989 
201667_PM_at GJA1 NM_000165 -2.35028 
215795_PM_at MYH7B NM_020884 -2.26467 
236114_PM_at --- --- -2.2604 
229899_PM_s_at NCRNA00275 
NR_003604 /// 
NR_003605 /// 
NR_003606 /// 
NR_036658 /// 
NR_036659 -2.24961 
205549_PM_at PCP4 NM_006198 -2.24821 
205267_PM_at POU2AF1 NM_006235 -2.24541 
236610_PM_at --- --- -2.21907 
218162_PM_at OLFML3 NM_020190 -2.21508 
231199_PM_at --- --- -2.20488 
202831_PM_at GPX2 NM_002083 -2.19997 
1556606_PM_at NAV2 
NM_001111018 /// 
NM_001111019 /// 
NM_145117 /// 
NM_182964 -2.18961 
232528_PM_at --- --- -2.13577 
229147_PM_at RASSF6 
NM_177532 /// 
NM_201431 -2.09525 
235028_PM_at --- --- -2.07442 
242671_PM_at --- --- -2.0559 
240690_PM_at --- --- -2.0495 
236163_PM_at LIX1 NM_153234 -2.03114 
1556331_PM_a_at --- --- -2.0198 
238883_PM_at --- --- -2.01325 
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243541_PM_at IL31RA NM_139017 -1.99815 
206002_PM_at GPR64 
NM_001079858 /// 
NM_001079859 /// 
NM_001079860 /// 
NM_001184833 /// 
NM_001184834 /// 
NM -1.96597 
236961_PM_at --- --- -1.95339 
241425_PM_at NUPL1 
NM_001008564 /// 
NM_014089 -1.93167 
240452_PM_at GSPT1 
NM_001130006 /// 
NM_001130007 /// 
NM_002094 -1.92388 
233303_PM_at --- --- -1.91824 
239653_PM_at --- --- -1.91582 
232979_PM_at --- --- -1.91179 
223746_PM_at STK4 NM_006282 -1.90884 
242918_PM_at NASP 
NM_001195193 /// 
NM_002482 /// 
NM_152298 -1.90822 
243768_PM_at --- --- -1.90306 
237992_PM_at --- --- -1.89083 
235693_PM_at --- --- -1.88934 
215599_PM_at GUSBP3 NR_027386 -1.88831 
232347_PM_x_at --- --- -1.88548 
239811_PM_at --- --- -1.88479 
230256_PM_at C1orf104 NM_001039517 -1.88323 
230712_PM_at NBPF1 NM_017940 -1.8774 
242837_PM_at SFRS4 NM_005626 -1.87292 
213517_PM_at PCBP2 
NM_001098620 /// 
NM_001128911 /// 
NM_001128912 /// 
NM_001128913 /// 
NM_001128914 /// 
NM -1.85011 
209458_PM_x_at HBA1 /// HBA2 
NM_000517 /// 
NM_000558 -1.8429 
243435_PM_at KCNQ1OT1 NR_002728 -1.84055 
230332_PM_at ZCCHC7 NM_032226 -1.82788 
1552423_PM_at ETV3 
NM_001145312 /// 
NM_005240 -1.82479 
1557527_PM_at --- --- -1.8186 
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235172_PM_at --- --- -1.81355 
225667_PM_s_at FAM84A NM_145175 -1.81051 
242110_PM_at --- --- -1.80345 
206488_PM_s_at CD36 
NM_000072 /// 
NM_001001547 /// 
NM_001001548 /// 
NM_001127443 /// 
NM_001127444 -1.80282 
222310_PM_at SFRS15 
NM_001145444 /// 
NM_001145445 /// 
NM_020706 -1.80274 
211653_PM_x_at AKR1C2 
NM_001135241 /// 
NM_001354 /// 
NM_205845 -1.79476 
239917_PM_at VPS8 
NM_001009921 /// 
NM_015303 -1.78746 
229467_PM_at PCBP2 
NM_001098620 /// 
NM_001128911 /// 
NM_001128912 /// 
NM_001128913 /// 
NM_001128914 /// 
NM -1.78444 
236229_PM_at --- --- -1.78304 
233300_PM_at --- --- -1.77553 
229434_PM_at --- --- -1.77548 
202409_PM_at IGF2 /// INS-IGF2 
NM_000612 /// 
NM_001007139 /// 
NM_001042376 /// 
NM_001127598 /// 
NR_003512 -1.7717 
204561_PM_x_at APOC2 NM_000483 -1.77042 
205348_PM_s_at DYNC1I1 
NM_001135556 /// 
NM_001135557 /// 
NM_004411 -1.77011 
206785_PM_s_at KLRC1 /// KLRC2 
NM_002259 /// 
NM_002260 /// 
NM_007328 /// 
NM_213657 /// 
NM_213658 -1.76422 
241865_PM_at --- --- -1.76234 
212980_PM_at USP34 NM_014709 -1.75969 
205506_PM_at VIL1 NM_007127 -1.75953 
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202489_PM_s_at FXYD3 
NM_001136007 /// 
NM_001136008 /// 
NM_001136009 /// 
NM_001136010 /// 
NM_001136011 /// 
NM -1.75854 
241786_PM_at --- --- -1.75822 
242121_PM_at NCRNA00182 NR_028379 -1.75602 
214375_PM_at PPFIBP1 
NM_003622 /// 
NM_177444 -1.75598 
241905_PM_at PIK3C2A NM_002645 -1.75475 
229193_PM_at LUC7L3 
NM_006107 /// 
NM_016424 -1.75458 
230964_PM_at FREM2 NM_207361 -1.75257 
237591_PM_at NCRNA00173 
NR_027345 /// 
NR_027346 -1.74915 
243489_PM_at --- --- -1.74248 
228455_PM_at RBM15 NM_022768 -1.74161 
230099_PM_at --- --- -1.74055 
242233_PM_at --- --- -1.73861 
205431_PM_s_at BMP5 NM_021073 -1.73747 
242389_PM_at LUC7L3 
NM_006107 /// 
NM_016424 -1.73482 
215012_PM_at ZNF451 
NM_001031623 /// 
NM_015555 -1.73275 
241838_PM_at --- --- -1.72584 
210306_PM_at L3MBTL1 
NM_015478 /// 
NM_032107 -1.72529 
236404_PM_at --- --- -1.72378 
216069_PM_at --- --- -1.72072 
232478_PM_at --- --- -1.71932 
229858_PM_at --- --- -1.71772 
244766_PM_at 
LOC100271836 /// 
LOC440354 /// 
LOC595101 /// 
LOC641298 /// SMG1 
NM_015092 /// 
NR_002453 /// 
NR_002473 /// 
NR_027154 /// 
NR_027155 -1.71696 
213593_PM_s_at TRA2A NM_013293 -1.71253 
238642_PM_at ANKRD13D 
NM_207354 /// 
NR_030767 -1.71205 
243514_PM_at --- --- -1.71196 
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205472_PM_s_at DACH1 
NM_004392 /// 
NM_080759 /// 
NM_080760 -1.70995 
230885_PM_at SPG7 
NM_003119 /// 
NM_199367 -1.70717 
217414_PM_x_at HBA1 /// HBA2 
NM_000517 /// 
NM_000558 -1.70587 
227760_PM_at IGFBPL1 NM_001007563 -1.70416 
242550_PM_at EIF3B 
NM_001037283 /// 
NM_003751 -1.69214 
226766_PM_at ROBO2 
NM_001128929 /// 
NM_002942 -1.68602 
232783_PM_at --- --- -1.68513 
213931_PM_at ID2 /// ID2B 
NM_002166 /// 
NR_026582 -1.68098 
235803_PM_at --- --- -1.68086 
205673_PM_s_at ASB9 
NM_001031739 /// 
NM_001168530 /// 
NM_001168531 /// 
NM_024087 -1.67782 
1557810_PM_at --- --- -1.67719 
238549_PM_at CBFA2T2 
NM_001032999 /// 
NM_001039709 /// 
NM_005093 -1.67661 
236907_PM_at --- --- -1.67562 
230064_PM_at --- --- -1.67288 
211980_PM_at COL4A1 NM_001845 -1.67279 
233198_PM_at GOLGA2B 
NR_024261 /// 
NR_036632 -1.67045 
221860_PM_at HNRNPL 
NM_001005335 /// 
NM_001533 -1.6682 
212384_PM_at ATP6V1G2 /// BAT1 
NM_004640 /// 
NM_080598 /// 
NM_130463 /// 
NM_138282 -1.66576 
204260_PM_at CHGB NM_001819 -1.66094 
225786_PM_at NCRNA00201 NR_026778 -1.65919 
1556568_PM_a_at --- --- -1.65795 
1557384_PM_at ZNF131 NM_003432 -1.65457 
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221768_PM_at LOC100506168 
XR_110484 /// 
XR_110485 /// 
XR_110486 /// 
XR_112062 /// 
XR_112063 /// 
XR_112064 /// XR_ -1.64742 
226318_PM_at TBRG1 
NM_032811 /// 
NR_016021 -1.64726 
229574_PM_at TRA2A NM_013293 -1.64498 
239040_PM_at HNRNPD 
NM_001003810 /// 
NM_002138 /// 
NM_031369 /// 
NM_031370 -1.64438 
1562722_PM_at 
PRR20A /// PRR20B /// 
PRR20C /// PRR20D /// 
PRR20E 
NM_001130404 /// 
NM_001130405 /// 
NM_001130406 /// 
NM_001130407 /// 
NM_198441 -1.64367 
226783_PM_at AGXT2L2 NM_153373 -1.64162 
227388_PM_at TUSC1 NM_001004125 -1.63602 
235551_PM_at WDR4 
NM_018669 /// 
NM_033661 -1.63564 
239102_PM_s_at --- --- -1.63552 
226848_PM_at --- --- -1.6353 
243431_PM_at --- --- -1.63503 
235123_PM_at --- --- -1.63485 
239841_PM_at --- --- -1.63469 
242146_PM_at SNRPA1 NM_003090 -1.63369 
239937_PM_at ZNF207 
NM_001032293 /// 
NM_001098507 /// 
NM_003457 -1.63211 
229593_PM_at --- --- -1.63147 
1556821_PM_x_at DLEU2 NR_002612 -1.63104 
217042_PM_at RDH11 NM_016026 -1.63083 
232476_PM_at --- --- -1.62932 
231848_PM_x_at ZNF207 
NM_001032293 /// 
NM_001098507 /// 
NM_003457 -1.62839 
236841_PM_at LOC100134445 XM_001720526 -1.62647 
207154_PM_at DIO3 NM_001362 -1.62509 
237398_PM_at --- --- -1.62387 
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243759_PM_at SFRS15 
NM_001145444 /// 
NM_001145445 /// 
NM_020706 -1.62268 
225815_PM_at CPLX2 
NM_001008220 /// 
NM_006650 -1.62194 
243608_PM_at COG2 
NM_001145036 /// 
NM_007357 -1.61733 
1552348_PM_at PRSS33 NM_152891 -1.61552 
236368_PM_at KIAA0368 NM_001080398 -1.61505 
239027_PM_at DOCK8 
NM_001190458 /// 
NM_001193536 /// 
NM_203447 -1.61482 
239516_PM_at --- --- -1.61463 
242467_PM_at --- --- -1.61418 
207981_PM_s_at ESRRG 
NM_001134285 /// 
NM_001438 /// 
NM_206594 /// 
NM_206595 /// 
NR_024099 -1.61302 
205825_PM_at PCSK1 
NM_000439 /// 
NM_001177875 /// 
NM_001177876 -1.61285 
227394_PM_at NCAM1 
NM_000615 /// 
NM_001076682 /// 
NM_181351 -1.61251 
1557521_PM_a_at --- --- -1.60944 
230312_PM_at --- --- -1.60637 
1557081_PM_at RBM25 NM_021239 -1.60477 
236149_PM_at --- --- -1.6035 
1569540_PM_at --- --- -1.60277 
1565786_PM_x_at FLJ45482 
XR_040445 /// 
XR_040446 /// 
XR_040447 -1.59368 
236428_PM_at --- --- -1.59361 
209757_PM_s_at MYCN NM_005378 -1.5922 
228338_PM_at C11orf93 NM_001136105 -1.59205 
227952_PM_at --- --- -1.59184 
226419_PM_s_at FLJ44342 
XR_109412 /// 
XR_115130 -1.59042 
136 
 
217523_PM_at CD44 
NM_000610 /// 
NM_001001389 /// 
NM_001001390 /// 
NM_001001391 /// 
NM_001001392 -1.59008 
213700_PM_s_at --- --- -1.58934 
239232_PM_at MSI2 
NM_138962 /// 
NM_170721 -1.58872 
209006_PM_s_at C1orf63 NM_020317 -1.58676 
233599_PM_at LOC728061 
XR_040680 /// 
XR_040681 /// 
XR_040682 -1.58504 
230961_PM_at --- --- -1.58439 
1559883_PM_s_at SAMHD1 NM_015474 -1.58404 
217585_PM_at NEBL 
NM_001173484 /// 
NM_006393 /// 
NM_213569 -1.58306 
1556035_PM_s_at ZNF207 
NM_001032293 /// 
NM_001098507 /// 
NM_003457 -1.58238 
205471_PM_s_at DACH1 
NM_004392 /// 
NM_080759 /// 
NM_080760 -1.58155 
230057_PM_at LOC285178 --- -1.57783 
239219_PM_at AURKB NM_004217 -1.57699 
240908_PM_at LOC100507153 XR_110384 -1.57655 
240221_PM_at --- --- -1.57638 
1559490_PM_at LRCH3 NM_032773 -1.57547 
222371_PM_at --- --- -1.57507 
239432_PM_at FLJ31306 
NR_029434 /// 
NR_029435 -1.57419 
215828_PM_at --- --- -1.57363 
233539_PM_at NAPEPLD 
NM_001122838 /// 
NM_198990 -1.57324 
1570259_PM_at LIMS1 
NM_001193482 /// 
NM_001193483 /// 
NM_001193484 /// 
NM_001193485 /// 
NM_001193488 /// 
NM -1.57309 
238453_PM_at FGFBP3 NM_152429 -1.57169 
242111_PM_at METTL3 NM_019852 -1.57098 
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232571_PM_at --- --- -1.56708 
242447_PM_at C3orf70 NM_001025266 -1.5664 
243112_PM_at --- --- -1.56635 
1556336_PM_at RBMX 
NM_001164803 /// 
NM_002139 /// 
NR_028476 /// 
NR_028477 -1.56601 
1561079_PM_at ANKRD28 
NM_001195098 /// 
NM_001195099 /// 
NM_015199 -1.56462 
240494_PM_at --- --- -1.56413 
228173_PM_at --- --- -1.56215 
223679_PM_at CTNNB1 
NM_001098209 /// 
NM_001098210 /// 
NM_001904 -1.56152 
232134_PM_at --- --- -1.56052 
1569353_PM_at CP110 NM_014711 -1.55986 
244075_PM_at --- --- -1.55906 
243282_PM_at CCDC93 NM_019044 -1.55885 
1560622_PM_at --- --- -1.55747 
204687_PM_at PARM1 NM_015393 -1.55735 
216983_PM_s_at ZNF224 NM_013398 -1.55735 
216379_PM_x_at CD24 NM_013230 -1.55722 
228912_PM_at VIL1 NM_007127 -1.55577 
1560297_PM_at --- --- -1.55496 
235190_PM_at --- --- -1.55451 
226663_PM_at ANKRD10 NM_017664 -1.55274 
242040_PM_at GCNT7 NM_080615 -1.55248 
228762_PM_at LFNG 
NM_001040167 /// 
NM_001040168 /// 
NM_001166355 /// 
NM_002304 -1.55154 
236808_PM_at FGFR1OP2 
NM_001171887 /// 
NM_001171888 /// 
NM_015633 -1.54983 
1569142_PM_at TRIM13 
NM_001007278 /// 
NM_005798 /// 
NM_052811 /// 
NM_213590 -1.54752 
1557780_PM_at --- --- -1.54735 
244342_PM_at PATL1 NM_152716 -1.54671 
241435_PM_at --- --- -1.54543 
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219255_PM_x_at IL17RB NM_018725 -1.54441 
1559993_PM_at SFXN3 NM_030971 -1.54432 
232141_PM_at U2AF1 
NM_001025203 /// 
NM_001025204 /// 
NM_006758 -1.54422 
204798_PM_at MYB 
NM_001130172 /// 
NM_001130173 /// 
NM_001161656 /// 
NM_001161657 /// 
NM_001161658 /// 
NM -1.54325 
213326_PM_at VAMP1 
NM_014231 /// 
NM_016830 /// 
NM_199245 -1.54311 
240383_PM_at UBE2D3 
NM_003340 /// 
NM_181886 /// 
NM_181887 /// 
NM_181888 /// 
NM_181889 /// 
NM_181890 /// 
NM_ -1.54061 
220796_PM_x_at SLC35E1 NM_024881 -1.5402 
244174_PM_at --- --- -1.54014 
1570248_PM_at --- --- -1.53989 
221973_PM_at 
LOC100506076 /// 
LOC100506123 
XR_109917 /// 
XR_109918 /// 
XR_109919 /// 
XR_109920 /// 
XR_109921 /// 
XR_109922 /// XR_ -1.53809 
243618_PM_s_at ZNF827 NM_178835 -1.53626 
208798_PM_x_at GOLGA8A 
NM_181077 /// 
NR_027409 -1.53411 
241699_PM_at --- --- -1.53312 
206619_PM_at DKK4 NM_014420 -1.53236 
219049_PM_at CSGALNACT1 
NM_001130518 /// 
NM_018371 /// 
NR_024040 -1.53201 
232601_PM_at --- --- -1.53014 
221831_PM_at LUZP1 
NM_001142546 /// 
NM_033631 -1.52959 
233055_PM_at --- --- -1.52877 
235511_PM_at --- --- -1.52789 
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238456_PM_at LOC100289230 NR_036530 -1.52633 
209446_PM_s_at C7orf44 NM_018224 -1.5259 
213194_PM_at ROBO1 
NM_001145845 /// 
NM_002941 /// 
NM_133631 -1.52572 
232291_PM_at MIR17HG 
NR_027349 /// 
NR_027350 -1.52529 
206224_PM_at CST1 NM_001898 -1.52523 
230464_PM_at S1PR5 
NM_001166215 /// 
NM_030760 -1.52433 
228180_PM_at --- --- -1.52319 
1560556_PM_a_at PLEKHA8 
NM_001197026 /// 
NM_001197027 /// 
NM_032639 -1.52257 
239445_PM_at --- --- -1.52253 
206822_PM_s_at L3MBTL1 
NM_015478 /// 
NM_032107 -1.52251 
226362_PM_at --- --- -1.52158 
242131_PM_at ATP6 --- -1.52022 
1557267_PM_s_at LOC284952 
XM_001126137 /// 
XM_001722633 -1.51949 
235732_PM_at ZNF704 NM_001033723 -1.51929 
230998_PM_at --- --- -1.51851 
244648_PM_at --- --- -1.51851 
215470_PM_at GTF2H2B NR_033417 -1.51656 
242431_PM_at --- --- -1.51612 
235879_PM_at MBNL1 
NM_021038 /// 
NM_207292 /// 
NM_207293 /// 
NM_207294 /// 
NM_207295 /// 
NM_207296 /// 
NM_ -1.51499 
235314_PM_at RPL32P3 NR_003111 -1.51422 
242576_PM_x_at N4BP2L2 
NM_014887 /// 
NM_033111 -1.51418 
219229_PM_at SLCO3A1 
NM_001145044 /// 
NM_013272 -1.51317 
1556432_PM_at --- --- -1.51173 
230180_PM_at --- --- -1.51108 
243691_PM_at --- --- -1.50955 
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221584_PM_s_at KCNMA1 
NM_001014797 /// 
NM_001161352 /// 
NM_001161353 /// 
NM_002247 -1.50899 
233976_PM_at --- --- -1.50884 
244849_PM_at SEMA3A NM_006080 -1.50728 
236411_PM_at --- --- -1.50641 
1565689_PM_at --- --- -1.50435 
229707_PM_at ZNF606 NM_025027 -1.50358 
242059_PM_at --- --- -1.50245 
232529_PM_at SP3 
NM_001017371 /// 
NM_001172712 /// 
NM_003111 -1.50184 
238876_PM_at --- --- -1.50183 
1555372_PM_at BCL2L11 
NM_006538 /// 
NM_138621 /// 
NM_207002 -1.50165 
204966_PM_at BAI2 NM_001703 -1.50112 
1553396_PM_a_at CCDC13 NM_144719 -1.50085 
244503_PM_at --- --- -1.50019 
239195_PM_at --- --- 1.50072 
242313_PM_at LOC728730 
XR_109973 /// 
XR_112311 /// 
XR_115530 1.50244 
1559584_PM_a_at C16orf54 NM_175900 1.50332 
228966_PM_at PANK2 
NM_024960 /// 
NM_153638 /// 
NM_153640 1.5059 
204984_PM_at GPC4 NM_001448 1.50633 
213994_PM_s_at SPON1 NM_006108 1.50703 
205796_PM_at TCP11L1 
NM_001145541 /// 
NM_018393 1.50719 
1554424_PM_at FIP1L1 
NM_001134937 /// 
NM_001134938 /// 
NM_030917 1.51532 
1553590_PM_at FAM27E1 /// FAM27E3 
XM_001720463 /// 
XR_110794 /// 
XR_113221 1.51584 
232202_PM_at --- --- 1.52145 
219232_PM_s_at EGLN3 NM_022073 1.52208 
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204982_PM_at GIT2 
NM_001135213 /// 
NM_001135214 /// 
NM_014776 /// 
NM_057169 /// 
NM_057170 /// 
NM_139201 1.52394 
229984_PM_at DTWD1 
NM_001144955 /// 
NM_020234 1.52436 
225940_PM_at EIF4E3 
NM_001134649 /// 
NM_001134650 /// 
NM_001134651 /// 
NM_173359 1.52459 
223799_PM_at KIAA1826 NM_032424 1.52611 
1554283_PM_at CCRN4L NM_012118 1.52653 
1555785_PM_a_at XRN1 
NM_001042604 /// 
NM_019001 1.52754 
230974_PM_at DDX19B 
NM_001014449 /// 
NM_001014451 /// 
NM_007242 1.53024 
235352_PM_at MR1 
NM_001194999 /// 
NM_001195000 /// 
NM_001195035 /// 
NM_001531 1.53488 
239468_PM_at MKX NM_173576 1.53601 
239515_PM_at --- --- 1.53671 
1553768_PM_a_at DCBLD1 NM_173674 1.54817 
217127_PM_at CTH 
NM_001190463 /// 
NM_001902 /// 
NM_153742 1.54891 
1558692_PM_at C1orf85 NM_144580 1.55024 
223349_PM_s_at BOK NM_032515 1.55057 
209062_PM_x_at NCOA3 
NM_001174087 /// 
NM_001174088 /// 
NM_006534 /// 
NM_181659 1.55834 
210004_PM_at OLR1 
NM_001172632 /// 
NM_001172633 /// 
NM_002543 1.56132 
1555787_PM_at C11orf63 
NM_024806 /// 
NM_199124 1.56286 
1561347_PM_a_at --- --- 1.56883 
219619_PM_at DIRAS2 NM_017594 1.57376 
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1569470_PM_a_at FRMD5 NM_032892 1.57505 
212096_PM_s_at MTUS1 
NM_001001924 /// 
NM_001001925 /// 
NM_001001931 /// 
NM_001166393 /// 
NM_020749 1.57703 
221577_PM_x_at GDF15 NM_004864 1.57893 
241984_PM_at FOXN3 
NM_001085471 /// 
NM_005197 1.57986 
201312_PM_s_at SH3BGRL NM_003022 1.58002 
206667_PM_s_at SCAMP1 NM_004866 1.58151 
1565823_PM_at 7-Sep 
NM_001011553 /// 
NM_001788 1.58158 
227752_PM_at SPTLC3 NM_018327 1.58785 
231765_PM_at ZFYVE20 NM_022340 1.59765 
226695_PM_at PRRX1 
NM_006902 /// 
NM_022716 1.60043 
242062_PM_at SAMD8 
NM_001174156 /// 
NM_144660 1.6036 
229927_PM_at LEMD1 NM_001001552 1.60472 
1556176_PM_at TAF8 NM_138572 1.60548 
222862_PM_s_at AK5 
NM_012093 /// 
NM_174858 1.60558 
229393_PM_at L3MBTL3 
NM_001007102 /// 
NM_032438 1.60835 
213806_PM_at PURA NM_005859 1.61156 
244353_PM_s_at SLC2A12 NM_145176 1.62088 
205239_PM_at AREG NM_001657 1.63475 
1553318_PM_at RIBC1 
NM_001031745 /// 
NM_144968 1.63611 
1564220_PM_a_at --- --- 1.64288 
223292_PM_s_at MRPS15 NM_031280 1.64681 
230383_PM_x_at --- --- 1.64805 
206085_PM_s_at CTH 
NM_001190463 /// 
NM_001902 /// 
NM_153742 1.64874 
1554003_PM_at RGNEF 
NM_001080479 /// 
NM_001177693 1.69981 
201925_PM_s_at CD55 
NM_000574 /// 
NM_001114752 1.7142 
236646_PM_at C12orf59 NM_153022 1.7346 
229441_PM_at PRSS23 NM_007173 1.75382 
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220266_PM_s_at KLF4 NM_004235 1.77572 
243999_PM_at SLFN5 NM_144975 1.78294 
226725_PM_at --- --- 1.79124 
205767_PM_at EREG NM_001432 1.81392 
202672_PM_s_at ATF3 
NM_001030287 /// 
NM_001040619 /// 
NM_001674 1.81546 
1554969_PM_x_at DIP2A 
NM_001146114 /// 
NM_001146115 /// 
NM_001146116 /// 
NM_015151 /// 
NM_206889 /// 
NM_20689 1.81723 
228360_PM_at LYPD6B NM_177964 1.88046 
234462_PM_at --- --- 1.92308 
210587_PM_at INHBE NM_031479 1.93314 
202014_PM_at PPP1R15A NM_014330 2.04829 
202620_PM_s_at PLOD2 
NM_000935 /// 
NM_182943 2.08166 
231265_PM_at COX7B2 NM_130902 2.32161 
228038_PM_at SOX2 NM_003106 2.36521 
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Table 8.  Probeset ID, gene symbol, refseq transcript ID and fold 
change from microarray analysis of SW480FJX1 treated with scramble siRNA 
(siSCR) versus SW480FJX1 treated with FJX1 specific siRNA (siFJX1) colon 
cancer cells. 
Probeset ID Gene Symbol RefSeq Transcript ID 
Fold-Change 
(FJX1 siFJX1 
vs. FJX1 
siSCR) 
210587_PM_at INHBE NM_031479 -4.16243 
227959_PM_at --- --- -3.9682 
219522_PM_at FJX1 NM_014344 -3.46637 
1555339_PM_at RAP1A 
NM_001010935 /// 
NM_002884 -3.23984 
1555340_PM_x_at RAP1A 
NM_001010935 /// 
NM_002884 -2.85722 
208760_PM_at UBE2I 
NM_003345 /// 
NM_194259 /// 
NM_194260 /// 
NM_194261 -2.70226 
204079_PM_at TPST2 
NM_001008566 /// 
NM_003595 -2.62307 
209695_PM_at PTP4A3 
NM_007079 /// 
NM_032611 -2.56625 
238604_PM_at --- --- -2.45679 
202409_PM_at IGF2 /// INS-IGF2 
NM_000612 /// 
NM_001007139 /// 
NM_001042376 /// 
NM_001127598 /// 
NR_003512 -2.39021 
205549_PM_at PCP4 NM_006198 -2.37463 
225671_PM_at SPNS2 NM_001124758 -2.3391 
224578_PM_at RCC2 
NM_001136204 /// 
NM_018715 -2.33736 
219429_PM_at FA2H NM_024306 -2.27513 
241367_PM_at TEX19 NM_207459 -2.27388 
222764_PM_at ASRGL1 
NM_001083926 /// 
NM_025080 -2.17904 
202967_PM_at GSTA4 NM_001512 -2.17295 
200917_PM_s_at SRPR 
NM_001177842 /// 
NM_003139 -2.16542 
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225897_PM_at MARCKS NM_002356 -2.15615 
229912_PM_at SDK1 
NM_152744 /// 
NR_027816 -2.15188 
202887_PM_s_at DDIT4 NM_019058 -2.10614 
203397_PM_s_at GALNT3 NM_004482 -2.07615 
200918_PM_s_at SRPR 
NM_001177842 /// 
NM_003139 -2.07377 
226181_PM_at TUBE1 NM_016262 -2.05642 
215795_PM_at MYH7B NM_020884 -2.03838 
225556_PM_at VMA21 NM_001017980 -2.0319 
225096_PM_at C17orf79 NM_018405 -2.0188 
209409_PM_at GRB10 
NM_001001549 /// 
NM_001001550 /// 
NM_001001555 /// 
NM_005311 -1.99853 
233949_PM_s_at MYH7B NM_020884 -1.97874 
1555867_PM_at GNG4 
NM_001098721 /// 
NM_001098722 /// 
NM_004485 -1.9721 
219032_PM_x_at OPN3 NM_014322 -1.96509 
243718_PM_at --- --- -1.96328 
229125_PM_at KANK4 NM_181712 -1.96257 
207529_PM_at DEFA5 NM_021010 -1.95514 
1555788_PM_a_at TRIB3 NM_021158 -1.95101 
208725_PM_at EIF2S2 NM_003908 -1.93676 
208510_PM_s_at PPARG 
NM_005037 /// 
NM_015869 /// 
NM_138711 /// 
NM_138712 -1.9332 
209395_PM_at CHI3L1 NM_001276 -1.92938 
229354_PM_at AHRR NM_020731 -1.91806 
226403_PM_at TMC4 
NM_001145303 /// 
NM_144686 -1.9044 
223167_PM_s_at USP25 NM_013396 -1.90212 
223339_PM_at ATPIF1 
NM_016311 /// 
NM_178190 /// 
NM_178191 -1.89871 
212816_PM_s_at CBS 
NM_000071 /// 
NM_001178008 /// 
NM_001178009 -1.89476 
218974_PM_at SOBP NM_018013 -1.89462 
218872_PM_at TESC 
NM_001168325 /// 
NM_017899 /// 
NR_031766 -1.89383 
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240152_PM_at --- --- -1.89234 
218857_PM_s_at ASRGL1 
NM_001083926 /// 
NM_025080 -1.88064 
219497_PM_s_at BCL11A 
NM_018014 /// 
NM_022893 /// 
NM_138559 -1.88048 
227506_PM_at SLC16A9 NM_194298 -1.87927 
226126_PM_at TBCK 
NM_001163435 /// 
NM_001163436 /// 
NM_001163437 /// 
NM_033115 -1.87503 
225111_PM_s_at NAPB NM_022080 -1.86992 
238681_PM_at GDPD1 
NM_001165993 /// 
NM_001165994 /// 
NM_182569 -1.85574 
222256_PM_s_at JMJD7 NM_001114632 -1.83753 
226519_PM_s_at AGXT2L2 NM_153373 -1.83542 
226552_PM_at IER5L NM_203434 -1.82281 
204394_PM_at SLC43A1 
NM_001198810 /// 
NM_003627 -1.82098 
228006_PM_at --- --- -1.80843 
1555890_PM_at 
OR2A20P /// 
OR2A9P 
NR_002157 /// 
NR_002158 -1.80708 
226560_PM_at --- --- -1.80366 
223464_PM_at OSBPL5 
NM_001144063 /// 
NM_020896 /// 
NM_145638 -1.80351 
203256_PM_at CDH3 NM_001793 -1.80335 
213558_PM_at PCLO 
NM_014510 /// 
NM_033026 -1.80035 
229544_PM_at --- --- -1.79352 
225704_PM_at FBRSL1 NM_001142641 -1.78371 
200952_PM_s_at CCND2 NM_001759 -1.78091 
227074_PM_at LOC100131564 NR_034089 -1.77972 
229407_PM_at SDK1 
NM_152744 /// 
NR_027816 -1.77729 
201670_PM_s_at MARCKS NM_002356 -1.76539 
235962_PM_at AZI2 
NM_001134432 /// 
NM_001134433 /// 
NM_022461 -1.76146 
226012_PM_at ANKRD11 NM_013275 -1.75877 
1552789_PM_at SEC62 NM_003262 -1.75521 
220609_PM_at LOC202181 NR_026921 -1.75166 
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210650_PM_s_at PCLO 
NM_014510 /// 
NM_033026 -1.74953 
227174_PM_at WDR72 NM_182758 -1.74705 
229963_PM_at BEX5 
NM_001012978 /// 
NM_001159560 -1.7446 
201010_PM_s_at TXNIP NM_006472 -1.74344 
239694_PM_at TRIM7 
NM_033342 /// 
NM_203293 /// 
NM_203294 /// 
NM_203295 /// 
NM_203296 /// 
NM_203297 -1.74072 
219188_PM_s_at MACROD1 NM_014067 -1.7395 
240180_PM_at --- --- -1.73858 
225527_PM_at CEBPG NM_001806 -1.73717 
201008_PM_s_at TXNIP NM_006472 -1.73636 
228999_PM_at CHD2 
NM_001042572 /// 
NM_001271 -1.73398 
235476_PM_at TRIM59 NM_173084 -1.73154 
217997_PM_at PHLDA1 NM_007350 -1.73046 
207236_PM_at ZNF345 NM_003419 -1.72877 
237213_PM_at --- --- -1.72849 
213002_PM_at MARCKS NM_002356 -1.72395 
1559132_PM_at TMEM80 
NM_001042463 /// 
NM_174940 -1.72171 
226820_PM_at ZNF362 NM_152493 -1.72142 
226548_PM_at SBK1 NM_001024401 -1.71667 
204134_PM_at PDE2A 
NM_001143839 /// 
NM_001146209 /// 
NM_002599 /// 
NR_026572 -1.71487 
204718_PM_at EPHB6 NM_004445 -1.71449 
212307_PM_s_at OGT 
NM_181672 /// 
NM_181673 -1.71252 
206082_PM_at HCP5 NM_006674 -1.71116 
221969_PM_at PAX5 NM_016734 -1.70843 
213601_PM_at SLIT1 NM_003061 -1.7079 
235309_PM_at RPS15A 
NM_001019 /// 
NM_001030009 -1.70684 
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1564907_PM_s_at MATR3 /// SNHG4 
NM_001194954 /// 
NM_001194955 /// 
NM_001194956 /// 
NM_018834 /// 
NM_199189 /// 
NR_00314 -1.70424 
205531_PM_s_at GLS2 NM_013267 -1.70377 
228108_PM_at PPM1L NM_139245 -1.70331 
224784_PM_at MLLT6 NM_005937 -1.69987 
221840_PM_at PTPRE 
NM_006504 /// 
NM_130435 -1.699 
217999_PM_s_at PHLDA1 NM_007350 -1.69827 
242998_PM_at RDH12 NM_152443 -1.69812 
218848_PM_at THOC6 
NM_001142350 /// 
NM_024339 -1.69766 
230486_PM_at --- --- -1.69632 
243209_PM_at KCNQ4 
NM_004700 /// 
NM_172163 -1.69604 
236453_PM_at --- --- -1.69587 
209083_PM_at CORO1A 
NM_001193333 /// 
NM_007074 -1.69254 
1558740_PM_s_at --- --- -1.69253 
226412_PM_at SFRS18 
NM_015491 /// 
NM_032870 -1.68923 
227404_PM_s_at EGR1 NM_001964 -1.68866 
227867_PM_at C2orf89 NM_001080824 -1.68844 
238029_PM_s_at SLC16A14 NM_152527 -1.68769 
238151_PM_at --- --- -1.686 
235275_PM_at BMP8B NM_001720 -1.68311 
226925_PM_at ACPL2 
NM_001037172 /// 
NM_152282 -1.68256 
203570_PM_at LOXL1 NM_005576 -1.67946 
226431_PM_at FAM117B NM_173511 -1.67802 
226457_PM_at --- --- -1.67723 
225942_PM_at NLN NM_020726 -1.67554 
221963_PM_x_at --- --- -1.67504 
243179_PM_at LOC100130360 --- -1.67504 
210410_PM_s_at C6orf26 /// MSH5 
NM_001039651 /// 
NM_002441 /// 
NM_025259 /// 
NM_172165 /// 
NM_172166 -1.67276 
1559222_PM_at --- --- -1.67098 
221878_PM_at C2orf68 NM_001013649 -1.67053 
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213889_PM_at --- --- -1.66683 
218902_PM_at NOTCH1 NM_017617 -1.66654 
1559227_PM_s_at VHL 
NM_000551 /// 
NM_198156 -1.66632 
228461_PM_at SH3RF3 NM_001099289 -1.66466 
242053_PM_at --- --- -1.66457 
201009_PM_s_at TXNIP NM_006472 -1.66361 
207173_PM_x_at CDH11 NM_001797 -1.6636 
228686_PM_at FLJ33630 NR_015360 -1.66359 
235772_PM_at --- --- -1.66349 
213285_PM_at TMEM30B NM_001017970 -1.66332 
1554250_PM_s_at TRIM73 NM_198924 -1.65704 
207760_PM_s_at NCOR2 
NM_001077261 /// 
NM_006312 -1.65449 
227641_PM_at FBXL16 NM_153350 -1.65431 
1557348_PM_at --- --- -1.65427 
230467_PM_at TMEM52 NM_178545 -1.65282 
1553972_PM_a_at CBS 
NM_000071 /// 
NM_001178008 /// 
NM_001178009 -1.65091 
202454_PM_s_at ERBB3 
NM_001005915 /// 
NM_001982 -1.65075 
212843_PM_at NCAM1 
NM_000615 /// 
NM_001076682 /// 
NM_181351 -1.6493 
238853_PM_at RAB3IP 
NM_001024647 /// 
NM_022456 /// 
NM_175623 /// 
NM_175624 /// 
NM_175625 -1.64749 
218145_PM_at TRIB3 NM_021158 -1.64634 
223630_PM_at C7orf13 NR_026865 -1.64601 
208291_PM_s_at TH 
NM_000360 /// 
NM_199292 /// 
NM_199293 -1.64585 
229983_PM_at TIGD2 NM_145715 -1.64528 
230752_PM_at --- --- -1.64526 
215785_PM_s_at CYFIP2 
NM_001037332 /// 
NM_001037333 /// 
NM_014376 -1.64381 
205402_PM_x_at PRSS2 NM_002770 -1.64275 
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231399_PM_at RAB3IP 
NM_001024647 /// 
NM_022456 /// 
NM_175623 /// 
NM_175624 /// 
NM_175625 -1.64265 
227708_PM_at EEF1A1 NM_001402 -1.64244 
204788_PM_s_at PPOX 
NM_000309 /// 
NM_001122764 -1.63854 
222360_PM_at DPH5 
NM_001077394 /// 
NM_001077395 /// 
NM_015958 -1.63497 
202847_PM_at PCK2 
NM_001018073 /// 
NM_004563 -1.63171 
230782_PM_at SORD 
NM_003104 /// 
NR_034039 -1.62999 
228771_PM_at ADRBK2 NM_005160 -1.62651 
240983_PM_s_at CARS 
NM_001014437 /// 
NM_001194997 /// 
NM_001751 /// 
NM_139273 /// 
NR_036542 -1.62618 
214110_PM_s_at --- --- -1.62133 
235191_PM_at LOC148189 NR_027301 -1.62114 
220196_PM_at MUC16 NM_024690 -1.61943 
229215_PM_at ASCL2 NM_005170 -1.61825 
203438_PM_at STC2 NM_003714 -1.61662 
209846_PM_s_at BTN3A2 
NM_001197246 /// 
NM_001197247 /// 
NM_001197248 /// 
NM_001197249 /// 
NM_007047 -1.6149 
200951_PM_s_at CCND2 NM_001759 -1.61442 
212192_PM_at KCTD12 NM_138444 -1.61434 
243356_PM_at --- --- -1.61348 
228090_PM_at NMNAT3 NM_178177 -1.61226 
213194_PM_at ROBO1 
NM_001145845 /// 
NM_002941 /// 
NM_133631 -1.61176 
242673_PM_at --- --- -1.61063 
242546_PM_at FLJ39632 
XR_110291 /// 
XR_112214 -1.61015 
218080_PM_x_at FAF1 NM_007051 -1.60982 
225812_PM_at C6orf225 NM_001033564 -1.60939 
226590_PM_at ZNF618 NM_133374 -1.60905 
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206463_PM_s_at DHRS2 
NM_005794 /// 
NM_182908 -1.60884 
226213_PM_at ERBB3 
NM_001005915 /// 
NM_001982 -1.60867 
205047_PM_s_at ASNS 
NM_001178075 /// 
NM_001178076 /// 
NM_001178077 /// 
NM_001673 /// 
NM_133436 /// 
NM_18335 -1.60816 
207610_PM_s_at EMR2 
NM_013447 /// 
NM_152916 /// 
NM_152917 /// 
NM_152918 /// 
NM_152919 /// 
NM_152920 /// NM_ -1.60806 
214823_PM_at ZNF204P 
NR_002722 /// 
NR_024553 -1.60465 
220762_PM_s_at GNB1L NM_053004 -1.60154 
225949_PM_at NRBP2 NM_178564 -1.60138 
207076_PM_s_at ASS1 
NM_000050 /// 
NM_054012 -1.59987 
242835_PM_s_at LOC728730 
XR_109973 /// 
XR_112311 /// 
XR_115530 -1.59774 
210482_PM_x_at MAP2K5 
NM_002757 /// 
NM_145160 -1.59745 
228156_PM_at --- --- -1.59619 
224156_PM_x_at IL17RB NM_018725 -1.59545 
201048_PM_x_at RAB6A 
NM_002869 /// 
NM_198896 -1.59506 
204351_PM_at S100P NM_005980 -1.59441 
235123_PM_at --- --- -1.59374 
228397_PM_at TUG1 NR_002323 -1.59288 
221951_PM_at TMEM80 
NM_001042463 /// 
NM_174940 -1.59018 
242558_PM_at --- --- -1.59001 
212942_PM_s_at KIAA1199 NM_018689 -1.59 
212512_PM_s_at CARM1 NM_199141 -1.58835 
201508_PM_at IGFBP4 NM_001552 -1.58827 
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227179_PM_at STAU2 
NM_001164380 /// 
NM_001164381 /// 
NM_001164382 /// 
NM_001164383 /// 
NM_001164384 /// NM -1.58755 
225846_PM_at ESRP1 
NM_001034915 /// 
NM_001122825 /// 
NM_001122826 /// 
NM_001122827 /// 
NM_017697 -1.5868 
242064_PM_at SDK2 NM_001144952 -1.58575 
236219_PM_at TMEM20 
NM_001134658 /// 
NM_153226 -1.5841 
201505_PM_at LAMB1 NM_002291 -1.58369 
231311_PM_at --- --- -1.58291 
220459_PM_at MCM3AP-AS NR_002776 -1.58265 
226124_PM_at ZFP90 NM_133458 -1.58126 
239082_PM_at FZD3 NM_017412 -1.58096 
224995_PM_at SPIRE1 
NM_001128626 /// 
NM_001128627 /// 
NM_020148 -1.57882 
227293_PM_at --- --- -1.57803 
213848_PM_at DUSP7 NM_001947 -1.57451 
1569923_PM_s_at LOC285708 --- -1.57435 
201694_PM_s_at EGR1 NM_001964 -1.57369 
235470_PM_at NAA38 NM_016200 -1.57364 
228066_PM_at C17orf96 NM_001130677 -1.57344 
222746_PM_s_at BSPRY NM_017688 -1.57325 
230606_PM_at LOC100287525 
XM_002343549 /// 
XM_002345023 /// 
XM_002347757 -1.57283 
214434_PM_at HSPA12A NM_025015 -1.5726 
229545_PM_at FERMT1 NM_017671 -1.5719 
220668_PM_s_at DNMT3B 
NM_006892 /// 
NM_175848 /// 
NM_175849 /// 
NM_175850 -1.57142 
220177_PM_s_at TMPRSS3 
NM_024022 /// 
NM_032405 /// 
NR_027348 -1.57077 
209368_PM_at EPHX2 NM_001979 -1.57033 
202148_PM_s_at PYCR1 
NM_006907 /// 
NM_153824 -1.56876 
203831_PM_at R3HDM2 NM_014925 -1.56843 
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205162_PM_at ERCC8 NM_000082 -1.56699 
229748_PM_x_at LOC100132288 NM_001033515 -1.56683 
218789_PM_s_at C11orf71 NM_019021 -1.56592 
209816_PM_at PTCH1 
NM_000264 /// 
NM_001083602 /// 
NM_001083603 /// 
NM_001083604 /// 
NM_001083605 /// 
NM_00 -1.56587 
218537_PM_at HCFC1R1 
NM_001002017 /// 
NM_001002018 /// 
NM_017885 -1.56474 
219270_PM_at CHAC1 
NM_001142776 /// 
NM_024111 -1.56473 
221582_PM_at HIST3H2A NM_033445 -1.56443 
224392_PM_s_at OPN3 NM_014322 -1.56425 
224694_PM_at ANTXR1 
NM_018153 /// 
NM_032208 /// 
NM_053034 -1.56375 
204411_PM_at KIF21B NM_017596 -1.56178 
236780_PM_at --- --- -1.56143 
211651_PM_s_at LAMB1 NM_002291 -1.56142 
225220_PM_at SNHG8 
NR_003584 /// 
NR_034010 /// 
NR_034011 -1.56117 
207291_PM_at PRRG4 NM_024081 -1.5592 
226534_PM_at KITLG 
NM_000899 /// 
NM_003994 -1.55836 
202597_PM_at IRF6 NM_006147 -1.55685 
217998_PM_at PHLDA1 NM_007350 -1.55558 
242111_PM_at METTL3 NM_019852 -1.55455 
225018_PM_at SPIRE1 
NM_001128626 /// 
NM_001128627 /// 
NM_020148 -1.55365 
224466_PM_s_at MAFG 
NM_002359 /// 
NM_032711 -1.55239 
213113_PM_s_at SLC43A3 
NM_014096 /// 
NM_017611 /// 
NM_199329 -1.55225 
203180_PM_at ALDH1A3 NM_000693 -1.55157 
226652_PM_at USP3 NM_006537 -1.54975 
221430_PM_s_at RNF146 NM_030963 -1.54946 
232396_PM_at --- --- -1.54906 
201693_PM_s_at EGR1 NM_001964 -1.54838 
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228341_PM_at NUDT16 
NM_001171905 /// 
NM_001171906 /// 
NM_152395 /// 
NR_033268 -1.54709 
209396_PM_s_at CHI3L1 NM_001276 -1.54702 
1554079_PM_at GALNTL4 NM_198516 -1.54682 
210341_PM_at MYT1 NM_004535 -1.54521 
221858_PM_at TBC1D12 NM_015188 -1.54462 
227801_PM_at TRIM59 NM_173084 -1.54308 
241114_PM_s_at --- --- -1.54303 
216867_PM_s_at PDGFA 
NM_002607 /// 
NM_033023 -1.54278 
239697_PM_x_at C3orf67 NM_198463 -1.54262 
224186_PM_s_at RNF123 NM_022064 -1.54262 
1553180_PM_at ADAMTS19 NM_133638 -1.54254 
230488_PM_s_at NCRNA00118 NR_002783 -1.54251 
214907_PM_at CEACAM21 
NM_001098506 /// 
NM_033543 -1.54215 
237299_PM_at --- --- -1.54174 
223541_PM_at HAS3 
NM_005329 /// 
NM_138612 -1.54016 
204199_PM_at RALGPS1 
NM_001190728 /// 
NM_001190729 /// 
NM_001190730 /// 
NM_014636 -1.53972 
232069_PM_at KIF26A NM_015656 -1.53907 
211370_PM_s_at MAP2K5 
NM_002757 /// 
NM_145160 -1.53804 
241972_PM_at LOC401588 NR_015378 -1.53794 
227446_PM_s_at C14orf167 
NR_023921 /// 
NR_023922 /// 
NR_023923 /// 
NR_023924 -1.53758 
238513_PM_at PRRG4 NM_024081 -1.53738 
236967_PM_at LOC645249 
XR_108719 /// 
XR_110785 /// 
XR_113097 /// 
XR_114128 -1.53709 
206574_PM_s_at PTP4A3 
NM_007079 /// 
NM_032611 -1.53693 
226849_PM_at DENND1A 
NM_020946 /// 
NM_024820 -1.53462 
243009_PM_at --- --- -1.53353 
226614_PM_s_at FAM167A NM_053279 -1.53253 
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207564_PM_x_at OGT 
NM_181672 /// 
NM_181673 -1.5324 
210999_PM_s_at GRB10 
NM_001001549 /// 
NM_001001550 /// 
NM_001001555 /// 
NM_005311 -1.53219 
211126_PM_s_at CSRP2 NM_001321 -1.53099 
210915_PM_x_at TRBC2 --- -1.53097 
218839_PM_at HEY1 
NM_001040708 /// 
NM_012258 -1.53036 
241687_PM_at --- --- -1.53009 
229058_PM_at ANKRD16 
NM_001009941 /// 
NM_001009943 /// 
NM_019046 -1.52968 
227250_PM_at KREMEN1 
NM_001039570 /// 
NM_032045 -1.52906 
229954_PM_at CHDH NM_018397 -1.5289 
225520_PM_at MTHFD1L NM_015440 -1.52887 
47560_PM_at LPHN1 
NM_001008701 /// 
NM_014921 -1.52871 
204875_PM_s_at GMDS NM_001500 -1.52812 
202157_PM_s_at CELF2 
NM_001025076 /// 
NM_001025077 /// 
NM_001083591 /// 
NM_006561 -1.52812 
229332_PM_at HPDL NM_032756 -1.52809 
218689_PM_at FANCF NM_022725 -1.5278 
227864_PM_s_at FAM125A NM_138401 -1.52728 
241234_PM_at LOC100506797 
XR_109881 /// 
XR_109882 /// 
XR_109883 /// 
XR_112377 /// 
XR_112378 /// 
XR_113370 /// XR_ -1.52688 
213411_PM_at ADAM22 
NM_004194 /// 
NM_016351 /// 
NM_021721 /// 
NM_021722 /// 
NM_021723 -1.52666 
224428_PM_s_at CDCA7 
NM_031942 /// 
NM_145810 -1.526 
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204820_PM_s_at 
BTN3A2 /// 
BTN3A3 
NM_001197246 /// 
NM_001197247 /// 
NM_001197248 /// 
NM_001197249 /// 
NM_006994 /// NM_00 -1.52578 
218677_PM_at S100A14 NM_020672 -1.52558 
202790_PM_at CLDN7 
NM_001185022 /// 
NM_001185023 /// 
NM_001307 -1.52435 
238549_PM_at CBFA2T2 
NM_001032999 /// 
NM_001039709 /// 
NM_005093 -1.52391 
226157_PM_at TFDP2 
NM_001178138 /// 
NM_001178139 /// 
NM_001178140 /// 
NM_001178141 /// 
NM_001178142 /// NM -1.52327 
223196_PM_s_at SESN2 NM_031459 -1.52307 
224217_PM_s_at FAF1 NM_007051 -1.52239 
222445_PM_at SLC39A9 NM_018375 -1.52204 
209610_PM_s_at SLC1A4 
NM_001193493 /// 
NM_003038 -1.52198 
212811_PM_x_at SLC1A4 
NM_001193493 /// 
NM_003038 -1.52174 
1569973_PM_at SEPT7P2 NR_024271 -1.52064 
219117_PM_s_at FKBP11 
NM_001143781 /// 
NM_001143782 /// 
NM_016594 -1.52054 
242857_PM_at --- --- -1.52035 
229393_PM_at L3MBTL3 
NM_001007102 /// 
NM_032438 -1.52025 
217833_PM_at SYNCRIP 
NM_001159673 /// 
NM_001159674 /// 
NM_001159675 /// 
NM_001159676 /// 
NM_001159677 /// NM -1.51865 
230085_PM_at PDK3 
NM_001142386 /// 
NM_005391 -1.51628 
209824_PM_s_at ARNTL 
NM_001030272 /// 
NM_001030273 /// 
NM_001178 -1.51571 
218792_PM_s_at BSPRY NM_017688 -1.51519 
226388_PM_at TCEA3 NM_003196 -1.51312 
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228752_PM_at EFCAB4B 
NM_001144958 /// 
NM_001144959 /// 
NM_032680 -1.51295 
204123_PM_at LIG3 
NM_002311 /// 
NM_013975 -1.5129 
223093_PM_at ANKH NM_054027 -1.51223 
229830_PM_at PDGFA 
NM_002607 /// 
NM_033023 -1.51174 
235583_PM_at ILDR1 NM_175924 -1.51151 
207413_PM_s_at SCN5A 
NM_000335 /// 
NM_001099404 /// 
NM_001099405 /// 
NM_001160160 /// 
NM_001160161 /// 
NM_19 -1.51131 
228200_PM_at ZNF252 NR_023392 -1.51107 
212810_PM_s_at SLC1A4 
NM_001193493 /// 
NM_003038 -1.51105 
223125_PM_s_at C1orf21 NM_030806 -1.50996 
225193_PM_at --- --- -1.50944 
1562013_PM_a_at --- --- -1.50854 
226301_PM_at C6orf192 NM_052831 -1.50774 
233016_PM_at --- --- -1.50769 
225928_PM_at VTI1B NM_006370 -1.50715 
203867_PM_s_at NLE1 
NM_001014445 /// 
NM_018096 -1.50553 
243747_PM_at ZNF599 NM_001007248 -1.50523 
219743_PM_at HEY2 NM_012259 -1.50508 
214095_PM_at SHMT2 
NM_001166356 /// 
NM_001166357 /// 
NM_001166358 /// 
NM_001166359 /// 
NM_005412 /// NR_02 -1.50499 
223184_PM_s_at AGPAT3 
NM_001037553 /// 
NM_020132 -1.50448 
235577_PM_at ZNF652 
NM_001145365 /// 
NM_014897 -1.50437 
224367_PM_at BEX2 
NM_001168399 /// 
NM_001168400 /// 
NM_001168401 /// 
NM_032621 -1.50398 
205258_PM_at INHBB NM_002193 -1.50394 
227417_PM_at MOSC2 NM_017898 -1.50379 
1564706_PM_s_at GLS2 NM_013267 -1.50313 
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214571_PM_at FGF3 NM_005247 -1.50309 
243224_PM_at --- --- -1.50233 
222930_PM_s_at AGMAT NM_024758 -1.50182 
205352_PM_at SERPINI1 
NM_001122752 /// 
NM_005025 -1.50168 
244769_PM_at --- --- -1.50136 
208886_PM_at H1F0 NM_005318 -1.5005 
205411_PM_at STK4 NM_006282 1.50071 
235235_PM_s_at PATL1 NM_152716 1.50121 
232083_PM_at KIF16B NM_024704 1.50123 
235371_PM_at GXYLT2 NM_001080393 1.50156 
230493_PM_at SHISA2 NM_001007538 1.50205 
238476_PM_at C5orf41 
NM_001168393 /// 
NM_001168394 /// 
NM_153607 1.50212 
213343_PM_s_at GDPD5 NM_030792 1.50229 
AFFX-r2-Bs-phe-
M_at --- --- 1.50356 
219471_PM_at C13orf18 NM_025113 1.50497 
201700_PM_at CCND3 
NM_001136017 /// 
NM_001136125 /// 
NM_001136126 /// 
NM_001760 1.50501 
210426_PM_x_at RORA 
NM_002943 /// 
NM_134260 /// 
NM_134261 /// 
NM_134262 1.5055 
209387_PM_s_at TM4SF1 NM_014220 1.50605 
37966_PM_at PARVB 
NM_001003828 /// 
NM_013327 1.50607 
228097_PM_at MYLIP NM_013262 1.50608 
217560_PM_at GGA1 
NM_001001560 /// 
NM_001001561 /// 
NM_001172687 /// 
NM_001172688 /// 
NM_013365 1.50623 
209459_PM_s_at ABAT 
NM_000663 /// 
NM_001127448 /// 
NM_020686 1.50667 
228260_PM_at ELAVL2 
NM_001171195 /// 
NM_001171197 /// 
NM_004432 1.50677 
230104_PM_s_at TPPP NM_007030 1.50806 
1556826_PM_s_at C1orf187 NM_198545 1.50825 
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229881_PM_at KLF12 NM_007249 1.50903 
210987_PM_x_at TPM1 
NM_000366 /// 
NM_001018004 /// 
NM_001018005 /// 
NM_001018006 /// 
NM_001018007 /// 
NM_00 1.51085 
229106_PM_at DYNLL2 NM_080677 1.51157 
219210_PM_s_at RAB8B NM_016530 1.51383 
217585_PM_at NEBL 
NM_001173484 /// 
NM_006393 /// 
NM_213569 1.51457 
211756_PM_at PTHLH 
NM_002820 /// 
NM_198964 /// 
NM_198965 /// 
NM_198966 1.51513 
230955_PM_s_at C20orf112 NM_080616 1.51543 
208926_PM_at NEU1 NM_000434 1.51552 
208596_PM_s_at 
UGT1A1 /// 
UGT1A10 /// 
UGT1A3 /// 
UGT1A4 /// 
UGT1A5 /// 
UGT1A6 /// 
UGT1A7 /// 
UGT1A8 /// 
UGT1A9 
NM_000463 /// 
NM_001072 /// 
NM_007120 /// 
NM_019075 /// 
NM_019076 /// 
NM_019077 /// NM_ 1.51589 
212758_PM_s_at ZEB1 
NM_001128128 /// 
NM_001174093 /// 
NM_001174094 /// 
NM_001174095 /// 
NM_001174096 /// NM 1.51634 
224128_PM_at C20orf43 NM_016407 1.51658 
208678_PM_at ATP6V1E1 
NM_001039366 /// 
NM_001039367 /// 
NM_001696 1.51664 
212602_PM_at WDFY3 NM_014991 1.51722 
203158_PM_s_at GLS NM_014905 1.51857 
208869_PM_s_at GABARAPL1 NM_031412 1.51871 
225372_PM_at C10orf54 NM_022153 1.51885 
238842_PM_at --- --- 1.51927 
231221_PM_at CLEC16A NM_015226 1.51941 
224790_PM_at ASAP1 NM_018482 1.51963 
203650_PM_at PROCR NM_006404 1.51973 
36552_PM_at C2CD3 NM_015531 1.52148 
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210964_PM_s_at GYG2 
NM_001079855 /// 
NM_001184702 /// 
NM_001184703 /// 
NM_001184704 /// 
NM_003918 1.52193 
215495_PM_s_at SAMD4A 
NM_001161576 /// 
NM_001161577 /// 
NM_015589 1.52233 
238419_PM_at PHLDB2 
NM_001134437 /// 
NM_001134438 /// 
NM_001134439 /// 
NM_145753 1.52329 
206518_PM_s_at RGS9 
NM_001081955 /// 
NM_001165933 /// 
NM_003835 1.52348 
224916_PM_at TMEM173 NM_198282 1.52421 
203870_PM_at USP46 
NM_001134223 /// 
NM_022832 1.52501 
204929_PM_s_at VAMP5 NM_006634 1.52511 
1555716_PM_a_at CXADR NM_001338 1.52532 
209290_PM_s_at NFIB 
NM_001190737 /// 
NM_001190738 /// 
NM_005596 1.52541 
209909_PM_s_at TGFB2 
NM_001135599 /// 
NM_003238 1.52554 
222045_PM_s_at PCIF1 NM_022104 1.52575 
215058_PM_at DENND5B NM_144973 1.52667 
221946_PM_at C9orf116 
NM_001048265 /// 
NM_144654 1.52731 
230035_PM_at BOC NM_033254 1.5295 
242439_PM_s_at ASXL1 
NM_001164603 /// 
NM_015338 1.53045 
202637_PM_s_at ICAM1 NM_000201 1.53071 
232206_PM_at ULK4 NM_017886 1.53089 
227019_PM_at C1orf226 
NM_001085375 /// 
NM_001135240 1.53172 
225093_PM_at UTRN NM_007124 1.53187 
201625_PM_s_at INSIG1 
NM_005542 /// 
NM_198336 /// 
NM_198337 1.5328 
228448_PM_at MAP6 
NM_033063 /// 
NM_207577 1.53303 
239825_PM_at --- --- 1.53364 
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201543_PM_s_at SAR1A 
NM_001142648 /// 
NM_020150 1.53413 
223739_PM_at PADI1 NM_013358 1.53517 
204220_PM_at GMFG NM_004877 1.53568 
238890_PM_at BRWD1 
NM_001007246 /// 
NM_018963 /// 
NM_033656 1.53701 
217176_PM_s_at ZFX 
NM_001178084 /// 
NM_001178085 /// 
NM_001178086 /// 
NM_001178095 /// 
NM_003410 1.53714 
235230_PM_at PLCXD2 
NM_001185106 /// 
NM_153268 1.53735 
227278_PM_at --- --- 1.53784 
1566671_PM_a_at PDXK NM_003681 1.53876 
228098_PM_s_at MYLIP NM_013262 1.5397 
235088_PM_at C4orf46 NM_001008393 1.5408 
212095_PM_s_at MTUS1 
NM_001001924 /// 
NM_001001925 /// 
NM_001001931 /// 
NM_001166393 /// 
NM_020749 1.54118 
235672_PM_at MAP6 
NM_033063 /// 
NM_207577 1.54157 
230492_PM_s_at GPCPD1 NM_019593 1.54192 
238917_PM_s_at DENND5B NM_144973 1.54208 
220766_PM_at BTG4 NM_017589 1.54221 
242322_PM_at --- --- 1.54238 
205805_PM_s_at ROR1 
NM_001083592 /// 
NM_005012 1.54252 
220254_PM_at LRP12 
NM_001135703 /// 
NM_013437 1.54366 
227410_PM_at FAM43A NM_153690 1.54513 
219403_PM_s_at HPSE 
NM_001098540 /// 
NM_001166498 /// 
NM_006665 1.5453 
224828_PM_at CPEB4 NM_030627 1.54543 
230747_PM_s_at TTC39C 
NM_001135993 /// 
NM_153211 /// 
NR_024232 1.54641 
223689_PM_at IGF2BP1 
NM_001160423 /// 
NM_006546 1.54662 
228185_PM_at ZNF25 NM_145011 1.54733 
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204633_PM_s_at RPS6KA5 
NM_004755 /// 
NM_182398 1.54763 
240369_PM_at --- --- 1.54774 
1563229_PM_at DLEU2 NR_002612 1.54891 
230962_PM_at DCLK1 
NM_001195415 /// 
NM_001195416 /// 
NM_001195430 /// 
NM_004734 1.54945 
227375_PM_at ANKRD13C NM_030816 1.55041 
242438_PM_at ASXL1 
NM_001164603 /// 
NM_015338 1.55059 
202368_PM_s_at TRAM2 NM_012288 1.55064 
212003_PM_at C1orf144 
NM_001114600 /// 
NM_015609 1.55095 
217234_PM_s_at EZR 
NM_001111077 /// 
NM_003379 1.55145 
219282_PM_s_at TRPV2 NM_016113 1.55151 
203913_PM_s_at HPGD 
NM_000860 /// 
NM_001145816 /// 
NR_027332 1.55217 
221766_PM_s_at FAM46A NM_017633 1.55284 
235004_PM_at RBM24 
NM_001143941 /// 
NM_001143942 /// 
NM_153020 1.55288 
242414_PM_at QPRT NM_014298 1.55451 
202082_PM_s_at SEC14L1 
NM_001039573 /// 
NM_001143998 /// 
NM_001143999 /// 
NM_001144001 /// 
NM_003003 1.55493 
232341_PM_x_at HABP4 NM_014282 1.55591 
222715_PM_s_at SYNRG 
NM_001163544 /// 
NM_001163545 /// 
NM_001163546 /// 
NM_001163547 /// 
NM_007247 /// NM_08 1.5561 
223185_PM_s_at BHLHE41 NM_030762 1.55643 
217763_PM_s_at RAB31 NM_006868 1.5574 
212844_PM_at RRP1B NM_015056 1.55861 
206907_PM_at TNFSF9 NM_003811 1.55861 
203429_PM_s_at C1orf9 
NM_014283 /// 
NM_016227 1.55975 
1559893_PM_at CCDC75 NM_174931 1.5605 
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204760_PM_s_at NR1D1 /// THRA 
NM_001190918 /// 
NM_001190919 /// 
NM_003250 /// 
NM_021724 /// 
NM_199334 1.56059 
226968_PM_at KIF1B 
NM_015074 /// 
NM_183416 1.56126 
201627_PM_s_at INSIG1 
NM_005542 /// 
NM_198336 /// 
NM_198337 1.56141 
203708_PM_at PDE4B 
NM_001037339 /// 
NM_001037340 /// 
NM_001037341 /// 
NM_002600 1.56207 
222692_PM_s_at FNDC3B 
NM_001135095 /// 
NM_022763 1.56254 
214719_PM_at SLC46A3 
NM_001135919 /// 
NM_181785 1.56301 
213407_PM_at PHLPP2 NM_015020 1.56311 
231121_PM_at HPS3 NM_032383 1.56324 
208481_PM_at ASB4 
NM_016116 /// 
NM_145872 1.56468 
227828_PM_s_at FAM176A 
NM_001135032 /// 
NM_032181 1.5647 
226810_PM_at OGFRL1 NM_024576 1.5657 
225856_PM_at --- --- 1.56594 
214108_PM_at MAX 
NM_002382 /// 
NM_145112 /// 
NM_145113 /// 
NM_145114 /// 
NM_145116 /// 
NM_197957 1.56638 
208881_PM_x_at IDI1 NM_004508 1.5672 
206022_PM_at NDP NM_000266 1.56747 
209420_PM_s_at SMPD1 
NM_000543 /// 
NM_001007593 1.56823 
232591_PM_s_at TMEM30A 
NM_001143958 /// 
NM_018247 1.56827 
239190_PM_at VRK3 
NM_001025778 /// 
NM_016440 1.56841 
229952_PM_at --- --- 1.56979 
1555358_PM_a_at ENTPD4 
NM_001128930 /// 
NM_004901 1.56999 
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1552485_PM_at LACTB 
NM_032857 /// 
NM_171846 1.57085 
207056_PM_s_at SLC4A8 
NM_001039960 /// 
NM_004858 1.57088 
213711_PM_at KRT81 NM_002281 1.57174 
59437_PM_at C9orf116 
NM_001048265 /// 
NM_144654 1.57483 
205443_PM_at SNAPC1 NM_003082 1.57552 
239212_PM_at LTV1 NM_032860 1.57559 
222847_PM_s_at EGLN3 NM_022073 1.57587 
221511_PM_x_at CCPG1 
NM_004748 /// 
NM_020739 1.57761 
1565558_PM_at --- --- 1.57772 
227840_PM_at C2orf76 NM_001017927 1.57944 
208427_PM_s_at ELAVL2 
NM_001171195 /// 
NM_001171197 /// 
NM_004432 1.58109 
202581_PM_at 
HSPA1A /// 
HSPA1B 
NM_005345 /// 
NM_005346 1.58261 
1557129_PM_a_at FAM111B 
NM_001142703 /// 
NM_001142704 /// 
NM_198947 1.58263 
244637_PM_at --- --- 1.58316 
202438_PM_x_at IDS 
NM_000202 /// 
NM_001166550 /// 
NM_006123 1.58447 
229317_PM_at KPNA5 NM_002269 1.58455 
227236_PM_at TSPAN2 NM_005725 1.58549 
204602_PM_at DKK1 NM_012242 1.58619 
226222_PM_at KIAA1432 
NM_001135920 /// 
NM_020829 1.58634 
210510_PM_s_at NRP1 
NM_001024628 /// 
NM_001024629 /// 
NM_003873 1.58793 
217762_PM_s_at RAB31 NM_006868 1.59086 
203729_PM_at EMP3 NM_001425 1.5914 
213603_PM_s_at RAC2 NM_002872 1.5918 
220198_PM_s_at EIF5A2 NM_020390 1.59333 
202458_PM_at PRSS23 NM_007173 1.59356 
227750_PM_at KALRN 
NM_001024660 /// 
NM_003947 /// 
NM_007064 /// 
NR_028136 1.59512 
204615_PM_x_at IDI1 NM_004508 1.59561 
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225912_PM_at TP53INP1 
NM_001135733 /// 
NM_033285 1.59618 
1554004_PM_a_at RGNEF 
NM_001080479 /// 
NM_001177693 1.59647 
221676_PM_s_at CORO1C NM_014325 1.59694 
218196_PM_at OSTM1 NM_014028 1.5973 
228121_PM_at TGFB2 
NM_001135599 /// 
NM_003238 1.59781 
204830_PM_x_at PSG5 
NM_001130014 /// 
NM_002781 1.59832 
213956_PM_at CEP350 NM_014810 1.59854 
206429_PM_at F2RL1 NM_005242 1.60018 
212944_PM_at SLC5A3 NM_006933 1.60046 
236719_PM_at --- --- 1.60142 
231270_PM_at CA13 NM_198584 1.60172 
203914_PM_x_at HPGD 
NM_000860 /// 
NM_001145816 /// 
NR_027332 1.6034 
210830_PM_s_at PON2 
NM_000305 /// 
NM_001018161 1.60586 
233587_PM_s_at SIPA1L2 NM_020808 1.60683 
222670_PM_s_at MAFB NM_005461 1.60801 
213199_PM_at C2CD3 NM_015531 1.60823 
208622_PM_s_at EZR 
NM_001111077 /// 
NM_003379 1.61055 
224823_PM_at MYLK 
NM_053025 /// 
NM_053026 /// 
NM_053027 /// 
NM_053028 /// 
NM_053031 /// 
NM_053032 1.61067 
202213_PM_s_at CUL4B 
NM_001079872 /// 
NM_003588 1.61124 
1558501_PM_at DNM3 
NM_001136127 /// 
NM_015569 1.61152 
233085_PM_s_at OBFC2A 
NM_001031716 /// 
NR_024415 1.61173 
204682_PM_at LTBP2 NM_000428 1.61227 
225059_PM_at AGTRAP 
NM_001040194 /// 
NM_001040195 /// 
NM_001040196 /// 
NM_001040197 /// 
NM_020350 1.61276 
1554471_PM_a_at ANKRD13C NM_030816 1.61354 
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235264_PM_at HCFC2 NM_013320 1.61357 
221903_PM_s_at CYLD 
NM_001042355 /// 
NM_001042412 /// 
NM_015247 1.6143 
211741_PM_x_at PSG3 NM_021016 1.61435 
212444_PM_at --- --- 1.6145 
206117_PM_at TPM1 
NM_000366 /// 
NM_001018004 /// 
NM_001018005 /// 
NM_001018006 /// 
NM_001018007 /// 
NM_00 1.61481 
214696_PM_at C17orf91 
NR_028502 /// 
NR_028503 /// 
NR_028504 /// 
NR_028505 1.61483 
222717_PM_at SDPR NM_004657 1.61643 
205767_PM_at EREG NM_001432 1.61777 
210619_PM_s_at HYAL1 
NM_007312 /// 
NM_033159 /// 
NM_153281 /// 
NM_153282 /// 
NM_153283 /// 
NM_153285 1.61841 
201108_PM_s_at THBS1 NM_003246 1.61859 
226189_PM_at ITGB8 NM_002214 1.6188 
238738_PM_at PSMD7 NM_002811 1.61946 
211260_PM_at BMP7 NM_001719 1.61997 
209506_PM_s_at NR2F1 NM_005654 1.62112 
223388_PM_s_at ZFYVE1 
NM_021260 /// 
NM_178441 1.62187 
228596_PM_at LOC728377 NR_033942 1.62193 
208191_PM_x_at PSG4 
NM_002780 /// 
NM_213633 1.6222 
208134_PM_x_at PSG2 NM_031246 1.62244 
203394_PM_s_at HES1 NM_005524 1.62341 
202551_PM_s_at CRIM1 NM_016441 1.62395 
229242_PM_at --- --- 1.62466 
204401_PM_at KCNN4 NM_002250 1.6247 
201995_PM_at EXT1 NM_000127 1.62524 
222747_PM_s_at SCML1 
NM_001037535 /// 
NM_001037536 /// 
NM_001037540 /// 
NM_006746 1.626 
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1560818_PM_at LOC100288701 --- 1.62648 
200800_PM_s_at 
HSPA1A /// 
HSPA1B 
NM_005345 /// 
NM_005346 1.62679 
226462_PM_at STXBP6 NM_014178 1.62929 
236083_PM_at BCL2L15 NM_001010922 1.62963 
212327_PM_at LIMCH1 
NM_001112717 /// 
NM_001112718 /// 
NM_001112719 /// 
NM_001112720 /// 
NM_014988 1.63109 
230050_PM_at NACC2 NM_144653 1.63115 
206584_PM_at LY96 
NM_001195797 /// 
NM_015364 1.63257 
239155_PM_at CXADR NM_001338 1.63352 
222942_PM_s_at TIAM2 
NM_001010927 /// 
NM_012454 1.63422 
206570_PM_s_at PSG11 
NM_001113410 /// 
NM_002785 /// 
NM_203287 1.63526 
223208_PM_at KCTD10 NM_031954 1.63551 
221566_PM_s_at NOL3 
NM_001185057 /// 
NM_001185058 /// 
NM_003946 1.63674 
204635_PM_at RPS6KA5 
NM_004755 /// 
NM_182398 1.63958 
215150_PM_at YOD1 NM_018566 1.63974 
214022_PM_s_at IFITM1 NM_003641 1.63977 
201564_PM_s_at FSCN1 NM_003088 1.64052 
219321_PM_at MPP5 NM_022474 1.64218 
224999_PM_at EGFR 
NM_005228 /// 
NM_201282 /// 
NM_201283 /// 
NM_201284 1.64329 
228369_PM_at CNPY3 NM_006586 1.64396 
214663_PM_at DSTYK 
NM_015375 /// 
NM_199462 1.644 
223595_PM_at TMEM133 NM_032021 1.64463 
212919_PM_at DCP2 NM_152624 1.645 
204077_PM_x_at ENTPD4 
NM_001128930 /// 
NM_004901 1.64554 
229493_PM_at LOC100506783 
XR_108398 /// 
XR_112435 /// 
XR_113393 1.64794 
227803_PM_at ENPP5 NM_021572 1.64795 
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223232_PM_s_at CGN NM_020770 1.64967 
235558_PM_at RBMS2 NM_002898 1.65352 
219181_PM_at LIPG NM_006033 1.65467 
214183_PM_s_at TKTL1 
NM_001145933 /// 
NM_001145934 /// 
NM_012253 1.65796 
214455_PM_at HIST1H2BC NM_003526 1.65829 
202547_PM_s_at ARHGEF7 
NM_001113511 /// 
NM_001113512 /// 
NM_001113513 /// 
NM_003899 /// 
NM_145735 1.65981 
203504_PM_s_at ABCA1 NM_005502 1.66276 
236979_PM_at BCL2L15 NM_001010922 1.66342 
209738_PM_x_at PSG6 
NM_001031850 /// 
NM_002782 1.66484 
209568_PM_s_at RGL1 NM_015149 1.66508 
212190_PM_at SERPINE2 
NM_001136528 /// 
NM_001136530 /// 
NM_006216 1.66535 
243610_PM_at C9orf135 NM_001010940 1.66535 
200632_PM_s_at NDRG1 
NM_001135242 /// 
NM_006096 1.66833 
223418_PM_x_at ANKRD13C NM_030816 1.66859 
210164_PM_at GZMB NM_004131 1.66866 
222872_PM_x_at OBFC2A 
NM_001031716 /// 
NR_024415 1.66968 
209146_PM_at SC4MOL 
NM_001017369 /// 
NM_006745 1.67077 
221696_PM_s_at STYK1 NM_018423 1.67147 
235970_PM_at LCORL 
NM_001166139 /// 
NM_153686 1.67167 
223233_PM_s_at CGN NM_020770 1.6717 
203382_PM_s_at APOE NM_000041 1.673 
226248_PM_s_at KIAA1324 NM_020775 1.67341 
214285_PM_at FABP3 NM_004102 1.6735 
227927_PM_at --- --- 1.67427 
205645_PM_at REPS2 
NM_001080975 /// 
NM_004726 1.6748 
1554757_PM_a_at INPP5A NM_005539 1.67813 
225681_PM_at CTHRC1 NM_138455 1.67814 
227531_PM_at --- --- 1.67866 
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202439_PM_s_at IDS 
NM_000202 /// 
NM_001166550 /// 
NM_006123 1.67894 
212298_PM_at NRP1 
NM_001024628 /// 
NM_001024629 /// 
NM_003873 1.67934 
211333_PM_s_at FASLG NM_000639 1.68114 
217230_PM_at EZR 
NM_001111077 /// 
NM_003379 1.68177 
76897_PM_s_at FKBP15 NM_015258 1.68228 
202067_PM_s_at LDLR 
NM_000527 /// 
NM_001195798 /// 
NM_001195799 /// 
NM_001195800 /// 
NM_001195802 /// 
NM_00 1.68272 
229017_PM_s_at DSTYK 
NM_015375 /// 
NM_199462 1.68275 
221567_PM_at NOL3 
NM_001185057 /// 
NM_001185058 /// 
NM_003946 1.6954 
203167_PM_at TIMP2 NM_003255 1.69748 
1555978_PM_s_at --- --- 1.69767 
204823_PM_at NAV3 NM_014903 1.69804 
227370_PM_at FAM171B NM_177454 1.70096 
203474_PM_at IQGAP2 NM_006633 1.70099 
229838_PM_at NUCB2 NM_005013 1.7022 
206706_PM_at NTF3 
NM_001102654 /// 
NM_002527 1.70395 
205602_PM_x_at PSG7 NM_002783 1.70465 
211549_PM_s_at HPGD 
NM_000860 /// 
NM_001145816 /// 
NR_027332 1.70516 
243362_PM_s_at LOC641518 
NR_029373 /// 
NR_029374 1.70535 
209348_PM_s_at MAF 
NM_001031804 /// 
NM_005360 1.70592 
205214_PM_at STK17B NM_004226 1.70606 
215821_PM_x_at PSG3 NM_021016 1.70717 
1558208_PM_at TARDBP NM_007375 1.70762 
1557128_PM_at FAM111B 
NM_001142703 /// 
NM_001142704 /// 
NM_198947 1.70834 
203706_PM_s_at FZD7 NM_003507 1.71008 
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201109_PM_s_at THBS1 NM_003246 1.71212 
242037_PM_at --- --- 1.71356 
202965_PM_s_at CAPN6 NM_014289 1.71441 
203705_PM_s_at FZD7 NM_003507 1.71471 
225328_PM_at --- --- 1.71792 
224279_PM_s_at CABYR 
NM_012189 /// 
NM_138643 /// 
NM_138644 /// 
NM_153768 /// 
NM_153769 /// 
NM_153770 1.7181 
207279_PM_s_at NEBL 
NM_001173484 /// 
NM_006393 /// 
NM_213569 1.71868 
242762_PM_s_at FAM171B NM_177454 1.71874 
229256_PM_at PGM2L1 NM_173582 1.7192 
226625_PM_at TGFBR3 
NM_001195683 /// 
NM_001195684 /// 
NM_003243 /// 
NR_036634 1.72004 
210257_PM_x_at CUL4B 
NM_001079872 /// 
NM_003588 1.72112 
211538_PM_s_at HSPA2 NM_021979 1.72396 
202083_PM_s_at SEC14L1 
NM_001039573 /// 
NM_001143998 /// 
NM_001143999 /// 
NM_001144001 /// 
NM_003003 1.72594 
49077_PM_at PPME1 NM_016147 1.72813 
222173_PM_s_at TBC1D2 NM_018421 1.72921 
214091_PM_s_at GPX3 NM_002084 1.73137 
203471_PM_s_at PLEK NM_002664 1.73224 
209594_PM_x_at PSG9 NM_002784 1.73245 
214247_PM_s_at DKK3 
NM_001018057 /// 
NM_013253 /// 
NM_015881 1.73366 
227752_PM_at SPTLC3 NM_018327 1.73475 
225373_PM_at C10orf54 NM_022153 1.73546 
207433_PM_at IL10 NM_000572 1.73588 
208257_PM_x_at PSG1 
NM_001184825 /// 
NM_001184826 /// 
NM_006905 1.74035 
209772_PM_s_at CD24 NM_013230 1.7406 
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202086_PM_at MX1 
NM_001144925 /// 
NM_001178046 /// 
NM_002462 1.74128 
200799_PM_at HSPA1A NM_005345 1.74239 
1554327_PM_a_at CANT1 
NM_001159772 /// 
NM_001159773 /// 
NM_138793 1.74611 
219603_PM_s_at ZNF226 
NM_001032372 /// 
NM_001032373 /// 
NM_001032374 /// 
NM_001146220 /// 
NM_015919 1.74648 
220921_PM_at 
SPANXB1 /// 
SPANXB2 /// 
SPANXF1 
NM_032461 /// 
NM_139019 /// 
NM_145664 1.74956 
202196_PM_s_at DKK3 
NM_001018057 /// 
NM_013253 /// 
NM_015881 1.74986 
211671_PM_s_at NR3C1 
NM_000176 /// 
NM_001018074 /// 
NM_001018075 /// 
NM_001018076 /// 
NM_001018077 /// 
NM_00 1.74999 
229004_PM_at ADAMTS15 NM_139055 1.75429 
218793_PM_s_at SCML1 
NM_001037535 /// 
NM_001037536 /// 
NM_001037540 /// 
NM_006746 1.75447 
230954_PM_at C20orf112 NM_080616 1.75541 
209879_PM_at SELPLG NM_003006 1.75575 
205034_PM_at CCNE2 NM_057749 1.75741 
229999_PM_at LOC100128416 --- 1.75742 
227123_PM_at RAB3B NM_002867 1.75792 
226460_PM_at FNIP2 NM_020840 1.75936 
239814_PM_at LOC100506860 
XR_108813 /// 
XR_108814 /// 
XR_110749 /// 
XR_110750 /// 
XR_113050 /// 
XR_113051 /// XR_ 1.76244 
208621_PM_s_at EZR 
NM_001111077 /// 
NM_003379 1.76316 
202510_PM_s_at TNFAIP2 NM_006291 1.76588 
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217173_PM_s_at LDLR 
NM_000527 /// 
NM_001195798 /// 
NM_001195799 /// 
NM_001195800 /// 
NM_001195802 /// 
NM_00 1.76869 
230831_PM_at FRMD5 NM_032892 1.77459 
239303_PM_at PIWIL2 
NM_001135721 /// 
NM_018068 1.77582 
227566_PM_at NTM 
NM_001048209 /// 
NM_001144058 /// 
NM_001144059 /// 
NM_016522 1.77609 
206132_PM_at MCC 
NM_001085377 /// 
NM_002387 1.77724 
244321_PM_at PGAP1 NM_024989 1.78204 
235619_PM_at 
ASB4 /// 
LOC285986 
NM_016116 /// 
NM_145872 1.7829 
230047_PM_at ARHGAP42 NM_152432 1.78304 
204588_PM_s_at SLC7A7 
NM_001126105 /// 
NM_001126106 /// 
NM_003982 1.78428 
225941_PM_at EIF4E3 
NM_001134649 /// 
NM_001134650 /// 
NM_001134651 /// 
NM_173359 1.78576 
1554493_PM_s_at THADA 
NM_001083953 /// 
NM_022065 1.78635 
210935_PM_s_at WDR1 
NM_005112 /// 
NM_017491 1.79493 
210538_PM_s_at BIRC3 
NM_001165 /// 
NM_182962 1.7952 
204044_PM_at QPRT NM_014298 1.79525 
201983_PM_s_at EGFR 
NM_005228 /// 
NM_201282 /// 
NM_201283 /// 
NM_201284 1.79635 
1553313_PM_s_at SLC5A3 NM_006933 1.79686 
204415_PM_at IFI6 
NM_002038 /// 
NM_022872 /// 
NM_022873 1.80067 
221127_PM_s_at DKK3 
NM_001018057 /// 
NM_013253 /// 
NM_015881 1.80079 
173 
 
211468_PM_s_at RECQL5 
NM_001003715 /// 
NM_001003716 /// 
NM_004259 1.80674 
218559_PM_s_at MAFB NM_005461 1.81066 
202627_PM_s_at SERPINE1 
NM_000602 /// 
NM_001165413 1.81117 
1556309_PM_s_at 
C1orf86 /// 
LOC100128003 
NM_001146310 /// 
NM_182533 /// 
NR_024445 1.81448 
1554114_PM_s_at SSH2 NM_033389 1.81568 
219687_PM_at HHAT 
NM_001122834 /// 
NM_001170564 /// 
NM_001170580 /// 
NM_001170587 /// 
NM_001170588 /// NM 1.81886 
214329_PM_x_at TNFSF10 
NM_001190942 /// 
NM_001190943 /// 
NM_003810 /// 
NR_033994 1.82518 
207980_PM_s_at CITED2 
NM_001168388 /// 
NM_001168389 /// 
NM_006079 1.82668 
205399_PM_at DCLK1 
NM_001195415 /// 
NM_001195416 /// 
NM_001195430 /// 
NM_004734 1.83121 
210002_PM_at GATA6 NM_005257 1.83152 
201012_PM_at ANXA1 NM_000700 1.83359 
230652_PM_at ARAF NM_001654 1.83472 
202901_PM_x_at CTSS NM_004079 1.83697 
228158_PM_at LOC645166 
NR_027354 /// 
NR_027355 /// 
NR_027356 1.83819 
229759_PM_s_at VEPH1 
NM_001167911 /// 
NM_001167912 /// 
NM_001167915 /// 
NM_001167916 /// 
NM_001167917 /// NM 1.84169 
217841_PM_s_at PPME1 NM_016147 1.85263 
229441_PM_at PRSS23 NM_007173 1.85366 
208115_PM_x_at C10orf137 NM_015608 1.85539 
203505_PM_at ABCA1 NM_005502 1.85581 
203108_PM_at GPRC5A NM_003979 1.85855 
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212325_PM_at LIMCH1 
NM_001112717 /// 
NM_001112718 /// 
NM_001112719 /// 
NM_001112720 /// 
NM_014988 1.86241 
212845_PM_at SAMD4A 
NM_001161576 /// 
NM_001161577 /// 
NM_015589 1.86244 
230363_PM_s_at INPP5F 
NM_014937 /// 
NR_003251 /// 
NR_003252 1.86522 
237145_PM_at EIF2AK4 NM_001013703 1.86588 
222693_PM_at FNDC3B 
NM_001135095 /// 
NM_022763 1.87117 
232397_PM_at LOC100507039 
XR_108413 /// 
XR_108414 1.8742 
222810_PM_s_at RASAL2 
NM_004841 /// 
NM_170692 1.87442 
227926_PM_s_at 
NBPF11 /// 
NBPF12 /// 
NBPF24 
NM_001101663 /// 
NM_183372 /// 
XM_001715810 1.87788 
228284_PM_at TLE1 NM_005077 1.88123 
218717_PM_s_at LEPREL1 
NM_001134418 /// 
NM_018192 1.88172 
202628_PM_s_at SERPINE1 
NM_000602 /// 
NM_001165413 1.88325 
219655_PM_at C7orf10 
NM_001193311 /// 
NM_001193312 /// 
NM_001193313 /// 
NM_024728 1.88405 
214748_PM_at N4BP2L2 
NM_014887 /// 
NM_033111 1.88411 
225922_PM_at FNIP2 NM_020840 1.88729 
205801_PM_s_at RASGRP3 
NM_001139488 /// 
NM_015376 /// 
NM_170672 1.88847 
204437_PM_s_at FOLR1 
NM_000802 /// 
NM_016724 /// 
NM_016725 /// 
NM_016729 1.88905 
207733_PM_x_at PSG9 NM_002784 1.88921 
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216442_PM_x_at FN1 
NM_002026 /// 
NM_054034 /// 
NM_212474 /// 
NM_212476 /// 
NM_212478 /// 
NM_212482 1.89031 
225924_PM_at FNIP2 NM_020840 1.89039 
239678_PM_at --- --- 1.89085 
219014_PM_at PLAC8 
NM_001130715 /// 
NM_001130716 /// 
NM_016619 1.89713 
220265_PM_at GPR107 
NM_001136557 /// 
NM_001136558 /// 
NM_020960 1.90845 
220111_PM_s_at ANO2 NM_020373 1.92518 
211719_PM_x_at FN1 
NM_002026 /// 
NM_054034 /// 
NM_212474 /// 
NM_212476 /// 
NM_212478 /// 
NM_212482 1.92606 
225123_PM_at --- --- 1.92757 
204471_PM_at GAP43 
NM_001130064 /// 
NM_002045 1.93104 
219836_PM_at ZBED2 NM_024508 1.93603 
210004_PM_at OLR1 
NM_001172632 /// 
NM_001172633 /// 
NM_002543 1.93603 
211548_PM_s_at HPGD 
NM_000860 /// 
NM_001145816 /// 
NR_027332 1.93877 
213069_PM_at HEG1 NM_020733 1.94034 
241014_PM_at LOC339400 
XR_108352 /// 
XR_111940 /// 
XR_114805 1.94662 
219944_PM_at CLIP4 NM_024692 1.95057 
215997_PM_s_at CUL4B 
NM_001079872 /// 
NM_003588 1.95074 
222963_PM_s_at IL1RAPL1 NM_014271 1.95879 
216379_PM_x_at CD24 NM_013230 1.96449 
1562960_PM_at LOC338653 --- 1.97664 
202803_PM_s_at ITGB2 
NM_000211 /// 
NM_001127491 1.9771 
206508_PM_at CD70 NM_001252 1.97794 
176 
 
212328_PM_at LIMCH1 
NM_001112717 /// 
NM_001112718 /// 
NM_001112719 /// 
NM_001112720 /// 
NM_014988 1.98133 
201110_PM_s_at THBS1 NM_003246 1.98482 
204731_PM_at TGFBR3 
NM_001195683 /// 
NM_001195684 /// 
NM_003243 /// 
NR_036634 1.98529 
212464_PM_s_at FN1 
NM_002026 /// 
NM_054034 /// 
NM_212474 /// 
NM_212476 /// 
NM_212478 /// 
NM_212482 1.98766 
230487_PM_at C6orf99 NM_001195032 1.99526 
203381_PM_s_at APOE NM_000041 1.99638 
228551_PM_at DENND5B NM_144973 1.99957 
236656_PM_s_at LOC100288911 
XR_108260 /// 
XR_109968 /// 
XR_115525 2.00259 
203305_PM_at F13A1 NM_000129 2.00397 
209357_PM_at CITED2 
NM_001168388 /// 
NM_001168389 /// 
NM_006079 2.0084 
210495_PM_x_at FN1 
NM_002026 /// 
NM_054034 /// 
NM_212474 /// 
NM_212476 /// 
NM_212478 /// 
NM_212482 2.01481 
266_PM_s_at CD24 NM_013230 2.01694 
229412_PM_at TAF8 NM_138572 2.01998 
1553708_PM_at MGC16075 
XR_000600 /// 
XR_000617 /// 
XR_001277 2.02565 
212822_PM_at HEG1 NM_020733 2.0337 
202638_PM_s_at ICAM1 NM_000201 2.03569 
225491_PM_at SLC1A2 
NM_001195728 /// 
NM_004171 2.03903 
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208228_PM_s_at FGFR2 
NM_000141 /// 
NM_001144913 /// 
NM_001144914 /// 
NM_001144915 /// 
NM_001144916 /// 
NM_00 2.04227 
205104_PM_at SNPH NM_014723 2.04294 
202688_PM_at TNFSF10 
NM_001190942 /// 
NM_001190943 /// 
NM_003810 /// 
NR_033994 2.04891 
207761_PM_s_at METTL7A NM_014033 2.05926 
202800_PM_at SLC1A3 
NM_001166695 /// 
NM_001166696 /// 
NM_004172 2.06912 
225847_PM_at NCEH1 
NM_001146276 /// 
NM_001146277 /// 
NM_001146278 /// 
NM_020792 2.07182 
209771_PM_x_at CD24 NM_013230 2.07521 
239203_PM_at C7orf53 
NM_001134468 /// 
NM_182597 2.07597 
225207_PM_at PDK4 NM_002612 2.0782 
1554364_PM_at PPP2R5C 
NM_001161725 /// 
NM_001161726 /// 
NM_002719 /// 
NM_178586 /// 
NM_178587 2.08137 
222862_PM_s_at AK5 
NM_012093 /// 
NM_174858 2.08229 
202687_PM_s_at TNFSF10 
NM_001190942 /// 
NM_001190943 /// 
NM_003810 /// 
NR_033994 2.10634 
214476_PM_at TFF2 NM_005423 2.10699 
206523_PM_at CYTH3 NM_004227 2.11618 
239202_PM_at RAB3B NM_002867 2.14163 
230508_PM_at DKK3 
NM_001018057 /// 
NM_013253 /// 
NM_015881 2.14737 
230121_PM_at C1orf133 NR_024337 2.15723 
228885_PM_at MAMDC2 NM_153267 2.17373 
220663_PM_at IL1RAPL1 NM_014271 2.21768 
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219928_PM_s_at CABYR 
NM_012189 /// 
NM_138643 /// 
NM_138644 /// 
NM_153768 /// 
NM_153769 /// 
NM_153770 2.22377 
203845_PM_at KAT2B NM_003884 2.2336 
204818_PM_at HSD17B2 NM_002153 2.23849 
201163_PM_s_at IGFBP7 NM_001553 2.23967 
227484_PM_at SRGAP1 NM_020762 2.24848 
240089_PM_at --- --- 2.25269 
209037_PM_s_at EHD1 NM_006795 2.2843 
1552546_PM_a_at LETM2 NM_144652 2.33461 
1569470_PM_a_at FRMD5 NM_032892 2.3398 
202902_PM_s_at CTSS NM_004079 2.35946 
1554010_PM_at NDST1 NM_001543 2.38454 
208651_PM_x_at CD24 NM_013230 2.39914 
214456_PM_x_at SAA1 /// SAA2 
NM_000331 /// 
NM_001127380 /// 
NM_001178006 /// 
NM_030754 /// 
NM_199161 2.40256 
229041_PM_s_at --- --- 2.41547 
208650_PM_s_at CD24 NM_013230 2.41638 
211814_PM_s_at CCNE2 NM_057749 2.4419 
201162_PM_at IGFBP7 NM_001553 2.49832 
232060_PM_at ROR1 
NM_001083592 /// 
NM_005012 2.50328 
205924_PM_at RAB3B NM_002867 2.51551 
209904_PM_at TNNC1 NM_003280 2.53513 
201289_PM_at CYR61 NM_001554 2.54444 
226425_PM_at CLIP4 NM_024692 2.62045 
227345_PM_at TNFRSF10D NM_003840 2.64458 
232914_PM_s_at SYTL2 
NM_001162951 /// 
NM_001162952 /// 
NM_001162953 /// 
NM_032379 /// 
NM_032943 /// 
NM_20692 2.67453 
209684_PM_at RIN2 NM_018993 2.6756 
210764_PM_s_at CYR61 NM_001554 2.70487 
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208607_PM_s_at SAA1 /// SAA2 
NM_000331 /// 
NM_001127380 /// 
NM_001178006 /// 
NM_030754 /// 
NM_199161 2.76187 
220158_PM_at LGALS14 
NM_020129 /// 
NM_203471 2.81139 
233537_PM_at KRTAP3-1 NM_031958 2.86541 
217228_PM_s_at ASB4 
NM_016116 /// 
NM_145872 2.96288 
229380_PM_at --- --- 2.98811 
200665_PM_s_at SPARC NM_003118 3.29503 
1552348_PM_at PRSS33 NM_152891 3.32338 
1562722_PM_at 
PRR20A /// 
PRR20B /// 
PRR20C /// 
PRR20D /// 
PRR20E 
NM_001130404 /// 
NM_001130405 /// 
NM_001130406 /// 
NM_001130407 /// 
NM_198441 3.3548 
239201_PM_at CDK15 NM_139158 3.43917 
207096_PM_at SAA4 NM_006512 3.47118 
225496_PM_s_at SYTL2 
NM_001162951 /// 
NM_001162952 /// 
NM_001162953 /// 
NM_032379 /// 
NM_032943 /// 
NM_20692 3.55404 
237732_PM_at PRR9 NM_001195571 3.60694 
1553995_PM_a_at NT5E NM_002526 3.71625 
203939_PM_at NT5E NM_002526 3.99018 
235818_PM_at VSTM1 NM_198481 4.65915 
1553994_PM_at NT5E NM_002526 5.96951 
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Table 9.  Probeset ID, gene symbol, refseq transcript ID and fold 
change from microarray analysis of SW480FJX1 treated with scramble siRNA 
(siSCR) versus SW480FJX1 treated with HIF1A specific siRNA (siHIF) colon 
cancer cells. 
 
Probeset ID Gene Symbol RefSeq Transcript ID 
Fold-
Change 
(FJX1 siIHIF 
vs. FJX1 
siSCR) 
200989_PM_at HIF1A NM_001530 /// NM_181054 -2.47572 
212992_PM_at AHNAK2 NM_138420 -1.74224 
215785_PM_s_at CYFIP2 
NM_001037332 /// 
NM_001037333 /// 
NM_014376 -1.71622 
212343_PM_at YIPF6 
NM_001195214 /// 
NM_173834 -1.70336 
235023_PM_at VPS13C 
NM_001018088 /// 
NM_017684 /// NM_018080 /// 
NM_020821 -1.69819 
241367_PM_at TEX19 NM_207459 -1.66703 
232890_PM_at --- --- -1.64772 
239917_PM_at VPS8 
NM_001009921 /// 
NM_015303 -1.64178 
203542_PM_s_at KLF9 NM_001206 -1.64177 
237119_PM_at --- --- -1.63131 
209695_PM_at PTP4A3 NM_007079 /// NM_032611 -1.61265 
211184_PM_s_at USH1C NM_005709 /// NM_153676 -1.60949 
232549_PM_at RBM11 NM_144770 -1.60642 
241624_PM_at LOC389834 NR_027420 -1.5903 
225812_PM_at C6orf225 NM_001033564 -1.58729 
243356_PM_at --- --- -1.57508 
204698_PM_at ISG20 NM_002201 -1.57446 
212340_PM_at YIPF6 
NM_001195214 /// 
NM_173834 -1.57377 
228771_PM_at ADRBK2 NM_005160 -1.57376 
222375_PM_at --- --- -1.5659 
240180_PM_at --- --- -1.56173 
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201540_PM_at FHL1 
NM_001159699 /// 
NM_001159700 /// 
NM_001159701 /// 
NM_001159702 /// 
NM_001159703 /// NM -1.55843 
1553502_PM_a_at PALM2 
NM_001037293 /// 
NM_053016 -1.54023 
212843_PM_at NCAM1 
NM_000615 /// 
NM_001076682 /// 
NM_181351 -1.54008 
231024_PM_at LOC572558 NR_015423 -1.53683 
212342_PM_at YIPF6 
NM_001195214 /// 
NM_173834 -1.53234 
227417_PM_at MOSC2 NM_017898 -1.52879 
226576_PM_at ARHGAP26 
NM_001135608 /// 
NM_015071 -1.52555 
220576_PM_at PGAP1 NM_024989 -1.52462 
229011_PM_at --- --- -1.52389 
211157_PM_at --- --- -1.5201 
231964_PM_at --- --- -1.5194 
232796_PM_at --- --- -1.51873 
242869_PM_at --- --- -1.51805 
210718_PM_s_at 
ARL17A /// 
LOC100294341 
NM_001113738 /// 
NM_016632 /// 
XM_002344068 -1.51668 
222061_PM_at CD58 
NM_001144822 /// 
NM_001779 /// NR_026665 -1.5158 
210102_PM_at VWA5A 
NM_001130142 /// 
NM_014622 /// NM_198315 -1.51549 
1570588_PM_at --- --- -1.51274 
219726_PM_at NLGN3 
NM_001166660 /// 
NM_018977 /// NM_181303 -1.51234 
214660_PM_at ITGA1 NM_181501 -1.51162 
1556951_PM_at --- --- -1.50907 
236322_PM_at --- --- -1.50895 
201925_PM_s_at CD55 
NM_000574 /// 
NM_001114752 -1.50861 
203158_PM_s_at GLS NM_014905 -1.50727 
225912_PM_at TP53INP1 
NM_001135733 /// 
NM_033285 1.5002 
218954_PM_s_at BRF2 NM_018310 1.50162 
207702_PM_s_at MAGI2 NM_012301 1.50256 
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235762_PM_at TAS2R14 NM_023922 1.50851 
216255_PM_s_at GRM8 
NM_000845 /// 
NM_001127323 /// 
NR_028041 1.50973 
204653_PM_at TFAP2A 
NM_001032280 /// 
NM_001042425 /// 
NM_003220 1.5099 
225990_PM_at BOC NM_033254 1.51277 
1555543_PM_a_at CLCC1 
NM_001048210 /// 
NM_015127 1.51338 
231538_PM_at C11orf1 NM_022761 1.51414 
235424_PM_at --- --- 1.51449 
219517_PM_at ELL3 /// SERINC4 
NM_001033517 /// 
NM_025165 1.5226 
222484_PM_s_at CXCL14 NM_004887 1.52742 
206022_PM_at NDP NM_000266 1.52755 
220394_PM_at FGF20 NM_019851 1.52981 
238528_PM_at UBR1 NM_174916 1.53069 
228915_PM_at DACH1 
NM_004392 /// NM_080759 /// 
NM_080760 1.53556 
208228_PM_s_at FGFR2 
NM_000141 /// 
NM_001144913 /// 
NM_001144914 /// 
NM_001144915 /// 
NM_001144916 /// NM_00 1.537 
215358_PM_x_at ZNF37BP NR_026777 1.53709 
241239_PM_at --- --- 1.53914 
206706_PM_at NTF3 
NM_001102654 /// 
NM_002527 1.54019 
228325_PM_at KIAA0146 NM_001080394 1.54893 
230755_PM_at RHBDL3 NM_138328 1.55084 
226775_PM_at ENY2 
NM_001193557 /// 
NM_020189 /// NR_036471 /// 
NR_036472 1.55461 
230278_PM_at --- --- 1.55478 
215283_PM_at LOC339290 NR_015389 1.55666 
216379_PM_x_at CD24 NM_013230 1.55706 
203221_PM_at TLE1 NM_005077 1.55708 
236213_PM_at --- --- 1.56203 
209684_PM_at RIN2 NM_018993 1.5636 
236163_PM_at LIX1 NM_153234 1.57 
218002_PM_s_at CXCL14 NM_004887 1.57267 
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206432_PM_at HAS2 NM_005328 1.57506 
1559382_PM_at C19orf42 NM_024104 1.57526 
1562736_PM_at LHX9 
NM_001014434 /// 
NM_020204 1.57781 
208998_PM_at UCP2 NM_003355 1.58208 
228284_PM_at TLE1 NM_005077 1.58477 
225491_PM_at SLC1A2 
NM_001195728 /// 
NM_004171 1.58593 
1557149_PM_at --- --- 1.58937 
229041_PM_s_at --- --- 1.59153 
241709_PM_s_at DOCK1 NM_001380 1.5962 
236656_PM_s_at LOC100288911 
XR_108260 /// XR_109968 /// 
XR_115525 1.60813 
200974_PM_at ACTA2 
NM_001141945 /// 
NM_001613 1.61099 
213169_PM_at SEMA5A NM_003966 1.61139 
227124_PM_at LOC221710 NM_001135575 1.6175 
242923_PM_at ZNF678 NM_178549 /// NR_033184 1.62247 
210964_PM_s_at GYG2 
NM_001079855 /// 
NM_001184702 /// 
NM_001184703 /// 
NM_001184704 /// 
NM_003918 1.62362 
236937_PM_at LOC100505729 
XR_108524 /// XR_112552 /// 
XR_113551 1.63659 
213830_PM_at TRD@ --- 1.64197 
239482_PM_x_at ZNF708 NM_021269 1.65647 
238761_PM_at ELK4 NM_001973 /// NM_021795 1.66864 
227760_PM_at IGFBPL1 NM_001007563 1.68164 
209348_PM_s_at MAF 
NM_001031804 /// 
NM_005360 1.68749 
211814_PM_s_at CCNE2 NM_057749 1.70147 
208651_PM_x_at CD24 NM_013230 1.70962 
214456_PM_x_at SAA1 /// SAA2 
NM_000331 /// 
NM_001127380 /// 
NM_001178006 /// 
NM_030754 /// NM_199161 1.75096 
207096_PM_at SAA4 NM_006512 1.75267 
209771_PM_x_at CD24 NM_013230 1.77005 
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208650_PM_s_at CD24 NM_013230 1.7919 
208607_PM_s_at SAA1 /// SAA2 
NM_000331 /// 
NM_001127380 /// 
NM_001178006 /// 
NM_030754 /// NM_199161 1.94786 
206363_PM_at MAF 
NM_001031804 /// 
NM_005360 2.01026 
212909_PM_at LYPD1 
NM_001077427 /// 
NM_144586 2.06227 
227566_PM_at NTM 
NM_001048209 /// 
NM_001144058 /// 
NM_001144059 /// 
NM_016522 2.08625 
208399_PM_s_at EDN3 
NM_000114 /// NM_207032 /// 
NM_207033 /// NM_207034 2.12032 
227752_PM_at SPTLC3 NM_018327 2.16876 
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